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Abstract 
Persistent infections with high-risk human papillomaviruses (hr-HPVs) may cause 
cervical and other types of cancer. The key event for the transformation of hr-HPV-
infected cells into malignant tumor cells is the deregulated expression of the hr-HPV 
oncogenes E6 and E7. Both gene products interfere with cell cycle checkpoints, inhibit 
DNA damage repair and induce chromosomal instability. Deregulation of hr-HPV 
oncogene expression as well as transformation of the host cells are driven by the 
hypermethylation of specific CpG dinucleotides in the viral and host cellular genome. 
Thereby, the HPV E2-mediated control of E6 and E7 transcription is disrupted and the 
expression of host cellular tumor suppressive genes and microRNAs is prevented. 
Therefore, we hypothesized that the application of demethylating agents might re-
establish these regulatory mechanisms reducing the hr-HPV oncogene expression and 
inhibiting cell proliferation. 
To test this hypothesis, the demethylating agent 5-aza-2’-deoxycytidine (DAC) was 
applied to a panel of six HPV-transformed cell lines. DAC treatment significantly 
decreased the expression of the HPV oncogenes. As a consequence, the levels of E6 
and E7 target proteins, including p53 and p21, increased repressing cell proliferation 
and colony formation. In addition, the application of DAC strongly induced the 
expression of tumor suppressive miR-375, which was shown to target and degrade E6 
and E7 transcripts. In conclusion, the presented data demonstrate the effectiveness of 
DAC in the treatment of HPV-transformed cells and suggest its testing in clinical trials. 
In addition to the evaluation of treatment strategies, the present thesis aimed to study 
the effects of HPV oncogene expression on chromosomal stability, gene expression 
patterns and DNA methylation levels. For this, chromosomally stable HCT116 cells were 
used as a model system to generate clones allowing the inducible HPV 16 E6 and E7 
expression. Immortalization of HCT116 cells, which is characterized by microsatellite 
instability, can be clearly distinguished from HPV-driven immortalization, which depends 
on the induction of chromosomal instability. Therefore, HCT116 cells represent an ideal 
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model system to study the HPV 16 oncogene-mediated induction of chromosomal 
instability. 
Induction of HPV 16 oncogene expression affected the chromosomal stability of HCT116 
cells by causing abnormal centrosome and spindle pole numbers, by inducing DNA 
damage and by increasing the number of aneuploid cells. Furthermore, a panel of genes 
was found to be differentially expressed after induction of HPV 16 oncogene expression 
potentially representing candidate genes and indicating pathways that might play a role 
during the transformation of HPV-infected cells. Taken together, HPV 16 oncogene 
expression seems to increase the genomic variability in the cell population presumably 
elevating the risk for the generation of highly proliferative subclones over time. 
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Zusammenfassung 
Persistierende Infektionen mit humanen Papillomviren der Hochrisiko-Typen (hr-HPVs) 
können die Entstehung von Zervixkarzinomen und anderen Tumoren hervorrufen. Die 
maligne Transformation von hr-HPV-infizierten Zellen wird durch eine unkontrollierte 
Überexpression der Onkogene E6 und E7 ausgelöst, wodurch vor allem der Zellzyklus 
beschleunigt, DNA Reparaturmechanismen gehemmt und chromosomale Instabilität 
induziert wird. Die Regulation der Onkogenexpression und die Transformation infizierter 
Zellen werden maßgeblich durch die verstärkte Methylierung bestimmter CpG 
Dinukleotide im Virus- und Wirtszellgenom beeinflusst, wodurch die HPV E2-abhängige 
Kontrolle der HPV Onkogenexpression gestört und die Expression wichtiger tumor-
suppressiver Gene und mikroRNAs verhindert wird. Dies lässt vermuten, dass die 
Anwendung demethylierender Substanzen zur Behandlung HPV-transformierter Zellen 
die genannten Regulationsmechanismen wiederherstellt und dadurch die HPV 
Onkogenexpression, sowie die Zellproliferation inhibiert. 
Zur Überprüfung dieser Hypothese wurden in dieser Studie sechs HPV-transformierte 
Zelllinien mit der demethylierenden Substanz 5-Aza-2'-desoxycytidin (DAC) behandelt. 
Die Behandlung führte zu einer signifikanten Reduktion der HPV Onkogenexpression, 
zu einer erhöhten Konzentration der Bindungspartner von E6 und E7, wie beispielsweise 
p53 und p21, und schließlich zur Hemmung der Zellproliferation. Zusätzlich ließ sich 
eine starke Expression der tumor-suppressiven miR-375 detektieren, die E6 und E7 
Transkripte bindet und deren Abbau auslöst. Die Behandlung von HPV-transformierten 
Zellen mit der demethylierenden Substanz DAC erscheint somit als ein 
vielversprechender Ansatz, um die HPV Onkogenexpression und die Proliferation der 
Zellen zu verhindern. 
Neben der Erforschung von Behandlungsstrategien, zielte diese Arbeit darauf ab, den 
Einfluss der HPV Onkogene auf die chromosomale Stabilität, sowie auf das 
Genexpressions- und DNA Methylierungsmuster genauer zu untersuchen. Als 
Modellsystem wurde dafür die chromosomal stabile Zelllinie HCT116 ausgewählt und 
mittels rekombinanten Kassettenaustauschs zur induzierbaren HPV 16 
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Onkogenexpression manipuliert. Die Immortalisierung von HCT116 Zellen beruht auf 
deren Mikrosatelliten-Instabilität und kann daher eindeutig vom HPV-induzierten 
Transformationsprozess unterschieden werden, der auf einer chromosomalen Instabilität 
der Wirtszellen basiert. Die Expression der HPV 16 Onkogene bedingte eine Erhöhung 
des Anteils der Zellen mit abnormalen Centrosomen und der Mitosen mit aberranten 
Spindelpolen, eine Zunahme von DNA Schädigungen, sowie eine Steigerung 
aneuploider Zellen und beeinträchtigte somit die chromosomale Stabilität der Zellen. 
Darüber hinaus wurden nach der HPV 16 E6 und E7 Expression einige differentiell 
exprimierte Gene identifiziert, die möglicherweise eine Rolle während der 
Transformation HPV-infizierter Zellen spielen könnten. Die Expression der HPV 
Onkogene scheint somit die genomische Variabilität der Zellpopulation zu erhöhen, 
wodurch die Entstehung von stärker proliferierenden Subklonen mit der Zeit gefördert 
würde. 
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Abbreviations 
A Adenosine hr-HPV High-risk human papillomavirus 
AmpR Ampicillin resistance gene lr-HPV Low-risk human papillomavirus 
Bidest. Bidestillatus Hyg Hygromycin B 
BSA Bovine serum albumin HygTK Hygromycin B 
phosphotransferase thymidine 
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C Cytosine IF Immunofluorescence 
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1. Introduction 
1.1. Human papillomaviruses 
Papillomaviruses infect epithelial cells of a variety of vertebrates including humans and 
may induce epithelial lesions in their respective host. Human papillomaviruses (HPVs) 
are non-enveloped, double-stranded DNA viruses, which infect the basal cells of the 
squamous epithelium of the skin and the mucosa. Since their discovery in the early 
1950s, almost 200 different HPV types have been identified (Bernard et al. 2010, 
Strauss et al. 1949). In the 1970s, Harald zur Hausen hypothesized that HPV infections 
might cause cervical cancer (Gissmann & zur Hausen 1976, zur Hausen 1974, zur 
Hausen 1975). This hypothesis was further substantiated in the following years by 
detecting HPV 16 and 18 in cervical cancer. Today, HPV is recognized as an important 
infectious and carcinogenic agent, which plays a major role during the development of 
different urogenital cancers including cancers of the cervix, vulva, vagina, penis and 
anus as well as of head and neck cancers. 
Despite the improvements in screening and vaccination, cervical cancer is still the fourth 
most frequent cancer in women. According to the World Health Organization (WHO) 
more than 270,000 women die from cervical cancer every year. In 2012, approximately 
530,000 new cervical cancer cases were estimated predominantly occurring in low-
income countries where the access to effective screening programs is limited. These 
numbers show that cervical and other HPV-associated cancer types still affect a high 
number of people worldwide. 
To effectively reduce the number of patients dying from HPV-driven tumors, four 
strategies seem to be essential. First, prophylactic HPV vaccination programs need to 
be continued and expanded. However, as prophylactic HPV vaccination can only be 
effective to prevent new HPV infections, there is still a strong need for therapeutic 
options helping patients who are already infected. Therefore, screening for cervical and 
other HPV-associated cancer types needs to be improved and expanded even further to 
detect the disease at an early stage offering a better prognosis. Thirdly, treatment 
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options for later staged patients need to be optimized. Several approaches are currently 
tested including therapeutic vaccination (e.g. against E7 and p16) as well as the 
application of demethylating agents, as discussed in section 1.4.2. However, these 
approaches and the development of novel therapeutic strategies require a detailed 
understanding of the mechanisms used by HPV to infect host cells and to transform 
these cells into proliferating tumor cells. Therefore, as a fourth key point to target HPV-
driven cancers, there is a continuous need for the development of model systems, which 
precisely mimic HPV infection and tumor development thereby promoting a better 
understanding of viral strategies. 
Depending on their carcinogenic potential, HPV types are categorized as either low-risk 
(lr) or high-risk (hr). Generally, infections with lr-HPV types can lead to the development 
of genital warts (condyloma) and are rarely found in malignancies (Bodily & Laimins 
2011). In contrast, infections with hr-HPV types may cause malignant transformation that 
potentially leads to the progression of cancer. About 99% of all cervical cancers contain 
genomic sequences of hr-HPV types (Ault 2006). Especially the hr-HPV types 16 and 
18, which are detected in about 70% of all cervical cancers, play a predominant role. 
However, hr-HPV infections do not necessarily lead to the formation of cancer. The vast 
majority of these infections does not cause any symptoms and can mostly be cleared by 
the host immune system. Only a small number of infections may persist and can then 
progress towards cancer. The progression from persistent infections to invasive cancers 
includes multiple stages representing different grades of precursor lesions (intraepithelial 
neoplasia grade 1 to 3) and generally spans years or even decades (Carter et al. 2011, 
zur Hausen 2002). 
 
1.1.1. HPV genome organization 
The HPV genome consists of double-stranded DNA organized in an episomal structure 
with about 8,000 base pairs (HPV16: 7904 bp) encoding six early and two late genes 
(Doorbar 2005) (Figure 1). The early genes (E1, E2 and E4-E7) are mainly involved in 
the replication of the viral genome, which is synchronized with the DNA replication of the 
host cell. Furthermore, they also play important roles in the transcriptional regulation of 
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viral genes (E2), in viral capsid maturation and release (E4) but also deregulate cell 
cycle control and apoptosis pathways (E5 and mainly E6 and E7) (reviewed in (Doorbar 
et al. 2012, Moody & Laimins 2010)). The late genes L1 and L2, which are expressed in 
the final steps of the viral life cycle, code for the major (L1) and minor (L2) capsid 
proteins. Both, early and late genes are transcribed as polycistronic mRNAs from a 
single HPV DNA strand and are then processed by the host cellular splicing machinery 
(reviewed in (Graham 2010)). The expression of the early genes is regulated by the 
upstream regulatory region (URR), which can be divided into 5` long control region 
(LCR), enhancer region and promoter region. This part of the HPV genome is not 
transcribed into mRNA but contains binding sites for numerous host cell and viral 
transcription factors regulating viral early gene expression (reviewed in (Thierry 2009)). 
In contrast, late gene expression is controlled by the late promoter, which is located in 
the genomic region coding for E7. The transcriptional activity of the late promoter 
depends on keratinocyte differentiation (del Mar Pena & Laimins 2001). In addition to the 
transcriptional activity of the two promoter regions, HPV gene expression also relies on 
appropriate polyadenylation and alternative splicing of the polycistronic RNA, as well as 
on its translation into the respective protein (reviewed in (Graham 2010)). Therefore, 
HPV early and late gene expression is not only regulated by viral but also by host 
cellular factors. The role of the viral proteins during the HPV life cycle and during 
malignant transformation of the host cells is described in the following chapters. 
 
1.1.2. HPV life cycle 
The HPV life cycle is tightly coupled to the differentiation state of the host cell and leads 
to the production and the release of infectious viral particles (Figure 1). HPV virions 
infect undifferentiated basal and parabasal epithelial cells through traumatic micro-
abrasions, which can occur during sexual intercourse (Schiller et al. 2010). First, the 
virus attaches and enters the target cell, which is mediated by receptors expressed on 
the surface of the host cell (Evander et al. 1997, Letian & Tianyu 2010). After disruption 
of the endosomal membrane by the viral L2 protein, the viral genome is transported into 
the nucleus of the host cell where it is maintained as an episome (Kamper et al. 2006). 
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This stage of infection is not associated with cytopathologic effects or detectable 
symptoms because expression of the viral genes is mainly repressed. Solely the early 
genes E1 and E2 were found to be expressed at low levels fusing the viral episomes to 
the host cellular chromosomes and thereby allowing the replication of the viral genome. 
Therefore, this state is classified as silent or latent phase of HPV infections (reviewed in 
(Doeberitz & Vinokurova 2009)). 
The distribution of the viral genome depends on the dividing capacity of the 
undifferentiated cells in the basal epithelium. After mitosis both of the two daughter cells 
contain episomal HPV copies in their nuclei. One of these daughter cells retains its 
dividing capacity by remaining in the basal epithelium and thereby functions as a viral 
reservoir for persistent HPV infections. The other daughter cell starts to migrate and 
differentiate towards the superficial cell layers. This process is accompanied by elevated 
transcription of the early viral genes E1 and E2, as well as of the oncogenes E6 and E7 
(reviewed in (Doorbar et al. 2012)). Thereby, replication of the viral episomes is 
promoted and subsequently uncoupled from the replication of the host genome leading 
to a substantial increase of viral episomes in the cells (reviewed in (Hebner & Laimins 
Figure 1: Schematic illustration of the HPV 16 genome and the HPV life cycle. 
(A) The HPV 16 genome contains 7904 nucleotides and encodes six early genes (green) including the 
two oncogenes E6 and E7 (red) and two late genes (orange). The LCR regulates the expression of the 
early genes. (Modified from (Doorbar et al. 2012) (B) HPV (red hexagons) infects the basal cells of the 
squamous epithelium through micro lesions in the skin and is established as episomes. After cell division 
one of the infected daughter cells remains in the basal cell layer and the other infected daughter cell 
migrates and differentiates towards the upper cell layers. During this process HPV early gene expression 
is activated, the viral genome is amplified and the late genes are subsequently transcribed (as indicated 
by the triangles). Afterwards, the virions are assembled and finally released from dying keratinocytes in 
the superficial cell layer thereby completing the HPV life-cycle. (Modified from (Moody & Laimins 2010)) 
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2006, Ibeanu 2011)). 
In the final step of the viral life cycle, the viral genomes are packed into infectious viral 
particles, which are then released potentially infecting other host cells. This process is 
initiated by the increasing transcriptional activity of the HPV late promoter during the 
migration of the host cell through intermediate and superficial epithelial cell layers. 
Transcriptional activation of the late promoter leads to the expression of the late genes 
L1 and L2. The major capsid protein L1 self-assembles into homopentamers forming 
icosahedral capsids of about 50 nm in diameter (reviewed in (Buck et al. 2013)). L2 
proteins have been shown to be located between L1 monomers in the inner surface of 
the virion (Lowe et al. 2008). The viral genome is then encapsulated and the infectious 
HPV particles are released from decaying keratinocytes at the epithelial surface. 
The mechanisms of viral genome replication and virion release evolved by HPVs 
effectively prevent the recognition and targeting of the virions or of infected cells by the 
host immune system (reviewed in (Stubenrauch & Laimins 1999). This is mainly 
accomplished by minimal viral gene expression in the basal epithelial cell layers and by 
the prevention of host cell disruption until reaching the upper epithelial cell layer. 
Thereby, HPV infections can persist over long time periods without being cleared by the 
host immune system. 
 
1.2. Deregulation of HPV oncogene expression mediates host cell 
transformation 
Persistence is assumed to be a prerequisite for the progression from permissive to 
transforming HPV infections. However, the molecular events triggering this transition, 
which may only occur in distinct host cells, are not completely understood. As illustrated 
in Figure 2, the key event causing the shift from permissive to transforming infections 
seems to be the deregulated expression of the HPV oncogenes E6 and E7. These viral 
proteins were found to interact with numerous host cellular factors influencing a variety 
of molecular pathways in the cells. Generally, both oncoproteins promote cell 
proliferation, inhibit apoptosis pathways and are assumed to induce genomic instability 
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in the host cells (reviewed in (Moody & Laimins 2010)). The mechanisms, how E6 and 
E7 affect host cellular pathways, have intensively been studied and are described in 
chapter 1.3. In contrast, molecular events that potentially result in the deregulation of E6 
and E7 expression are only superficially described. In the following paragraphs four 
major concepts are introduced that aim to explain the shift from permissive to 
transforming HPV infections. 
In 2012, Herfs and colleagues suggested that squamous columnar junction cells are the 
source of cervical cancer (Herfs et al. 2012). This embryonic cell population, which is 
located at the transformation zone between endocervical columnar and ectocervical 
squamous epithelium, shows a distinct morphology and a unique gene expression 
profile. Moreover, the authors identified markers specific for this type of cells that are 
maintained in both squamous cell carcinomas and adenocarcinomas, further 
substantiating the assumption that cervical carcinogenesis primarily originates from 
Figure 2: Pathogenesis of HPV-induced cervical lesions. 
HPV (blue particles) infects the basal cells of the squamous epithelium through micro lesions in the skin. 
After viral uptake and transport to the nucleus the viral genome is maintained as episomes (red circles, 
latent infection). During S phase of the cell cycle, the viral genome is replicated and then distributed onto 
the daughter cells during mitosis. The viral life cycle continuous as described previously and results in the 
release of infectious viral particles (light grey cells, permissive infection). Especially at the squamous 
columnar junction zone the expression of the viral genes in the basal cells might become deregulated 
resulting in the overexpression of the oncogenes E6 and E7. These cells are assumed to bear an 
increased risk for malignant transformation and subsequent tumor progression (red cells, transforming 
infection). The Figure was modified according to (Doeberitz & Vinokurova 2009). 
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squamous columnar junction cells. Based on these observations the authors proposed 
that basal cells of the columnar epithelium, of the squamous epithelium as well as of the 
squamous columnar junction can be infected by HPV, however, only the infected 
squamous columnar junction cells expressing the identified marker genes harbor an 
elevated risk of carcinogenic progression. If the proposed model holds true, excision of 
the squamous columnar junction, which seems to lack the potential for regeneration, 
might be an option to cure early cervical lesions. Future trials, however, need to clarify 
whether squamous columnar junction specific genes reliably predict the likelihood of 
progression of infected cells and whether ablation of these cells really lowers the risk of 
developing cervical cancer. 
In addition to the cell population infected by HPV, several other factors seem to play an 
important role in mediating the shift from permissive to transforming infections. At the 
molecular level this includes the status of the viral genome, but also epigenetic marks 
regulating the expression of the viral oncogenes. 
Transcription of E6 and E7 is mainly controlled by the URR, which contains several 
transcription factor binding sites including four that allow the interaction with the viral 
protein E2 (Figure 3). The E2 binding sites (E2BSs) bind E2 proteins with different 
affinities facilitating a tight regulation of early gene expression. Interaction of E2 with the 
high affinity E2BS 1 activates the early promoter stimulating the production of early viral 
proteins including E2 itself, as well as E6 and E7 (Rapp et al. 1997, Steger & Corbach 
1997). Rising levels of E2 then also result in interaction with the low affinity proximal 
E2BSs 2, 3 and 4, which represses transcription by displacing the transcription factors 
Sp1 and TATA-binding protein (TBP) from their respective binding sites (Stubenrauch et 
al. 1998). This feedback mechanism ensures the continuous low expression levels of the 
early genes and simultaneously prevents their overexpression potentially avoiding 
recognition by the host immune system (reviewed in (Thierry 2009)). Thereby, the HPV 
E2 protein functions as the master regulator of the viral life cycle (Singh et al. 2016). 
Abrogation of this regulatory mechanism might therefore constitute an important initial 
step towards malignant transformation. Loss of E2 expression is frequently observed 
after viral integration into the host genome, which often causes disruption of the E2 ORF 
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(Cullen et al. 1991, Pett & Coleman 2007). Integration of viral genomes can be found in 
many cervical carcinoma cell lines and occurs frequently in advanced HPV-associated 
lesions (Jeon & Lambert 1995). Considerable numbers of cervical lesions associated 
with transforming HPV infections, however, lack integrated viral genome copies 
suggesting that viral genome integration might be a rather late event during carcinogenic 
transformation (Cullen et al. 1991, Wentzensen et al. 2004). Based on these 
observations other mechanisms seem to exist explaining the deregulated expression of 
E6 and E7 in early low-grade lesions that only contain episomal HPV copies. 
One of these mechanisms proposes that altered DNA methylation patterns of CpG 
dinucleotides located in the E2BSs may affect the E2-mediated transcriptional 
regulation. Methylation at the 5` position of cytosines in the DNA functions as epigenetic 
Figure 3: Schematic illustration showing the location of the URR and the E2BSs in the HPV 16 
genome. 
The HPV 16 URR regulates early gene transcription and can be divided into 5`LCR, enhancer and 
promoter region. These regions contain binding sites for different host cellular transcription factors 
including nuclear factor 1 (NF1), thyrotroph embryonic factor (Tef) and specificity protein 1 (Sp1). Most 
important for the present study are the four E2BSs allowing the interaction with the viral protein E2. The 
E2BSs contain several CpG dinucleotides that can be differentially methylated during HPV-mediated 
carcinogenesis strongly affecting the regulatory function of E2. The Figure was modified according to 
(Doeberitz & Vinokurova 2009). 
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mark influencing the transcriptional activity of the respective genomic locus. The E2BSs 
in the HPV URR share a consensus DNA sequence (5`-ACCG(N4)CGGT-3`) containing 
two CpG dinucleotides, which were found to be hypermethylated in HPV-associated 
lesions that harbor episomal viral copies as well as in HPV-related cancers that contain 
the viral genome integrated as a concatemer (Baker et al. 1987, Chaiwongkot et al. 
2013, Romanczuk et al. 1990). E2BS methylation blocks the interaction with E2 proteins 
abrogating the E2-mediated transcriptional repression of E6 and E7 and thereby 
deregulating HPV oncogene expression (Kim et al. 2003, Thain et al. 1996). 
In addition to elevated E2BS methylation, changes in the methylation pattern at other 
sites in the viral as well as in the host cellular genome seem to be involved in the 
transformation of HPV-infected cells. Hypermethylation of several viral genes including 
the late genes L1 and L2, but also E2, E5 and the URR, distinguishes low-grade lesions 
(cervical intraepithelial neoplasia (CIN) grade 1 and 2) from high-grade CINs and 
malignant tumors ((Kalantari et al. 2004, Mirabello et al. 2013, Vinokurova & von Knebel 
Doeberitz 2011) and reviewed in (Clarke et al. 2012, Johannsen & Lambert 2013)). 
Additionally, the transition from low- to high-grade lesions is characterized by 
methylation-dependent silencing of host cellular tumor suppressor genes, e.g. cell 
adhesion factors like cadherin 1 (CDH1) and cell adhesion molecule 1 (CADM1) (Kang 
et al. 2006, Narayan et al. 2003, Shivapurkar et al. 2007), as well as apoptotic factors 
including death-associated protein kinase 1 (DAPK1) ((Feng et al. 2005) and reviewed in 
(Wentzensen et al. 2009)). 
As an additional regulatory mechanism, the expression of HPV-encoded genes can be 
affected by the presence of microRNAs (miRNAs) that effectively target mRNA 
transcripts. One of these candidates is miR-375, which was shown to interact with HPV 
16 and 18 E6 and E7 transcripts, thereby triggering their subsequent degradation by 
endonucleases of the RNA-induced silencing complex (RISC) (Jung et al. 2014). 
Moreover, this miRNA seems to play a tumor suppressive role in HPV-associated 
cancer types as it also suppresses the expression of important host cellular factors 
including the transcription factor Sp1, telomerase reverse transcriptase (TERT) and the 
E6-associated protein (E6AP) ((Bierkens et al. 2013, Jung et al. 2014, Wang et al. 2011) 
and reviewed in (Yan et al. 2014)). Expression of the gene encoding miR-375 was found 
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to be repressed by hypermethylation of its promoter, which can be observed in HPV-
associated preneoplastic lesions and invasive carcinomas (Wilting et al. 2013). 
In conclusion, the introduced concepts show that the deregulated expression of E6 and 
E7, especially in squamocolumnar junction cells, seems to be the key event for the shift 
from permissive to transforming HPV infections. Additionally, hypermethylation seems to 
play an important role in silencing suppressive factors involved in the regulation of HPV 
oncogene expression. Therefore, reversing hypermethylation in HPV-transformed 
tumors might be a potent therapeutic strategy to restore these regulatory mechanisms. 
As an alternative approach, it might be effective to target host cellular pathways that 
have been manipulated by the HPV oncogenes. The identification of such pathways and 
the involved factors requires the precise understanding of E6- and E7-mediated host 
cellular transformation, which in turn depends on the presence of powerful model 
systems. The following section summarizes the most important host cellular pathways 
and regulatory mechanisms that are affected by the HPV oncoproteins E6 and E7. 
 
1.3. Role of E6 and E7 during HPV-mediated carcinogenesis 
The hr-HPV proteins E6 and E7 are the main viral factors that facilitate the initiation and 
progression of HPV-associated cancers. The enhanced expression of both oncogenes 
seems to be the key event for the progression from permissive HPV infections (CIN 1) to 
transforming high-grade lesions (CIN 2, 3 and squamous cell carcinoma). During this 
process E6 and E7 interact with numerous host cellular proteins resulting in the 
deregulation of important pathways. Thereby, E6 and E7 have an impact on all cancer 
hallmarks described by Hanahan and Weinberg (Hanahan & Weinberg 2000) (Figure 4). 
The structure and the biological activity of these two proteins, including their binding 
partners and affected pathways, have been extensively studied resulting in various 
research papers and review articles, e.g. (Klingelhutz & Roman 2012, Moody & Laimins 
2010, Roman & Munger 2013). As a common feature, both oncoproteins relax cell cycle 
checkpoints, inhibit apoptosis and induce genomic instability upon overexpression in 
infected cells. 
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1.3.1. Hr-HPV E6 and E7 manipulate cell cycle regulation 
Permanent expression of hr-HPV E6 and E7 promotes the sustained proliferation of their 
host cells, which is mainly mediated by the inhibition of tumor suppressive proteins that 
play key roles in cell cycle regulation. Hr-HPV E7 effectively binds to pocket protein 
family members including the retinoblastoma protein (pRB), p107 and p130 resulting in 
their proteasomal degradation (Berezutskaya et al. 1997, Boyer et al. 1996, Genovese 
et al. 2008, Gonzalez et al. 2001, Zhang et al. 2006). The pocket protein family 
members are mainly involved in cell cycle regulation by inhibiting G1 to S-phase 
transition (reviewed in (Cobrinik 2005)). This function is predominantly mediated by their 
ability to bind to different members of the E2F transcription factor family. Upon 
phosphorylation of pocket proteins, E2F transcription factors are released promoting the 
expression of genes that stimulate cell cycle progression (Arroyo et al. 1993, Chellappan 
et al. 1992, Huang et al. 1993, Wu et al. 1993, Zerfass et al. 1995). Moreover, E2F 
transcription factor binding sites were found in promoters of genes regulating 
differentiation and apoptosis (DeGregori & Johnson 2006). To decelerate cell cycle 
progression the release of E2F transcription factors is prevented by the expression of 
p16INK4a, which inhibits cyclin dependent kinases, such as CDK4 and CDK6 that are 
needed for phosphorylation of pRb. By degrading pocket proteins, hr-HPV E7 efficiently 
blocks p16INK4a-mediated G1 cell cycle arrest (Giarre et al. 2001). Consequently, high 
levels of p16INK4a, as commonly detected in transforming HPV-associated lesions, are 
not able to inhibit cell cycle progression and can therefore be used as a marker for 
progressing HPV infections (reviewed in (von Knebel Doeberitz et al. 2012)). 
Degradation of pocket proteins and the resulting E2F-mediated cell cycle stimulation 
lead to accumulation of the cell cycle regulator p53 (Demers et al. 1994). The tumor 
suppressive protein p53 regulates the cell cycle, DNA damage response as well as the 
initiation of apoptosis and has therefore been described as “the guardian of the genome” 
(Lane 1992). During the cell cycle p53 levels increase in response to DNA damage 
frequently resulting from replicative stress (reviewed in (Lakin & Jackson 1999, Zeman & 
Cimprich 2014)). As a consequence, mitosis is arrested at the G1 or G2 checkpoint, 
respectively, and the DNA damage repair machinery is activated simultaneously. If the 
damaged DNA can be repaired, p53 levels will decrease again allowing the cell cycle to 
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continue. However, permanent presence of p53 resulting from irreparable DNA damage 
initiates apoptosis in affected cells (reviewed in (Fridman & Lowe 2003)). 
To overcome this growth inhibitory effect, hr-HPV E6 efficiently targets p53. This is 
mediated by the interaction between E6, p53 and the E6-associated protein (E6AP) 
forming a trimeric complex that results in the ubiquitination and proteasomal degradation 
of p53 (Huibregtse et al. 1993). Additionally, E6 can also bind to p53 in the absence of 
E6AP. Thereby, p53-mediated transcriptional regulation is blocked preventing the 
expression of genes involved in cell cycle arrest, DNA damage repair and apoptosis 
(Lechner & Laimins 1994). Moreover, the presence of hr-HPV E6 proteins indirectly 
influences the activity of p53 by binding histone acetyltransferases that are needed for 
p53 acetylation and stabilization (Patel et al. 1999, Zimmermann et al. 1999). Taken 
together, hr-HPV E6 and E7 work hand in hand to inactivate tumor suppressors 
subsequently deregulating the cell cycle and promoting the proliferation of infected cells. 
 
1.3.2. Expression of hr-HPV E6 and E7 prevents apoptosis 
Besides manipulating cell cycle control, overexpression of hr-HPV E6 and E7 also 
effectively inhibits apoptosis pathways. As mentioned previously, this is predominantly 
mediated by the ability of hr-HPV E6 to degrade p53. Moreover, hr-HPV E6 prevents 
apoptosis induced by tumor necrosis factors (TNFs) and by the Fas pathway ((Filippova 
et al. 2004, Filippova et al. 2002, Garnett et al. 2006) and reviewed in (Garnett & 
Duerksen-Hughes 2006)). However, not only hr-HPV E6, but also E7 is involved in 
manipulating apoptosis pathways by targeting different host cellular factors. The 
presence of hr-HPV E7 proteins stimulates PKB/Akt signaling, which promotes cell 
survival and prevents apoptosis (Pim et al. 2005). Furthermore, hr-HPV E7 targets the 
insulin-like growth factor binding protein 3 (IGFBP-3), which is overexpressed in 
senescent cells (Mannhardt et al. 2000). All in all, overexpression of hr-HPV E6 and E7 
effectively delays or even completely prevents the induction of apoptosis allowing the 
accumulation of highly DNA-damaged cells. 
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1.3.3. Effects of hr-HPV oncoproteins on genomic stability 
Generally, genomic instability can be defined as the inability of cells to preserve their 
genomic integrity during DNA replication and subsequent cell division. As most cancers 
show genetic or chromosomal alterations, genomic instability is assumed to be a cancer 
hallmark and seems to be necessary for tumor development (reviewed in (Negrini et al. 
2010)). Genomic instability can either be observed at the nucleotide level resulting in 
substitutions, insertions and deletions of nucleotides, or at the chromosomal level 
leading to gains and losses of whole chromosomes or to chromosomal translocation 
(Lengauer et al. 1998). The first of these two forms of genomic instability seems to be 
predominantly caused by biallelic mutations in DNA mismatch repair genes (e.g. hMLH1 
or hMSH2) resulting in the accumulation of mutations mainly located in long repetitive 
nucleotide stretches called microsatellites. Microsatellite instability (MSI) can be 
detected in several cancer types predominantly colorectal cancer (CRC). Despite their 
high mutation rate mismatch repair-deficient cancers are mostly diploid and show normal 
rates of chromosomal variations (reviewed in (Boland & Goel 2010)). 
In contrast, chromosomal instability is characterized by gains and losses of whole 
chromosomes resulting in the formation of aneuploid tumor cells. This form of genomic 
instability can be observed in the majority of cancers including HPV-related cancers 
((Olaharski et al. 2006) and reviewed in (Sen 2000)). The molecular basis of 
chromosomal instability seems to be the alteration of genes that regulate cell cycle 
progression and the precise allocation of chromosomes to the daughter cells during 
mitosis. 
As the expression of both HPV oncogenes effectively compromises DNA damage 
response pathways and deregulates cell cycle checkpoints, it is not surprising that 
chromosomal instability can be commonly observed in hr-HPV-associated cervical 
neoplasia and in HPV-immortalized cell lines (Hashida & Yasumoto 1991, Heselmeyer 
et al. 1996, Solinas-Toldo et al. 1997, White et al. 1994). Induction of chromosomal 
instability constitutes an early and central event during HPV-mediated transformation as 
HPV-associated lesions are already aneuploid at noninvasive stages (Bulten et al. 1998, 
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Duensing et al. 2000, Steinbeck 1997). In contrast, aneuploidy seems to be absent in 
lesions caused by lr-HPV types (Fu et al. 1981).  
 
1.3.4. Hr-HPV E6 and E7 affect centrosome duplication and mitotic fidelity 
Centrosomes are the main microtubule organizing organelles in the cell and therefore 
play an important role in the formation of spindle poles during mitosis. Generally, 
centrosomes consist of two centrioles (mother and daughter centriole) surrounded by 
pericentriolar material. Depending on the cell cycle phase cells contain either one or two 
centrosomes. During S phase of the cell cycle the centrosome is duplicated, which 
occurs concomitant to DNA replication (reviewed in (Brownlee & Rogers 2013)). 
Afterwards, the centrosomes migrate to opposite cell poles forming a bipolar spindle. 
Errors during centrosome replication potentially result in the formation of more than two 
spindle poles during mitosis, which can be a source for the generation of aneuploid 
daughter cells. 
Multipolar mitoses are common in cervical cancer and have been suggested as 
diagnostic marker for the progression of HPV-transformed cervical lesions (Crum et al. 
1984). Furthermore, it was found that the number of cells containing abnormal 
centrosomes increases with the progression of HPV-associated lesions (Skyldberg et al. 
2001). The generation of abnormal centrosome numbers seems to be associated with 
the overexpression of the hr-HPV oncogenes. Duensing et al. showed that stable HPV 
16 E6 and E7 expression promotes numerical centrosome abnormalities in normal 
human keratinocytes (NHKs) (Duensing et al. 2000). Under transient conditions the 
expression of HPV 16 E7 seems to play a predominant role, as the induction of 
abnormal centrosome numbers was observed already within 48 hours. In contrast, 
transient expression of HPV 16 E6 showed only minor influences on centrosome 
numbers (Duensing et al. 2000). 
Abnormal centrosome numbers can be the consequence of different mechanisms, which 
need to be distinguished, as the affected cells are assumed to show different risks to 
generate viable offspring. On the one hand, numeric centrosomal aberrations might 
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result from cytokinesis failures and errors during mitosis. As a consequence, the 
accumulation of centrosomes is accompanied by nuclear abnormalities including multi-
nucleation and the formation of micro-nuclei. However, the affected cells are assumed to 
mostly produce non-viable progeny and are therefore unlikely to contribute to the 
formation of chromosomally unstable cells. On the other hand, centrosome numbers can 
be increased by deregulated centrosome duplication control (overduplication) potentially 
as a consequence of the separation of DNA and centrosome replication during S phase 
of the cell cycle. These cells show fewer nuclear abnormalities and are more likely to 
generate viable, but chromosomally unstable daughter cells (reviewed in (Duensing 
2005)). 
The effect of HPV 16 E7 on the host cellular centrosome numbers seems to be caused 
by centrosome duplication errors because E7 expression was found to alter the ratio 
between mature and immature centrioles by increasing the proportion of functionally 
immature daughter centrioles (Duensing & Munger 2002). Consequently, abnormal 
centrosome numbers caused by HPV 16 E7 more likely originate from centrosome 
overduplication than from centrosome accumulation. The mechanism by which HPV 16 
E7 affects centrosome duplication seems to involve its ability to degrade pocket 
proteins. Many factors, which coordinate centrosome duplication, are activated by E2F 
including cdk2/cyclin A and cdk2/cyclin E complexes (Martin et al. 1998, Zerfass et al. 
1995). Therefore, hyperactivation of these factors might interfere with the tight coupling 
between centrosome and DNA duplication. 
Taken together, expression of hr-HPV E6 and E7 very likely induces accumulation as 
well as overduplication of centrosomes. During mitosis these cells are prone to form 
more than two spindle poles potentially generating aneuploid progeny. Although most of 
these cells might not be viable, even moderate increases in genetic variability may 
contribute to the selection and subsequent outgrowth of highly proliferative subclones. 
This process occurs over several years or even decades and eventually leads to the 
formation of HPV-associated tumors. 
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Figure 4: Deregulated expression of HPV 16 E6 and E7 affects all hallmarks of cancer. 
The host cellular pathways and factors manipulated by the deregulated expression of HPV 16 (A) E6 and 
(B) E7 are schematically illustrated. Thereby, both HPV 16 oncoproteins affect the hallmarks of cancer 
described by Hanahan and Weinberg highlighting the potency of continuous HPV 16 E6 and E7 expression 
in the malignant transformation of infected cells. The Figure was modified based on (Hanahan & Weinberg 
2000). 
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1.3.5. Hr-HPV E6 and E7 compromise genomic integrity 
In addition to the induction of centrosome duplication errors, expression of hr-HPV E6 
and E7 is associated with elevated rates of DNA damage (Duensing et al. 2000, 
Duensing & Munger 2002). Stable expression of HPV 16 E6 and E7 in NHK cells was 
shown to increase the number of DNA double strand breaks as detected by nuclear γ-
H2AX foci (Duensing & Munger 2002). Due to the E6-mediated degradation of p53 
highly DNA damaged cells may accumulate and seem to be specifically prone to 
chromosomal breakages. Moreover, these cells might undergo mitosis because cell 
cycle checkpoint control mechanisms are efficiently abrogated by both HPV 
oncoproteins. As a consequence, the frequency of lagging chromosomes and anaphase 
bridges during mitosis is elevated potentially giving rise to chromosomal changes in the 
resulting daughter cells. Thus, this effect seems to be another mechanism how hr-HPV 
E6 and E7 contribute to the induction of structural and numerical chromosome 
instabilities in their host cells. 
 
1.3.6. Epigenetic alterations upon hr-HPV oncogene expression 
Another important effect of hr-HPV E6 and E7 expression is the alteration of epigenetic 
patterns that may affect the expression of host cellular and viral genes. Hr-HPV E6 was 
detected to induce upregulation of DNA methyltransferase 1 (DNMT1) by suppressing its 
transcriptional inhibitor p53 (Au Yeung et al. 2010). In addition, HPV 16 E7 oncoproteins 
were shown to bind and subsequently enhance the activity of DNMT1 (Burgers et al. 
2007). The DNMT-stimulating effect of both oncoproteins was further substantiated by Li 
et al. who reported the reduced expression of several DNA methyltransferases (DNMT1, 
DNMT3A, DNMT3B and DNMT3L) upon short-hairpin RNA knock down of HPV 16 E6 
and E7 expression (Li et al. 2015). The authors also observed the re-activated 
expression of numerous tumor suppressor genes due to reduced methylation levels in 
their promoter regions. This study suggests that deregulated expression of hr-HPV E6 
and E7 might promote hypermethylation and subsequent silencing of tumor suppressive 
factors, which is frequently observed during progression from low-grade HPV-associated 
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lesions to transforming high-grade intraepithelial neoplasia (Bierkens et al. 2013, 
Henken et al. 2007, Laurson et al. 2010, Narayan et al. 2003). 
Overall, continuous expression of hr-HPV E6 and E7 deregulates important mechanisms 
in the host cells including cell cycle progression, apoptosis and gene expression. 
Thereby, both oncogenes establish an environment that stimulates permanent 
replication of infected cells. Malignant transformation seems to be further promoted by 
the induction of numerical and structural chromosomal instability causing high genetic 
variability. 
 
1.4. Therapeutic strategies 
As other cancer types, treatment of HPV-associated tumors involves three general and 
combinable options: surgery, radiotherapy and chemotherapy. The therapy of choice 
strongly depends on the diagnosed stage of the tumor. In early stages (stage 0 and I) 
the tumor can usually be resected either by conization, especially in cases with early 
stromal invasion, or by hysterectomy eliminating the risk for recurring cervical cancer. 
Depending on the diagnosed stage and the degree of tumor invasion in the surrounding 
tissue, surgery is combined with adjuvant radiotherapy or chemotherapy (reviewed in 
(Adams et al. 2014)). Most of the chemotherapeutic agents are either platinum-based 
substances (e.g. cisplatin or carboplatin) or taxanes (e.g. paclitaxel), which are 
frequently administered in combination resulting in increased response rates. Combined 
chemotherapy, however, results in low response rates between 25% and 35% in 
recurrent and metastatic tumors (Long et al. 2005, Moore et al. 2004). Furthermore, side 
effects can be severe as these agents are applied systemically and are not able to 
distinguish between tumor and normal cells. Therefore, novel therapeutic agents that 
target HPV-transformed cells more efficiently and more specifically are highly needed. 
Identification of potent substances, of relevant pathways as well as of prognostic 
biomarkers, in turn, depends on the development of model systems that precisely reflect 
the progression of HPV-associated tumors. 
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1.4.1. Vaccination approaches 
Generally, vaccination approaches can be divided into prophylactic and therapeutic 
strategies. Prophylactic vaccines mainly prevent the infection with hr-HPV types, 
whereas patients suffering from persistent HPV infections would only benefit from 
therapeutic vaccination approaches. Currently, there are three prophylactic vaccines 
commercially available: Cervarix® (GlaxoSmithKline), Gardasil® (Merck & Co) and 
Gardasil 9 (Merck & Co). Cervarix® is a bivalent vaccine, which contains virus like 
particles (VLPs) derived from HPV 16 and 18 L1 capsid proteins and therefore efficiently 
protects against HPV 16 and 18 infections. In addition, Gardasil® also prevents the 
infection with lr-HPV 6 and 11, which are responsible for a substantial number of genital 
warts. In 2014, the nine-valent vaccine Gardasil 9 was approved by the FDA additionally 
protecting against HPV 31, 33, 45, 52 and 58 (Petrosky et al. 2015). Although, cross-
protection may occur, vaccination is not assumed to prevent infections with HPV types 
that are not covered by the respective vaccine ((Combita et al. 2002) and reviewed in 
(Frazer 2010)). The main disadvantage of these approaches is their lack of therapeutic 
efficacy, as established HPV infections and especially high-grade lesions seem not to be 
cleared by using Cervarix® or Gardasil® ((Hildesheim et al. 2007) and reviewed in 
(Kanodia et al. 2008)). The lack of therapeutic efficacy might be explained by the 
observation that L1 capsid production decreases with the progression of HPV-
associated lesions, as high-grade lesions and HPV-associated tumors tend to show a 
low L1 expression rate (Lee et al. 2008, Yoshida et al. 2008). 
The development of therapeutic vaccines aims to overcome these limitations by initiating 
effective cellular immune responses (especially T cell-mediated) against HPV infected 
cells. Currently, several therapeutic vaccination approaches are investigated including 
trials based on VLPs, peptides, vectors or nucleic acids (reviewed in (Pouyanfard & 
Muller 2017) and (Su et al. 2010)). Frequently, these trials are designed to stimulate 
immune responses against viral antigens, mostly E6 and E7, as both are continuously 
expressed at high levels in HPV-associated lesions (reviewed in (Hung et al. 2007)). 
Moreover, host cellular proteins might be promising targets for vaccination. One of these 
candidates might be the cyclin dependent kinase inhibitor p16INK4A, which was shown to 
be strongly expressed in transforming HPV infections (reviewed in (von Knebel 
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Doeberitz et al. 2012)). Therefore, p16INK4A is widely used as a marker for progressing 
HPV-associated lesions. However, targeting proteins expressed by the host cells bears 
the risk of autoimmunity, which needs to be excluded before entering clinical trials. 
Altogether, the challenges for therapeutic vaccines are high as they need to induce 
strong immune responses and at the same time need to overcome immunosuppression 
in the tumor micro-environment as well as tumor evasion strategies. Therefore, the 
combination of immunotherapeutic and chemotherapeutic approaches might be an 
attractive future strategy. 
 
1.4.2. Demethylating agents 
As hypermethylation of important viral and host genes was shown to play an important 
role during HPV-mediated cervical carcinogenesis, the application of demethylating 
agents might be a promising approach for the treatment of HPV-associated lesions 
(reviewed (Johannsen & Lambert 2013, Steenbergen et al. 2014). Especially cytidine 
analogs have been extensively tested in cancer therapy (reviewed in (Gowher & Jeltsch 
2004). 5-aza-2'-deoxycytidine (decitabine or DAC) is one of the most prominent cytidine 
analogs and clinically used for the treatment of myelodysplastic syndrome (MDS) (Gore 
et al. 2006). The mechanism of action of DAC is highly dose dependent. Administered at 
high doses, DAC is incorporated into the DNA during replication and forms covalent 
adducts between DNMTs and the DNA causing cytotoxicity by inducing the formation of 
DNA double-strand breaks (DSBs) and subsequent apoptosis (Juttermann et al. 1994). 
At lower doses, DAC is incorporated into the DNA at much lower rates and exerts a 
demethylating effect by selectively inducing the proteasomal degradation of DNMT1 
((Creusot et al. 1982, Ghoshal et al. 2005, Jones & Taylor 1980) and reviewed in (Jones 
1985)). 
In addition to MDS, several studies investigated the effect of systemic DAC treatment on 
solid tumors. The patient response rate varied significantly between different types of 
cancer and was highly dependent on the administered dose (reviewed in (Cowan et al. 
2010, Nie et al. 2014)). However, these studies did not monitor the demethylating effect 
of the treatment in the respective tumor cells. Therefore, the patient response rates 
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cannot be correlated with the demethylation of the tumor cells complicating the 
interpretation of the results. The effects of DAC treatment on HPV-transformed tumor 
cells have also been investigated in in vitro studies. DAC treatment repressed 
proliferation of HPV-transformed cell lines, which was accompanied by reduced 
methylation levels in the viral and host cellular genome (Kalantari et al. 2008, Zhang et 
al. 2015). Especially, the E2 binding sites in the HPV genome were shown to become 
demethylated possibly explaining the decreased E6 and E7 expression, which has been 
observed in the HPV 16-transformed cell lines CaSki and UM-SCC-47 (Fernandez et al. 
2009, Zhang et al. 2015). 
Taken together, the application of DAC might represent a promising option to treat HPV-
associated lesions. There is, however, still a strong need for studies that systematically 
analyze the detailed effects of DAC treatment on HPV-transformed cell lines. 
 
1.5. Rationale and aims of the project 
The present thesis consists of two interconnected parts. In the first part the use of the 
demethylating agent DAC is systematically evaluated as a therapeutic approach to 
inhibit the overexpression of E6 and E7 in HPV-transformed cells and thereby to 
effectively prevent proliferation and colony formation of these cells. In the second part of 
the study a novel, cell line based model system is developed that allows the inducible 
expression of HPV 16 E6 and E7. Additionally, the validation of the biological relevance 
of the system as well as analyses to study the effects of HPV 16 oncogene expression 
on gene copy number variations and methylation levels are presented in this part. Figure 
5 summarizes the experimental steps that were performed in each of the project parts. 
Despite the progress in the development of prophylactic vaccines as well as in surgical 
methods, there is still a strong need for therapeutic agents especially for the treatment of 
late stage HPV-associated tumors. As discussed previously, hypermethylation of 
regulatory regions in the viral and host cell genome seems to play an important role 
during HPV-mediated transformation. Therefore, we hypothesized the reactivation of 
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these mechanisms by treating HPV-transformed cells with the demethylating substance 
DAC. 
Based on this assumption, a panel of hr-HPV-transformed cell lines was treated with 
different concentrations of DAC followed by the quantification of HPV oncogene 
expression, proliferation and colony formation. Furthermore, the study aimed to clarify 
potential mechanisms activated by DAC treatment that might be involved in the 
regulation of HPV oncogene expression. These include demethylation of E2BSs in the 
HPV upstream regulatory region as well as re-expression of miR-375, which has been 
shown to play a tumor suppressive role in HPV-mediated cancers by directly targeting 
and degrading E6 and E7 transcripts. 
Taken together, the first part of the present study addresses the following objectives: 
 Effects of DAC treatment on HPV oncogene expression, proliferation and 
colony formation in HPV-transformed cell lines 
 Identification of mechanisms that re-establish the regulation of HPV 
oncogene expression 
The development of novel and more targeted therapies, as well as the identification of 
biomarkers predicting the progression of HPV-associated lesions require the availability 
of model systems that precisely reflect the biology of HPV-transformed tumors. The 
knowledge about the effects of HPV oncogene expression on their host cells has mainly 
been derived from studies in primary human keratinocytes and in established cervical 
cancer cell lines. However, these model systems have some disadvantages, as on the 
one hand primary human keratinocytes are very critical for continuous culturing and can 
therefore not be used to study long-term effects of HPV oncogene expression. On the 
other hand, established cervical cancer cell lines are already transformed into immortal 
tumor cells and thus do not allow to analyze early mechanisms of deregulated HPV 
oncogene expression. Especially the induction of chromosomal instability, potentially 
caused by the overexpression of HPV E6 and E7, cannot be studied in cervical 
carcinoma cell lines, as these cells are already chromosomally unstable. 
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To overcome these limitations the aim of the second part of the study was to generate 
an inducible HPV 16 E6 and E7 expression system, which would allow investigating the 
consequences of both HPV 16 oncoproteins in a time-dependent manner. For this, the 
well-characterized and microsatellite-unstable colon cancer cell line HCT116 was 
selected (Brattain et al. 1981). This cell line shows a nearly diploid karyotype and very 
low rates of chromosomal alterations (Lengauer et al. 1997, Thompson & Compton 
2008). Therefore, HCT116 cells are considered as chromosomally stable making them 
specifically suitable to study HPV 16 E6- and E7-mediated effects on mitotic progression 
and genomic integrity. To facilitate inducible HPV 16 E6 and E7 expression in HCT116 
cells the previously published HCT116-HygTK clone was used, which enables the 
integration of the HPV 16 E6 and E7 genes as single copies into a defined chromosomal 
Figure 5: Overview of experimental strategy. 
The figure highlights major experimental steps conducted in the present study to analyze the effects of 
DAC treatment on HPV-transformed cell lines (A) as well as the effects of inducible HPV 16 E6 and E7 
expression on genomic stability in HCT116 cells (B). 
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locus (Lee et al. 2013). Thereby, disruption of host cellular genes during E6 and E7 
integration is avoided. After validating and characterizing the inducible system, the 
effects of HPV 16 oncogene expression on cell cycle progression and genomic integrity 
were investigated. In detail, this included the analysis of centrosome numbers in 
interphase cells, of spindle pole formation during mitosis, of DNA double strand break 
induction, of the number of aneuploid cells as well as of gene copy number variations. 
Additionally, alterations in host cellular gene expression and methylation levels were 
studied after induction of HPV 16 oncogene expression. 
In summary, the second part of the thesis aims to 
 generate and characterize an inducible HPV 16 E6 and E7 expression system 
 validate the biological relevance of the established system by studying the effects 
of HPV 16 E6 and E7 on chromosomal stability and genomic integrity 
 identify novel effects of E6 and E7 on gene expression and methylation patterns 
By evaluating the efficiency of DAC treatment in HPV-associated cancer cell lines and 
by studying the effects of HPV 16 oncogene expression on host cellular mechanisms, 
this thesis not only addresses basic scientific questions, but also focuses on 
translational approaches, which might serve as the basis for future clinical trials. 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Cell lines 
The cervical carcinoma cell line CaSki was purchased from CLS Cell Lines Service 
GmbH (Pattillo et al. 1977). The other cervical carcinoma cell lines C4-1 (Herz et al. 
1977), SiHa (Friedl et al. 1970) and SW756 (Freedman et al. 1982) were authenticated 
by multiplex human cell line authentication tests (Multiplexion). The head and neck 
squamous cell carcinoma (HNSCC) cell lines UM-SCC-47 and UM-SCC-104 were kindly 
provided by Professor Thomas E. Carey (University of Michigan) (Brenner et al. 2010, 
Tang et al. 2012). 
HCT116 is a commonly used and well characterized colorectal cancer cell line, which 
was established from a single human colonic carcinoma derived from a male patient in 
1981 (Brattain et al. 1981). Due to a mutation in the hMLH1 gene HCT116 cells are DNA 
mismatch repair (MMR) deficient causing MSI. Moreover, these cells carry a mutation in 
codon 13 of the ras proto-oncogene leading to growth stimulation. HCT116 cells contain 
a nearly diploid set of chromosomes and show low frequencies of chromosomal 
alterations (Ertych et al. 2014, Lengauer et al. 1997, Thompson & Compton 2008). 
Therefore, this cell line is considered as chromosomally stable. The parental master cell 
line HCT116-HygTK was kindly provided by Dr Jennifer Lee and Dr Johannes Gebert 
(Lee et al. 2013). 
 
2.1.2. Plasmids 
The plasmid S2F-cLM2CG-FRT3 was used to clone vectors that allow doxycycline 
(dox)-inducible expression of HPV 16 E6 and E7 (Loew et al. 2006, Weidenfeld et al. 
2009). S2F-cLM2CG-FRT3 encodes a tetracycline (tet)-controlled bidirectional promoter 
(Ptetbi) that facilitates transcription of the reporter genes firefly luciferase and mCherry 
(Supplementary Figure 1). The heterospecific Flp-recognition sites F3 and F are located 
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at the flanks of this expression cassette and were needed for subsequent 
recombination-mediated cassette exchange (RMCE) (Schlake & Bode 1994). 
The EcoRI/NotI cleavage sites were used to excise the mCherry fragment from the S2F-
cLM2CG-FRT3 vector and to replace it either by the sequence encoding HPV 16 E6 
(GenBank: K02718.1, nt 83-560) or HPV 16 E7 (GenBank: K02718.1, nt 562-858). 
Thereby, the retroviral vectors S2F-cLM2CG-FRT3-HPV16-E6 and S2F-cLM2CG-FRT3-
HPV16-E7 were generated. To clone the vector S2F-cLM2CG-FRT3-HPV16 E6-E7 for 
the expression of both HPV 16 oncogenes the mCherry fragment of S2F-cLM2CG-FRT3 
was replaced by the HPV 16 E6 sequence as described above. Afterwards, the 
sequence encoding HPV 16 E7 was inserted into the SalI/BamHI restriction site of the 
S2F-cLM2CG-FRT3-HPV16-E6 vector replacing the firefly luciferase reporter gene. 
Maps of the generated vectors can be found in Supplementary Figure 1. 
The vectors pVPack-GP and pVPack-VSV-G were used for retroviral assembly 
(Stratagene) and RMCE was mediated by the enzyme Flpo-recombinase encoded by 
the plasmid pCAGGS-Flpo-IRES-Puro obtained from Michael Hahn (DKFZ, Heidelberg). 
 
2.1.3. Primer 
Name Forward (5` - 3`) Reverse (5` - 3`) 
Amplicon 
(bp) 
Primers for RT-qPCR 
HPV 16 E6 
TTG CTT TTC GGG ATT 
TAT GC 
CAG GAC ACA GTG GCT 
TTT GA 
204 
HPV 16 E6*I 
ACT GCG ACG TGA GGT 
GTA TTA AC 
TGG AAT CTT TGC TTT 
TTG TCC 
85 
HPV 16 E7 
CAG CTC AGA GGA GGA 
GGA TG 
GCC CAT TAA CAG GTC 
TTC CA 
166 
HPV 18 E6*I 
TGT ATA TTG CAA GAC 
AGT ATT 
GCT GGA TTC AAC GGT 
TTC TGG 
249 
HPV 18 E7 
CCC CAA AAT GAA ATT 
CCG GT 
GTC GCT TAA TTG CTC 
GTG ACA TA 
51 
β-actin 
ATG TGG CCG AGG ACT 
TTG ATT 
AGT GGG GTG GCT TTT 
AGG ATG 
107 
Primers for methylation-specific qPCR 
Hsa-miR-375 
gene 
GGG GCG TTG TGT AGT 
ATT GAG TTC 
GAA ACG AAA ACG AAA 
AAC CCG 
91 
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β-actin gene 
TGG TGA TGG AGG AGG 
TTT AGT AAG T 
AAC CAA TAA AAC CTA 
CTC CTC CCT TAA 
133 
Primers for bisulfite-based pyrosequencing of HPV 16 E2BS 3 and 4 
Amplification 
primers 
TTG TAA AAT TGT ATA 
TGG GTG TG 
Bio- AAA TCC TAA AAC 
ATT ACA ATT CTC 
180 
Sequencing 
primer 
AAT TTA TGT ATA AAA 
TTA AGG G 
  
Primers for cloning of HPV 16 E6 and E7 
HPV 16 E6 
(EcoRI and 
NotI) 
ATG AAT TCG CCA CCA 
TGC ACC AAA AGA GAA 
CTG CAA TG 
ATG CGG CCG CTT ACA 
GCT GGG TTT CTC TAC 
GTG 
501 
HPV 16 E7 
(EcoRI and 
NotI) 
ATG AAT TCG CCA CCA 
TGC ATG GAG ATA CAC 
CTA CAT TG 
ATG CGG CCG CTT ATG 
GTT TCT GAG AAC AGA 
TGG G 
321 
HPV 16 E7 
(SalI and 
BamHI) 
ATG TCG ACG CCA CCA 
TGC ATG GAG ATA CAC 
CTA CAT TG 
ATA GGA TCC GTT ATG 
GTT TCT GAG AAC AGA 
TGG G 
321 
Sequencing primer for HPV 16 E6 and E7 
HPV 16 E6 
ATG CAC CAA AAG AGA 
ACT GCA ATG 
TTA CAG CTG GGT TTC 
TCT ACG TG 
477 
HPV 16 E7 
ATG CAT GGA GAT ACA 
CCT ACA TTG C 
TTA TGG TTT CTG AGA 
ACA GAT GG 
297 
Transcriptome validation 
KLF11 
AGG GAG CTG TGA TGT 
TGG TC 
TCC TCC TTC GGG AAA 
AGT CT 
171 
PKM2 
ATT ATT TGA GGA ACT 
CCG CCG CCT 
ATT CCG GGT CAC AGC 
AAT GAT GG 
190 
BLOC1S1 
CCC AAT TTG CCA AGC 
AGA CA 
CAT CCC CAA TTT CCT 
TGA GTG C 
78 
VSNL1 
AAG TGA TGG AGG ACC 
TGG TG 
GTC GCT CTT TGC AGC 
TTC TT 
503 
CKLF 
TCG CTT CGC AGA ACC 
TAC TCA 
TAT TTT CGG CTG CAC 
GTT ATC C 
100 
PLK2 
CCA CCA TTC GCA CTC G CGG CGT AGA CTT TGT 
TAT TT 
149 
CDKN1A 
GTA CCA CCC AGC GGA 
CAA GT 
CCT CAT CCC GTG TTC 
TCC TTT 
97 
TP53I3 
GGC CAG GAA CAA TAT 
GTT AGC C 
GTG GGT CAT ACT GGC 
CTT GTC T 
173 
PERP 
GGC TTC ATC ATC CTG 
GTG AT 
ACA GCA GCC AAG GCA 
AGG AG 
110 
TP53INP3 
TTT CCT GTT TAC CGG 
CAT CTC T 
TGG ACA TGA CTC AAA 
CTG GAG AA 
77 
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2.1.4. Antibodies 
Antibody Source Clone 
Application 
(Dilution) 
Company (City, 
Country) 
β-actin mouse mAb C4 WB (1:20,000) 
MP Biomedicals 
(Solon, USA) 
γ-tubulin mouse mAb GTU-88 IF (1:100) 
Sigma-Aldrich 
(Taufkirchen, 
Germany) 
HPV 16 E7 mouse mAb NM-2 WB (1:500) 
Santa Cruz 
Biotechnology 
(Santa Cruz, 
USA) 
HPV 18 E7 mouse mAb F-7 WB (1:500) 
Santa Cruz 
Biotechnology 
(Santa Cruz, 
USA) 
Mouse IgG-
Alexa488 
goat pAb  IF (1:750) 
Thermo Fisher 
Scientific (Ulm, 
Germany) 
p21 rabbit pAb C-19 WB (1:200) 
Santa Cruz 
Biotechnology 
(Santa Cruz, 
USA) 
p53 mouse mAb DO-1 WB (1:500) 
Santa Cruz 
Biotechnology 
(Santa Cruz, 
USA) 
Phospho-
Histone H2A.X 
(Ser 139) 
rabbit mAb 20E3 IF (1:200) 
Cell Signaling 
Technology 
(Danvers, USA) 
Rabbit IgG-
Alexa488 
goat pAb  IF (1:750) 
Thermo Fisher 
Scientific (Ulm, 
Germany) 
 
2.1.5. Enzymes 
Enzyme Company (City, Country) 
Absolute qPCR SYBR Green ROX Mix Thermo Fisher Scientific (Ulm, Germany) 
BamHI New England Biolabs (Frankfurt, Germany) 
DNase I, Amplification Grade Life Technologies (Darmstadt, Germany) 
EcoRI New England Biolabs (Frankfurt, Germany) 
HOT FIREPol DNA Polymerase Solis Biodyne (Tartu, Estonia) 
NotI New England Biolabs (Frankfurt, Germany) 
Phusion High-Fidelity DNA Polymerase Thermo Fisher Scientific (Ulm, Germany) 
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(Platinum) Taq DNA Polymerase Life Technologies (Darmstadt, Germany) 
RNase A Thermo Fisher Scientific (Ulm, Germany) 
SalI New England Biolabs (Frankfurt, Germany) 
SuperScript II Reverse Transcriptase Life Technologies (Darmstadt, Germany) 
TaqMan® Universal PCR Master Mix Thermo Fisher Scientific (Ulm, Germany) 
 
2.1.6. Buffer 
Buffer Ingredients 
Crystal violet staining solution 
25% ethanol 
1% formaldehyde 
0.125% NaCl 
0.25% crystal violet 
ad H2O 
TE-Buffer 
10 mM Tris-HCl 
1 mM EDTA 
Western Blot Buffer I 
300 mM Tris 
20% methanol 
pH 10.4 
Western Blot Buffer II 
25 mM Tris 
20% methanol 
pH 10.4 
Western Blot Buffer III 
25 mM Tris 
40 mM norleucine 
20% methanol 
pH 9.4 
 
2.1.7. Reagents 
Reagent Company (City, Country) 
5-aza-2`-deoxycytidine (Decitabine) Sigma-Aldrich (Taufkirchen, Germany) 
Bacto-agar Fluka Chemie (Buchs, Switzerland) 
BigDye® Terminator v1.1 Ready Reaction 
Mix 
Thermo Fisher Scientific (Ulm, Germany) 
BSA Sigma-Aldrich (Taufkirchen, Germany) 
Bromophenol blue Schmid (Köngen, Germany) 
Crystal Violet Sigma-Aldrich (Taufkirchen, Germany) 
DL-Norleucine Sigma-Aldrich (Taufkirchen, Germany) 
DMEM Thermo Fisher Scientific (Ulm, Germany) 
DMSO Serva (Heidelberg, Germany) 
DNA ladder Thermo Fisher Scientific (Ulm, Germany) 
dNTP Set (100 mM) Life Technologies (Darmstadt, Germany) 
Donkey serum Sigma-Aldrich (Taufkirchen, Germany) 
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Doxycycline Sigma-Aldrich (Taufkirchen, Germany) 
DTT Life Technologies (Darmstadt, Germany) 
Ethanol Sigma-Aldrich (Taufkirchen, Germany) 
FBS Thermo Fisher Scientific (Ulm, Germany) 
Formaldehyde Sigma-Aldrich (Taufkirchen, Germany) 
Ganciclovir Sigma-Aldrich (Taufkirchen, Germany) 
Gentamicin Thermo Fisher Scientific (Ulm, Germany) 
Glutamine Thermo Fisher Scientific (Ulm, Germany) 
Goat serum Sigma-Aldrich (Taufkirchen, Germany) 
Hi-Di™ Formamide Life Technologies (Darmstadt, Germany) 
Hygromycin B Sigma-Aldrich (Taufkirchen, Germany) 
Isopropanol 
Center of distribution, University of 
Heidelberg (Heidelberg, Germany) 
Kodak BioMax films Sigma-Aldrich (Taufkirchen, Germany) 
Laemmli Buffer Sigma-Aldrich (Taufkirchen, Germany) 
MEM Non-Essential Amino Acids Solution 
(100x) 
Thermo Fisher Scientific (Ulm, Germany) 
β-Mercaptoethanol Sigma-Aldrich (Taufkirchen, Germany) 
Methanol Carl Roth (Karlsruhe, Germany) 
Midori Green Biozym (Hessisch Oldendorf, Germany) 
Na2EDTA Sigma-Aldrich (Taufkirchen, Germany) 
Norleucine Sigma-Aldrich (Taufkirchen, Germany) 
NuPAGE® Sample Reducing Agent (10x) Life Technologies (Darmstadt, Germany) 
Oligo(dT) primers Life Technologies (Darmstadt, Germany) 
PBS Thermo Fisher Scientific (Ulm, Germany) 
Penicillin/streptomycin Thermo Fisher Scientific (Ulm, Germany) 
Phosphatase inhibitor Sigma-Aldrich (Taufkirchen, Germany) 
Ponceau Red Sigma-Aldrich (Taufkirchen, Germany) 
Precision Plus Protein™ Prestained 
Standard 
Bio-Rad Laboratories (München, 
Germany) 
Propidium iodide Sigma-Aldrich (Taufkirchen, Germany) 
Protease inhibitor Sigma-Aldrich (Taufkirchen, Germany) 
PyroMark 10x Wash Buffer Qiagen (Hilden, Germany) 
PyroMark Annealing Buffer Qiagen (Hilden, Germany) 
PyroMark Binding Buffer Qiagen (Hilden, Germany) 
PyroMark Q24 Gold Reagents Qiagen (Hilden, Germany) 
Quick Start ™ Bradford 1x Dye Reagent 
Bio-Rad Laboratories (München, 
Germany) 
Recovery ™ Cell Culture Freezing Medium Thermo Fisher Scientific (Ulm, Germany) 
Restore™ Western Blot Stripping Buffer Thermo Fisher Scientific (Ulm, Germany) 
RIPA buffer Sigma-Aldrich (Taufkirchen, Germany) 
RNaseOUT Life Technologies (Darmstadt, Germany) 
RPMI Thermo Fisher Scientific (Ulm, Germany) 
Single-stranded random hexanucleotides Bioron (Ludwigshafen, Germany) 
S.O.C medium Life Technologies (Darmstadt, Germany) 
Sodium acetate J.T. Baker (Deventer, Netherland) 
2. Materials and Methods 
 
31 
 
Sodium chloride (NaCl) Sigma-Aldrich (Taufkirchen, Germany) 
Sodium hydroxide (NaOH) Carl Roth (Karlsruhe, Germany) 
SYBR Green ROX Mix Thermo Fisher Scientific (Ulm, Germany) 
TBE buffer AppliChem (Darmstadt, Germany) 
Tris-base Carl Roth (Karlsruhe, Germany) 
Tris/Glycine/SDS Running buffer (10x) 
Bio-Rad Laboratories (München, 
Germany) 
Tris-HCl Carl Roth (Karlsruhe, Germany) 
Triton-X-100 Sigma-Aldrich (Taufkirchen, Germany) 
Trypan blue Sigma-Aldrich (Taufkirchen, Germany) 
Trypsin-EDTA Thermo Fisher Scientific (Ulm, Germany) 
Tween-20 Sigma-Aldrich (Taufkirchen, Germany) 
UltraPureTM agarose Life Technologies (Darmstadt, Germany) 
Water, DNase, RNase-FREE MP Biomedicals (Solon, USA) 
 
2.1.8. Kits 
Kit Company (City, Country) 
Blood and Cell Culture DNA Mini Kit Qiagen (Hilden, Germany) 
CyQuant® NF Cell Proliferation Assay Kit Thermo Fisher Scientific (Ulm, Germany) 
CytoTox 96® Non-Radioactive Cytotoxicity 
Assay 
Promega (Madison, USA) 
High Pure PCR Product Purification Kit Roche (Mannheim, Germany) 
Methylamp™ DNA Modification Kit Epigentek (Farmingdale, USA) 
Novex Western Breeze Chemiluminescent 
Immunodetection System 
Thermo Fisher Scientific (Ulm, Germany) 
NucleoSpin Plasmid Kit Machery Nagel (Düren, Germany) 
PyroMark LINE-1 Kit Qiagen (Hilden, Germany) 
QIAquick Gel Extraction Kit Qiagen (Hilden, Germany) 
QIAquick® PCR Purification Kit Qiagen (Hilden, Germany) 
RNeasy Mini Kit Qiagen (Hilden, Germany) 
SuperScript® II Reverse Transcriptase Kit Thermo Fisher Scientific (Ulm, Germany) 
TaqMan® MicroRNA Assay miR-375 Thermo Fisher Scientific (Ulm, Germany) 
TaqMan® MicroRNA Assay snRNA U6 Thermo Fisher Scientific (Ulm, Germany) 
TaqMan® MicroRNA Reverse 
Transcription Kit 
Thermo Fisher Scientific (Ulm, Germany) 
 
2.1.9. Instruments 
Instrument Company (City, Country) 
Cell Culture Hood (Biowizard Silverline) 
Ewald Innovationstechnik GmbH (Bad 
Nenndorf, Germany) 
Centrifuge (Heraeus Fresco 21) Heraeus Instruments (Hanau, Germany) 
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Centrifuge (5810 R) 
 
Eppendorf (Hamburg, Germany) 
 
Centrifuge (Microcentrifuge 1-14) 
Sigma Laborzentrifugen (Osterode, 
Germany) 
ChemiDoc Imaging System Bio-Rad Laboratories (Munich, Germany) 
FACS (FACSCalibur) Becton Dickinson (Franklin Lakes, USA) 
Ice Machine 
Ziegra Eismaschinen GmbH (Isernhagen, 
Germany) 
Incubator Heraeus Holding (Hanau, Germany) 
Luminometer (Lumat LB 9507) 
Berthold Technologies (Bad Wildbad, 
Germany) 
Microscope (Leica DM5000 B) Leica (Bensheim, Germany) 
Microscope (Olympus CK40) Olympus (Hamburg, Germany) 
Microwave Siemens (Munich, Germany) 
Photometer (Ultrospec 3300) Amersham Pharmacia (Cambridge, UK) 
Pipettes (10 μL; 20 μL; 200 μL; 1000 μL) Gilson (Limburg-Offheim, Germany) 
Power supply (Power Pac 300) Bio-Rad Laboratories (Munich, Germany) 
Protein Electrophoresis System (NuPAGE) Thermo Fisher Scientific (Ulm, Germany) 
Real-Time PCR System (StepOnePlus) Life Technologies (Darmstadt, Germany) 
Scale BP 310 S Sartorius (Göttingen, Germany) 
Shaker Certomat H Sartorius (Göttingen, Germany) 
Spectrophotometer Nanodrop (ND-1000) Thermo Fisher Scientific (Ulm, Germany) 
Thermocycler (peqStar 96 universal) 
VWR International GmbH (Erlangen, 
Germany) 
Thermomixer (5436) Eppendorf (Hamburg, Germany) 
Ultracentrifuge (TLA-100.2) Beckmann Coulter (Krefeld, Germany) 
Ultrasound UW 2070 Bandelin electronics (Berlin, Germany) 
Vortex (MS1 Minishaker) IKA (Staufen, Germany) 
Waterbath Grant (Cambridge, UK) 
 
2.2. Methods 
2.2.1. Cell culture techniques 
2.2.1.1. Maintenance of cell lines 
C4-1, CaSki, SiHa, SW756 and HCT116 cells were cultured in DMEM (Gibco) 
supplemented with heat-inactivated 10% FBS (Gibco) and 1% penicillin/streptomycin 
(Gibco). The HNSCC cell lines UM-SCC-47 and UM-SCC-104 were grown in RPMI 
(Gibco) containing 10% FBS (Gibco), 1% MEM Non-Essential Amino Acids Solution 
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(Gibco), 1% glutamine (Gibco) and 25 µg/mL gentamicin (Gibco). All cell lines were 
cultured in a humidified incubator at 37 °C and 5% CO2. 
Confluent grown cells were splitted 1:10 or 1:20. For this, the growth medium was 
removed and the cells were washed once with pre-warmed PBS (Gibco). To detach the 
cells 0.05% Trypsin-EDTA (Gibco) was added and the cells were incubated at 37 °C. 
After cell detachment growth medium was added to inactivate the Trypsin-EDTA and the 
cells were collected in a falcon tube. Finally, the appropriate volume of collected cells 
was transferred back into the cell flask, growth medium was added and the cell flask 
was incubated in a humidified incubator at 37 °C and 5% CO2 until further use. 
 
2.2.1.2. Cryo-conservation and reculturing of cell lines 
For long-term storage the cells were harvested and pelleted by centrifugation at 1,200 
rpm for 5 minutes (min) and 4 °C. The cell pellet was resuspended in Recovery ™ Cell 
Culture Freezing Medium (Gibco) containing 10% DMSO. Afterwards, 5x106 cells were 
transferred to cryo-vials, which were then gradually cooled to -80 °C in an isopropanol 
containing cell freezing box overnight. The cells were then stored in liquid nitrogen. 
Reculturing was performed by thawing frozen cell vials at 37 °C and then transferring 
the cells to a centrifuge tube. After centrifugation at 1,200 rpm for 5 min the DMSO-
containing freezing medium was removed, the pelleted cells were resuspended in pre-
warmed growth medium and the suspension was transferred into T75 cell culture flasks. 
The cells were incubated in a humidified incubator at 37 °C and 5% CO2 until further 
use. 
 
2.2.1.3. Determination of cell number and viability 
Before applying different substances the number of seeded cells was determined. For 
this, harvested cells were diluted with trypan blue solution in a 1:1 ratio. Trypan blue is a 
diazo dye, which cannot pass intact cell membranes. The substance, however, 
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penetrates the membrane of necrotic and apoptotic cells and is therefore used as a 
marker to distinguish dead from intact cells. 
The cells were counted by using a hemocytometer (Neubauer improved counting 
chamber). The number of cells was quantified in at least four quarters of the counting 
chamber. Each quarter has the volume of 0.1 mm³. Thus, the mean number of cells per 
quarter was multiplied with 104 to calculate the number of cells per mL in the dilution. 
Finally, the result was multiplied with the dilution factor to receive the number of cells per 
mL in the original suspension. 
Suspension [cells/mL] = 
                        
                          
                   
 
2.2.1.4. Treatment of HPV-transformed cell lines with 5-aza-2`-deoxycytidine 
In order to treat CaSki, SiHa, UM-SCC-47, UM-SCC-104, C4-1 and SW756 cells with 5-
aza-2`-deoxycytidine (DAC), the cells were seeded in T75 cell culture flasks and kept 
without treatment for 24 hours to allow adherence of the cells. Afterwards, one of the 
following concentrations of DAC dissolved in DMSO was added: 0.1, 0.5 or 1.0 µM. Half 
of the medium was changed every 24 hours and fresh DAC-containing medium was 
added. The treatment was continued for 72 hours and the cells were harvested 
afterwards. 
 
2.2.1.5. Hygromycin B and ganciclovir treatment 
Presence of the HygTK expression cassette in the generated HCT116 clones was 
monitored by treating the cells with hygromycin B and with ganciclovir. Therefore, the 
cells were seeded in a 12-well plate format and treated by adding growth medium 
containing 200 µg/mL hygromycin B or 40 µM ganciclovir. The medium was renewed 
every 24 hours and after a total treatment period of seven days the cells were fixed and 
stained using crystal violet as described in the respective section. 
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2.2.1.6. Dox treatment of inducible HCT116 cell clones 
HCT116 cell clones generated for inducible expression of HPV 16 E6, E7 or E6 and E7 
were treated over different time periods and with different concentrations of dox to 
analyse the effects of HPV 16 oncogene expression (Table 1). Therefore, the cells were 
seeded in 10 cm plates containing DMEM supplemented with 10% FBS, 1% 
penicillin/streptomycin as well as 100 or 500 ng/mL dox. The growth medium was 
renewed every 48 hours. After the treatment the cells were harvested and pelleted by 
centrifugation at 1,200 rpm for 5 min at 4 °C. Cell pellets were stored at -80 °C until 
further use. 
To characterize the induction and silencing of the dox-sensitive promoter in a time 
dependent manner, dox was removed from the growth medium and HPV 16 E6 and E7 
levels were quantified after different time periods. For this, the HCT116 cell clones were 
seeded as described previously and treated with 500 ng/mL dox for 48 hours. 
Afterwards, the dox-containing growth medium was removed and the cells were washed 
three times with dox-free growth medium and then cultured in dox-free growth medium. 
The cells were then harvested six hours, 24 hours and 48 hours later. The cell pellets 
were stored at -80 °C until they were used for E6 and E7 mRNA or protein 
quantification. 
Table 1: List of time periods, dox concentrations and number of seeded cells used for the 
treatment of HCT116-HPV 16 E6 and E7 cell clones. 
Duration of treatment Dox concentrations Number of seeded cells 
48 hours 100 and 500 ng/mL 1.5x106 
96 hours 500 ng/mL 0.5x106 
9 days 100 and 500 ng/mL 0.1x106 
Dox removal experiment 
54 hours 
48 hours 500 ng/mL 
1.5x106 
6 hours no dox 
72 hours 
48 hours 500 ng/mL 
0.7x106 
24 hours no dox 
96 hours 
48 hours 500 ng/mL 
0.5x106 
48 hours no dox 
 
2. Materials and Methods 
 
36 
 
2.2.1.7. Crystal violet staining 
Crystal violet staining supports the visualization of cell colonies and can therefore be 
used to monitor colony formation. After the respective treatment, the cells were washed 
with PBS (Gibco) and stained with crystal violet staining solution consisting of H20, 25% 
ethanol (Sigma Aldrich), 1% formaldehyde (Sigma Aldrich), 0.125% NaCl (Sigma 
Aldrich) and 0.25% Crystal Violet (Sigma Aldrich) for 60 seconds (s). After several 
washing steps using PBS (Gibco), images were taken using an Olympus CK40 
microscope. 
 
2.2.1.8. Proliferation Assay 
Cell proliferation of DAC-treated cell lines as well as of HCT116-HPV 16 oncogene 
expressing clones was quantified using the CyQuant® NF Cell Proliferation Assay Kit 
(Invitrogen) according to the manufacturer`s protocol. The assay employs a fluorescent 
dye that binds to the DNA. Thereby, cell proliferation is indirectly determined by 
measuring the DNA content. 
To analyse the effect of HPV 16 oncogene expression on proliferation in HCT116 cells, 
4000 cells were seeded per well in a 96-well plate format and treated with 500 ng/mL 
dox to induce HPV 16 oncogene expression as described previously. Proliferation was 
then quantified after six, 24, 48, 72 and 96 hours. The dox-containing growth medium 
was renewed every 48 hours. 
The effects of DAC treatment on cell proliferation was analysed by seeding the cells into 
96-well plates (1000 cells/well) and treating the cells as described previously. 
Afterwards, the growth medium was removed and 50 µL of dye solution (containing 
CyQuant NF dye reagent) was added. The cells were then incubated for 30 min at 37°C. 
Finally, incorporation of the fluorescence dye was measured by using a plate reader 
(excitation at 485 nm and emission at 542 nm). 
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2.2.1.9. Transfection of miR-375 in CaSki and SiHa cells 
The effects of miR-375 on HPV 16 oncogene expression in CaSki and SiHa cells were 
investigated by transfecting miR-375 mimics. For this, the cells were seeded in six well 
plates and cultured at 37°C and 5% CO2 for 48 hours. At the time of transfection the 
cells were approx. 70% confluent. Transfection was performed by diluting Lipofectamine 
2000 (Invitrogen) in OptiMEM (Gibco) reduced serum medium in a ratio of 1:10. Next, 
hsa-miR-375 mimics (Sigma Aldrich) and non-specific negative controls (Mission® 
miRNA, Negative Control 1, Sigma Aldrich) were diluted in OptiMEM (Gibco), added to 
the diluted Lipofectamine 2000 in a ratio of 1:1, incubated for 5 min at room temperature 
and then pipetted dropwise to the medium of the cells to reach a final concentration of 
100 nM for hsa-miR-375 and 25 nM for non-specific negative controls. Afterwards, the 
cells were incubated at 37°C and 5% CO2 for 48 hours and then harvested, pelleted and 
frozen at -80 °C until they were used to quantify HPV 16 oncogene expression. 
 
2.2.1.10. Quantification of aneuploid cells 
Flow cytometry of propidium iodide (PI) stained HCT116 clones was performed to 
quantify the DNA content indicating the cell cycle phase. For this, dox-treated HCT116 
clones were harvested using trypsin and washed with PBS. The cells were then fixed 
and permeabilized by adding ice-cold 70% ethanol. The cells were vortexed gently to 
prevent cell aggregation and incubated for one hour at -20 °C. Afterwards, the ethanol-
suspended cells were centrifuged for 5 min at 300 g, the ethanol was removed and the 
cells were washed twice with cold PBS. To degrade RNA, 106 cells were resuspended in 
1 mL PBS, 50 µg RNase A (Thermo Fisher) was added and the cell suspension was 
incubated for 45 min at 37 °C. Next, PI (Sigma Aldrich) was added to a final 
concentration of 10 µg/mL and the suspension was kept in the dark for 30 min at room 
temperature. PI stained DNA was then measured using flow cytometry (BD 
FACSCalibur). Histograms were prepared to assign the cells to the different cell cycle 
phases, thereby allowing distinguishing between subG1, G1, S, G2/M and aneuploid 
cells. Control samples lacking either PI staining or RNase A treatment were prepared 
and analysed for every treatment condition. 
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2.2.2. Cloning and sequencing 
2.2.2.1. Isolation of genomic DNA 
Whole DNA was extracted by using the Blood and Cell Culture DNA Mini Kit (Qiagen) as 
recommended by the manufacturer`s protocol. Afterwards, the DNA concentration was 
measured spectrophotometrically at 260 nm using a NanoDrop 1000 Spectrophoto-
meter. 
 
2.2.2.2. Polymerase chain reaction (PCR) 
PCR was performed to amplify DNA sequences for subsequent cloning procedures, to 
confirm the presence of an inserted DNA fragment and to provide enough copies for 
sequencing reactions. 
The amplification of inserts for subsequent cloning procedures was performed utilizing 
Phusion High-Fidelity DNA Polymerase with proofreading capability. The reactions 
consisted of 4 µL template DNA (20 ng), 2.5 µL 10x buffer, 2 µL MgCl2 (25 mM), 2.5 µL 
dNTPs (2 mM), 2.5 µL primer (forward and reverse, 5 µM), 0.125 µL Phusion DNA 
Polymerase (5 U/µL) and DNase- and RNase-free water to a final volume of 25 µL. After 
preparing the reactions on ice, PCR was performed using the following cycling 
conditions: initial denaturation at 95 °C for 15 min, 30-40 cycles consisting of 
denaturation at 95 °C for 30 s, annealing at 60 °C for 30 s and elongation at 72 °C for 
30-60 s and a final elongation step at 72 °C for 2-10 min. Amplification of the HPV 16 
oncogenes for the generation of S2F-cLM2CG-FRT3-HPV16 E6 and/or E7 was 
conducted by using primers that either carried EcoRI and NotI or SalI and BamHI 
restriction sites. The amplified PCR products were then purified using the High Pure 
PCR Product Purification Kit (Roche), following the manufacturer`s instructions. 
To confirm correct expression of the inserted HPV 16 E6- and E7-coding sequences in 
the generated HCT116 clones, transcription was first induced by treating the clones with 
dox and the expressed E6 and E7 mRNA was then sequenced. Therefore, the purified 
RNA isolated from dox-treated HCT116 clones was transcribed into cDNA as described 
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in section 2.2.3.3. Reverse Transcription. Afterwards, E6 and E7 transcripts were 
amplified by utilizing specific primers (listed in chapter 2.1.3. Primer). The following 
components and concentrations were used for PCR amplification: 5 µL template cDNA 
(10 ng), 2.5 µL 10x PCR buffer, 0.75 µL MgCl2 (50 mM), 0.5 µL dNTPs (10 mM), 1 µL 
primer (forward and reverse, 15 µM), 0.2 µL Platinum Taq Polymerase (5 U/µL) and 
DNase-, RNase-free water to a final volume of 25 µL. After preparing the amplification 
reaction on ice, the PCR tubes were briefly centrifuged and transferred into a PCR 
cycler. The program run to amplify the DNA fragments included the following steps: 
initial denaturation at 95 °C 5 min, 38 cycles consisting of denaturation at 95 °C for 30 s, 
annealing at 53 °C (E6) or 48 °C (E7) for 30 s and elongation at 72 °C for 30 s as well as 
final elongation at 72 °C for 7 min. Afterwards, the size of the PCR products was 
analysed by agarose gel electrophoresis. 
 
2.2.2.3. Agarose gel electrophoresis 
Agarose gel electrophoresis was used to assess the amplification and the size of PCR 
products. Phosphate residues in the DNA carry negative electric charges and therefore 
move towards the positively charged anode when applying an electric field during 
electrophoresis. The velocity of the migrating DNA sequences correlates with the size of 
the fragments. The separated DNA fragments can then be visualized by using DNA 
binding dyes (e.g. Midori Green). 
1% agarose gels were prepared by dissolving 1 g of powdered agarose in 100 mL 1x 
TBE buffer. The solution was then boiled until the agarose was completely dissolved und 
cooled at room temperature to approx. 60 °C. Afterwards, Midori Green dye was added 
(1:25,000) and the solution was poured into a gel casting tray. A comb was inserted and 
after solidifying the gel was transferred into the running chamber containing 1x TBE 
buffer. 5 µL of the PCR product was mixed with 6x loading dye and pipetted into the 
pockets of the gel after removing the comb. To quantify the size of the PCR fragments 
the 100 bp DNA ladder (Invitrogen) was included as a reference marker. The 
electrophoresis was then performed for 30 min at 120 V and the DNA fragments were 
visualized under UV light. 
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2.2.2.4. Restriction digest 
Restriction endonucleases were used to cut DNA at specific recognition sites. For sticky 
end ligation the PCR products of HPV 16 E6 and E7, as well as the vector S2F-
cLM2CG-FRT3 were cleaved in a double digestion either using EcoRI and NotI or SalI 
and BamHI. The reactions were conducted utilizing 30 µg of vector DNA and 80 µL of 
purified PCR product. Next, BSA, NEBuffer compatible to the respective enzyme, 
double-distilled water and the restriction endonucleases (40 U/µL, NEB) were added to 
the DNA and the reaction was incubated for at least three hours at 37 °C. The enzymes 
were then heat-inactivated for 20 min at 65 °C. Afterwards, proper digestion of the 
vector DNA was confirmed using agarose gel electrophoresis. The vector DNA was then 
excised from the gel and purified using the QIAquick Gel Extraction Kit (Qiagen) 
following the manufacturer`s protocol. 
 
2.2.2.5. Dephosphorylation and ligation 
For the cloning of S2F-cLM2CG-FRT3-HPV16-E6 and/or E7 plasmids, 
dephosphorylation and ligation were carried out using the Rapid DNA Dephos & Ligation 
Kit (Roche) as recommended by the manufacturer`s instructions. A molar ratio of 1:5 
(vector:insert) was applied. Vector self-ligation was monitored by performing the reaction 
in the absence of insert DNA. 
 
2.2.2.6. Bacterial transformation 
Chemocompetent E.coli DH5α was used for transformation of the ligation product. 
Briefly, 50 µL of bacteria were thawed on ice and incubated for 30 min with 2 µL of 
ligation mixture. The cells were then heat-shocked for 45 s at 42 °C, incubated for 2 min 
on ice and subsequently resuspended in 300 µL S.O.C medium. Afterwards, the mixture 
was incubated for one hour at 37 °C shaking at 300 rpm. In the last step, the bacteria 
were plated on pre-warmed LB-agar plates containing 50 µg/mL ampicillin. The plates 
were incubated overnight at 37 °C and then stored at 4 °C. 
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2.2.2.7. Colony-PCR 
In order to identify E.coli clones carrying the correct insert, colony PCR was performed. 
A minimum of five single bacteria clones were picked from the agar plates after bacterial 
transformation. The picked clones were used as templates for subsequent colony-PCR. 
The PCR primers were designed to specifically amplify the HPV 16 E6 or E7 cDNA 
insert. PCR was conducted as described in previous sections and the size of the 
amplified sequence was evaluated by agarose gel electrophoresis. 
 
2.2.2.8. Plasmid isolation from bacterial cells 
After confirming that the picked bacterial colony carried the vector with the correct DNA 
insert, the bacterial colony was inoculated into 3-5 mL of LB-medium supplemented with 
50 µg/mL ampicillin. The bacteria were grown overnight at 37 °C shaking at 200 rpm. 
The plasmids were then isolated from the bacteria using the NucleoSpin Plasmid Kit 
(Machery Nagel) according to the manufacturer`s instructions. The concentration of the 
plasmid DNA was quantified spectrophotometrically at 260 nm. 
 
2.2.2.9. Purification of PCR products 
PCR products that had been amplified for subsequent sequencing were purified using 
the QIAquick® PCR Purification Kit (Qiagen) following the manufacturer`s instructions. 
Briefly, 20 µL of the PCR product was mixed with 100 µL buffer PB and loaded onto a 
spin column provided by the kit. After centrifuging 3 min at 13,200 rpm and removing the 
flow through, the column bound DNA fragments were washed with 700 µL buffer PE. 
Again, the column was centrifuged for 3 min at 13,200 rpm and the flow through was 
removed. In the next step, the column was placed into a new collection tube and 
centrifuged for 1 min at 13,200 rpm to remove the remaining washing buffer. The column 
was then transferred to a 1.5 mL collection tube and 40 µL EB buffer was added to the 
2. Materials and Methods 
 
42 
 
column. After incubating the column for 20 min at room temperature the column bound 
DNA fragments were eluted by centrifuging for 3 min at 13,200 rpm. The purified PCR 
products were stored at -20 °C until further use. 
 
2.2.2.10. Single-stranded linear amplification using terminator dyes 
To sequence the previously amplified and purified DNA fragments single-stranded linear 
amplification was performed using ABI PRISM® BigDye® Terminator Ready Reaction 
mix. The reagent contains dideoxynucleotide triphosphates (ddNTPs) to terminate 
elongation during PCR. Each of these terminators is labelled with a specific fluorescent 
dye emitting at different wavelengths. During single strand amplification ddNTPs are 
incorporated into the growing DNA chain with a certain probability terminating and 
labelling the chain corresponding to the final base (Sanger sequencing method). The 
following components were used for linear amplification: 4 µL of the purified PCR 
product, 4 µL of BigDye® Terminator v1.1 Ready Reaction Mix and 2 µL of primer 
(forward or reverse, 1.5 µM). The reaction was then performed for 5 min at 95 °C 
following 25 cycles of 10 s at 96 °C, 10 s at 53 °C for E6 and 48 °C for E7 as well as 4 
min at 60 °C. In order to verify the results, both DNA strands were sequenced using 
either the forward or the reverse primer. 
 
2.2.2.11. DNA precipitation 
After incorporating fluorescently labelled chain-terminating ddNTPs, the single stranded 
DNA was purified using ethanol precipitation. For this, the amplification product was 
diluted in 90 µL RNase- and DNase-free H2O and 250 µL ethanol mixed with 10 µL 
sodium acetate (pH 4.6) was added. By mixing the solution the DNA was precipitated. 
The samples were then centrifuged for 15 min at 13,000 rpm to pellet the DNA. The 
supernatant was gently removed and the pelleted DNA was dried at room temperature. 
In the next step, 250 µL of 75% ethanol was added and the samples were mixed and 
again centrifuged for 6 min at 13,000 rpm. After removing the supernatant and drying the 
pellets at room temperature, the remaining humidity was eradicated by vacuum drying 
2. Materials and Methods 
 
43 
 
for 6 min. The DNA pellet was then dissolved in 12 µL Hi-Di™ formamide and 
sequenced by capillary electrophoresis. 
 
2.2.2.12. Capillary electrophoresis 
To retrieve the sequence of the fluorescently labelled DNA fragments capillary 
electrophoresis was performed. Therefore, the samples diluted in Hi-Di™ formamide 
were pipetted into 96-well plates, shortly centrifuged at 1000 rpm and loaded into the 
ABI PRISM® 3100 Genetic Analyser. The signals obtained by capillary electrophoresis 
were then converted into an electronic DNA sequence trace chromatogram and 
subsequently analysed using the Sequencing Analysis Software v.6. 
 
2.2.2.13. Recombination-mediated cassette exchange 
After generating three retroviral vectors for the expression of HPV 16 E6 and/or E7 
(S2F-cLM2CG-FRT3-HPV16-E6 and/or E7), RMCE was performed to create HCT116-
HPV 16 E6 and/or E7 clones. Briefly, 5x105 HCT116-HygTK cells were seeded on 6-well 
plates and cultured overnight. The cells were then co-transfected with 1 µg of S2F-
cLM2CG-FRT3-HPV16-E6 and/or E7 vectors (that contain HPV 16 E6 and/or E7 flanked 
by two Flp recombination sites, Supplementary Figure 1) and 1 µg of pCAGGS-Flpo-
IRES-Puro. Transfection was carried out using FuGENE HD Transfection Reagents as 
recommended by the manufacturer`s instructions. Due to the exchange of the HygTK 
cassette, single clones could be selected and grown under ganciclovir treatment. Single 
clones were then picked, expanded and tested for their dox-inducible expression of HPV 
16 oncogenes. 
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2.2.3. Quantification of gene expression 
2.2.3.1. RNA purification 
For the isolation of total RNA 1x106 cells were harvested and washed by using PBS 
(Gibco). Total RNA extraction was then performed using the RNeasy Mini Kit (Qiagen) 
including DNaseI (Invitrogen) treatment according to the manufacturer`s instructions. In 
the final step, the RNA was eluted in 40 µL of RNase-free water and the concentration 
was measured spectrophotometrically at 260 nm using a NanoDrop 1000 
Spectrophotometer. 
 
2.2.3.2. Gene expression profiling 
Whole transcriptome analyses were performed in cooperation with the Genomics and 
Proteomics Core Facility at the DKFZ using Illumina HumanHT-12 microarray 
technology. For this, HCT116-HPV 16 E6 and E7 clones were treated for 48 hours with 
dox as described in previous sections. Total RNA was submitted to the core facility as 
recommended by the guidelines of the core facility. Subsequent steps were conducted 
at the core facility including quality control, labelling and hybridization of the samples to 
the microarray as well as image acquisition. Afterwards, the raw data were evaluated 
and normalized. Tables containing the expression of each gene on the microarray 
comparing dox-treated to untreated control were prepared and used to identify 
differentially expressed candidate genes, which were then validated by using RT-qPCR. 
The submitted samples are listed in Table 2. 
Table 2: List of HCT116-HPV 16 E6 and E7 clones and respective treatment conditions used for 
gene expression profiling. 
Clone Treatment 
Concentration 
of dox 
Biological 
replicates 
HCT116-HPV 16 E6 
48 hours no dox 3 
48 hours 500 ng/mL 3 
HCT116-HPV 16 E7 
48 hours no dox 3 
48 hours 500 ng/mL 3 
HCT116-HPV 16 E6 and E7 
48 hours no dox 3 
48 hours 500 ng/mL 3 
HCT116-HygTK 
48 hours no dox 3 
48 hours 500 ng/mL 3 
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2.2.3.3. Reverse Transcription 
For reverse transcription of mRNA into cDNA SuperScript® II Reverse Transcriptase Kit 
(Invitrogen) was used as described in the manufacturer`s protocol. Each reaction 
consisted of 1 µg of total RNA, 4 µL of 5x RT buffer, 2 µL of 0.1 M dithiothreitol (DTT), 
0.5 µL of 0.5 µg/µL oligo(dT) primers (Invitrogen), 0.5 µL of 0.5 µg/µL single stranded 
random hexanucleotides (Bioron), 1 µL of 10 mM dNTPs (Invitrogen) and 0.5 µL of 
SuperScript® II Reverse Transcriptase (200 U/µL), and was incubated at 37°C for 15 
min, at 42°C for 60 min and at 90°C for 5 min. 
Reverse transcription to quantify hsa-miR-375 expression was conducted by using 
TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems) in combination 
with hsa-miR-375 and snRNA U6 specific stem-loop RT primers according to the 
TaqMan® MicroRNA Assays (Applied Biosystems) protocol. Therefore, 50 ng of total 
RNA were reverse transcribed. The reactions were incubated at 16 °C for 30 min, at 
42°C for 30 min and at 85°C for 5 min. 
 
2.2.3.4. Quantitative PCR 
Quantitative PCR (qPCR) was performed to determine the levels of E6 and E7 mRNA 
expression after treating HPV-transformed cell lines with DAC as well as after inducing 
HCT116 cell clones with dox. For this, the Applied Biosystems StepOne™ Real-Time 
PCR system and the Absolute qPCR SYBR Green ROX Mix (Thermo Scientific) were 
used. Primers used for qPCR amplification are listed in chapter 2.1.3. Primer. Cycling 
conditions were 95°C for 15 min and 40 cycles of 95°C for 15 s, 60°C for 30 s and 72°C 
for 30 s. Melting curves were included in each run to check for amplification specificity. 
Actin mRNA levels were quantified as a reference control and all samples were run in 
triplicates. Relative mRNA expression levels were determined by performing the ΔΔCt 
method and the fold change was calculated as 2-ΔΔCt. 
Expression of hsa-miR-375 expression was quantified using TaqMan® MicroRNA 
Assays (Applied Biosystems) for qPCR. The assay utilizes specific stem-loop RT 
primers for reverse transcription as described in the previous section. TaqMan® 
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Universal PCR Master Mix (Applied Biosystems) was then used for subsequent qPCR 
amplification. Therefore, the reaction was incubated at 95 °C for 10 min and then 40 
cycles were performed with the following conditions: 95 °C for 15 s and 60 °C for 60 s. 
All samples were run in triplicates. Hsa-miR-375 expression was measured relative to 
snRNA U6 levels by performing the ΔΔCt method and the fold change was calculated as 
2-ΔΔCt. 
 
2.2.4. Protein analyses 
2.2.4.1. Preparation of RIPA-lysates  
RIPA-lysates were prepared for subsequent detection and quantification of proteins by 
performing SDS-PAGE and Western blot. First, the cells were harvested and washed by 
using PBS (Gibco). Afterwards, the cells were lysed by adding RIPA buffer (Sigma 
Aldrich) supplemented with protease and phosphatase inhibitor (Sigma Aldrich). 
Subsequently, the cell pellets were disrupted by sonication for 10 s and the lysates were 
then incubated for 30 min on ice. After centrifugation at 13,200 rpm for 15 min at 4 °C 
the supernatant was collected and stored at -80 °C until further use. 
 
2.2.4.2. Bradford Assay 
Bradford Assay was performed to quantify the protein concentration in RIPA lysates. For 
this, the cell lysates were diluted 1:20 in RNase-free water and 20 µL of the dilution were 
mixed with 1 mL of Quick Start ™ Bradford 1x Dye Reagent (BioRad). Next, serial 
dilutions of BSA standards were prepared to quantify the protein concentration in the 
sample. 20 µL of the serial dilutions were then mixed with 1 mL of Quick Start ™ 
Bradford 1x Dye Reagent (BioRad) and the protein concentration was calculated based 
on the absorbance at 595 nm. 
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2.2.4.3. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was used to separate denatured proteins according to their electrophoretic 
mobility depending on the charge, the molecular weight and the conformation of the 
proteins. 
For sample preparation, Laemmli Buffer (4x) and NuPAGE® Sample Reducing Agent 
(10x) were mixed with 40 µg proteins as quantified by Bradford Assay after cell lysate 
preparation. After incubating the mixture at 95 °C for 10 min to disrupt any protein-
protein interactions, the samples were loaded onto 4-20% Mini-PROTEAN® TGX™ gels 
(BioRad) and run in 1x Running Buffer (BioRad) at 45 mA until the bromophenol blue 
reached the bottom of the gel. Precision Plus Protein™ Prestained Standard (BioRad) 
was used as protein marker to estimate the size of the separated proteins. 
 
2.2.4.4. Western Blot 
In order to detect proteins by binding of specific antibodies the separated proteins were 
blotted onto PVDF membranes. Therefore, the PVDF membrane was incubated for 10 s 
in 100% methanol, for 5 min in H2O bidest. and then for 5 min in Buffer III. 
Simultaneously, two Whatman papers were incubated in Buffer I, three in Buffer II and 
five in Buffer III. The sandwich for the semi-dry blotting was prepared by stacking two 
Whatman paper soaked in Buffer I, three in Buffer II, the activated PVDF membrane, the 
SDS gel and five Whatman paper incubated in Buffer III (listed from the positive pole at 
the bottom to the negative pole on top of the blotting chamber). Air bubbles were 
removed by rolling over the sandwich with a glass pipette. The proteins were then 
blotted onto the membrane at 230 mA for one hour. 
Protein transfer was checked by staining the membrane with Ponceau Red solution 
(Sigma Aldrich). Afterwards, the membrane was destained using H2O bidest. The 
following steps were performed using the Novex Western Breeze Chemiluminescent 
Immunodetection System (Life technologies) according to the instructions of the 
manufacturer. Briefly, the PVDF membrane was blocked in Blocking Solution for one 
hour at room temperature. After washing twice with H2O bidest. for 5 min, the membrane 
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was incubated in primary antibody overnight at 4°C. All primary antibodies used in this 
study were diluted as described in the datasheets of the manufacturers. Unbound 
primary antibody was removed by washing the membrane four times in Antibody Wash 
for 5 min. In the next step, the membrane was incubated with the secondary antibody 
coupled to Alkaline Phosphatase for one hour at room temperature. The membrane was 
again washed four times with Antibody Wash for 5 min, followed by two washing steps 
with H2O bidest. for 2 min. After adding Novex AP Chemiluminescent Substrate CDP 
Star® (Life technologies) onto the membrane light sensitive films (Lumi-Film 
Chemiluminescent Detection Film, Roche Diagnostics) were used to detect PVDF 
membrane bound secondary antibodies. Protein expression levels were normalized to 
actin. 
For the detection of other proteins the antibodies bound to the PVDF membrane were 
removed by incubating the membrane in Restore™ Western Blot Stripping Buffer 
(Thermo Fisher Scientific). Therefore, the PVDF membrane was washed twice in PBS to 
remove the chemiluminescent substrate and was then incubated for one hour in 
stripping buffer pre-heated to 37 °C. After washing again twice with PBS the 
immunodetection procedure was repeated starting with the blocking step. 
 
2.2.4.5. Immunocytochemistry 
Immunofluorescence staining of cultured cells was used to visualize and localize specific 
proteins in dox-induced HCT116 cell clones. Therefore, monoclonal antibodies were 
utilized specifically targeting γ-tubulin and phosphorylated-H2AX (γH2AX). 
First, cover slips (15 mm in diameter) were placed in 10 cm cell dishes. In the next step, 
HCT116 cells were seeded and induced with dox for the expression of HPV 16 E6 
and/or E7 as described previously. After dox treatment, the cover slips were transferred 
to 12-well plates (cell site up) and washed twice with PBS. Ice cold methanol was then 
pipetted onto the cells to fix the cells on the cover slips and to dissolve lipids from the 
cell membrane making it permeable to antibodies used to detect intracellular antigens. 
The plates were then incubated for 20 min at 4 °C before the methanol was removed 
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and the cover slips were washed twice with PBS. To prevent non-specific binding of the 
antibodies the cover slips were incubated in 2% goat serum (Sigma Aldrich) diluted in 
PBS for one hour at 4 °C. After blocking the cover slips were washed twice with PBS 
and incubated in primary antibody diluted in PBS overnight at 4 °C in a humidified 
chamber. The chamber was prepared using 10 cm square dishes with water-soaked 
filter papers covered by a layer of parafilm. The cover slips were then incubated in 50 µL 
drops of primary antibody solution pipetted onto the parafilm. In the next day, the cover 
slips were again transferred to 12-well plates and washed twice with PBS. Afterwards, 
the cover slips were incubated with the fluorophore-conjugated secondary antibody 
diluted in PBS for three hours at 37 °C. Next, the cells were washed twice with PBS and 
were then mounted onto microscope glass slides. The slides were analysed using a 
Leica DM5000 B fluorescence microscope or were stored at 4 °C until further use. 
 
2.2.5. Detection of DNA methylation 
2.2.5.1. Bisulfite conversion 
Bisulfite conversion was performed to detect and subsequently analyse DNA 
methylation patterns. Treatment of purified DNA with sodium bisulfite deaminates 
unmethylated cytosine residues to uracile, whereas 5-methylacytosine remains 
unaffected. Afterwards, sequencing or hybridization techniques allow distinguishing 
between methylated and unmethylated positions in the DNA sequence. Bisulfite 
conversion was conducted by using the Methylamp™ DNA Modification Kit (Epigentek) 
as described in the manufacturer`s protocol. For this, 24 μL of isolated DNA were 
employed. The bisulfite-modified DNA was eluted in 30 μL of sterile water and then 
stored at –20 °C. 
 
2.2.5.2. Pyrosequencing for detection of E2BS and LINE1 methylation 
In order to quantify the methylation level in E2BSs 3 and 4 as well as in LINE1, bisulfite-
converted DNA was first amplified using bisulfite-specific primers and then 
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pyrosequenced. The primers designed to cover the proximal E2BSs 3 and 4 are listed in 
the primers section. LINE1 methylation analysis was carried out by using PyroMark 
LINE1 reagents (Qiagen). 
Amplification of the respective regions was performed using the following reagents: 1.25 
μL 10X Qiagen PCR buffer, 15 mM MgCl2 , 0.25 μL 10 mM deoxynucleotide 
triphosphates (dNTPs), 0.125 μL of each PCR primer (25 μM), 0.1 μL (0.5 U) HotStar 
Taq Plus DNA Polymerase (Qiagen) and 2 μL of the bisulfite-modified DNA. The volume 
was then adjusted to 12.5 µL by adding ddH2O and the PCR was under the following 
conditions: initial activation step at 95°C for 5 min followed by 50 cycles of denaturation 
at 94°C for 40 s, annealing at 50°C for 30 s, extension at 72°C for 40 s and final 
extension 72°C for 6 min. Correct amplification was checked by agarose gel 
electrophoresis. 
Pyrosequencing was then performed by using PyroMark Gold Q24 reagents, the 
Vacuum Prep Workstation and the Q24 instrument (all Qiagen) as recommended by the 
manufacturer. 
 
2.2.5.3. Methylation-specific qPCR 
Methylation-specific qPCR was performed to measure the methylation level in the hsa-
miR-375 promoter region. Therefore, qPCR primers were used specifically binding to the 
methylated and bisulfite-converted form of regions in the hsa-miR-375 promoter as 
published in (Wilting et al. 2013). QPCR was then performed as described previously to 
amplify this region. As a reference, bisulfite-converted and unmethylated sequences of 
β-actin were amplified ensuring DNA quality and efficient DNA modification. 
 
2.2.5.4. Whole methylome analysis and evaluation of copy number variations 
The methylation status of about 850,000 CpG dinucleotides as well as the presence of 
gene copy number variations was assessed by using Infinium® MethylationEPIC 
BeadChips (Illumina). Therefore, HPV 16 oncogene expression was induced in the 
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generated HCT116 clones by treating them for 48 hours or nine days with 500 ng/mL 
dox. After DNA purification and bisulfite conversion, the samples were hybridized to the 
array. The bisulfite conversion, the hybridization step and the generation of the raw data 
including respective quality checks were performed by the DKFZ Genomics and 
Proteomics Core Facility. The raw data was then further processed in cooperation with 
the Neuropathology Department using their previously established R-based analysis 
pipelines. 
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3. Results 
3.1. 5-aza-2`-deoxycytidine (DAC) treatment of HPV-transformed cell 
lines 
As hypermethylation of viral as well as host cellular genomic loci is assumed to play an 
important role during HPV-driven tumor formation and as treatment with the 
demethylating agent DAC showed promising results in myelodysplastic syndrome and in 
a number of solid tumors, the first aim of the present study was to systematically analyze 
the effects of DAC treatment on HPV oncogene expression as well as on the growth 
behavior of HPV-transformed cells. DAC prevents the maintenance of DNA methylation 
in dividing cells by being incorporated into the DNA during replication and by directly 
interacting with DNMT1 (Creusot et al. 1982, Jones 1985, Jones & Taylor 1980). 
Therefore, DAC treatment is assumed to globally reduce CpG methylation levels in 
replicating cells. 
The data that are presented in the first part of this study were generated in cooperation 
with Maximilian Stich and resulted in the following publication (Stich et al. 2016). 
To cover a wide range of HPV-transformed cell lines the cervical carcinoma cell lines 
CaSki, SiHa (both HPV 16 positive), SW756 and C4-1 (both HPV 18 positive) as well as 
the HPV 16-transformed head and neck squamous-cell carcinoma (HNSCC) cell lines 
UM-SCC-47 and UM-SCC-104 were included in this study (Table 3). The cell lines were 
treated for 72 hours using three different concentrations of DAC (0.1 µM, 0.5 µM and 1.0 
µM). First, the effectiveness of the treatment was confirmed by quantifying CpG 
methylation in the retrotransposon Long Interspersed Nuclear Element 1 (LINE1) (Figure 
6). LINE1 CpGs are frequently methylated and widely used as surrogate markers to 
assess global DNA methylation levels (Yang et al. 2004). In all tested cell lines the 
methylation level of three CpGs located in LINE1 decreased substantially confirming the 
effectiveness of the performed treatment. The most potent demethylating effects could 
be detected using 0.1 µM and 0.5 µM DAC. Increasing the DAC concentration to 1.0 µM 
was not found to enhance its demethylating effect, as illustrated by a U-shaped LINE1 
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methylation profile (Figure 6). These dose-dependent characteristics of DAC treatment 
have been described previously and can be explained by a dual effect of the drug 
(reviewed in (Taby & Issa 2010)). At low doses, DNA demethylation can be detected 
after a low number of cell divisions, whereas at higher doses, DAC treatment shows an 
immediate cytotoxic effect preventing cell cycle progression. However, the cytotoxic 
effect of high dose DAC treatment is not assumed to be specific for HPV-transformed 
cells and thus only causes severe side effects by depleting regularly dividing non-tumor 
cells strongly limiting its clinical use. Therefore, low dose treatment causing 
demethylation, but not directly cytotoxicity was hypothesized to be more suitable for the 
treatment of HPV-transformed cells. Additionally, the level of LINE1 demethylation was 
found to differ between the tested cell lines, probably as a consequence of varying cell 
cycle lengths. 
 
Table 3: Characteristics of the cell lines selected for DAC treatment including HPV type, origin, 
chromosomal HPV integration site, E2BS methylation level and the status of the E2 gene (modified 
from (Stich et al. 2016)). (Gallego et al. 1994) (Mincheva et al. 1987, Popescu et al. 1987) (Yee et al. 
1985) 
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3.1.1. DAC treatment represses E6 and E7 oncogene expression 
To test the hypothesis that DAC treatment reinforces regulatory mechanisms repressing 
HPV early gene expression, E6 and E7 mRNA expression and protein levels were 
analyzed. RT-qPCR quantification revealed a decrease of E6*I and E7 mRNA levels in 
all DAC-treated cell lines (Figure 7A). The most significant decrease was observed in 
CaSki, UM-SCC-47, UM-SCC-104 and SW756 cells, whereas the oncogene mRNA 
expression was only moderately reduced in SiHa and C4-1 cells. The lowest tested 
concentration of 0.1 µM DAC was sufficient to downregulate E6 and E7 mRNA 
expression, although the effect was more pronounced using 0.5 and 1.0 µM DAC. 
Reduction of HPV E6 and E7 expression was also confirmed on the protein level as 
shown in Figure 7B. Due to the lack of sensitive antibodies specific for HPV 16 and 18 
E6 proteins, the levels of the target proteins p53 and p21 were measured as an indirect 
read-out of HPV E6 protein levels. As expected, p53 and p21 levels increased in the 
analyzed cell lines after DAC treatment indicating a reduction of E6 protein production. 
In agreement with the mRNA data decreasing HPV oncoprotein levels were already 
detectable for samples treated with 0.1 µM DAC, however, stronger effects were again 
observed after increasing the DAC concentration to 0.5 and 1.0 µM. In summary, DAC 
treatment represses HPV oncogene expression in a wide range of HPV-transformed cell 
lines and causes an increase in p53 and p21 protein levels. 
 
3.1.2. Application of DAC decelerates cell proliferation and prevents colony 
formation of HPV-transformed cell lines 
Due to the prominent roles of p53 and p21 in the activation of cell cycle checkpoints, in 
the detection of DNA damage as well as in the induction of apoptosis, their joint 
reactivation, as a consequence of reduced E6 and E7 expression under DAC treatment, 
was assumed to affect proliferation and colony formation of the cells. Proliferation as 
well as colony formation was significantly impaired in the tested cell lines after treatment 
with DAC (Figure 8). In CaSki, UM-SCC-47, UM-SCC-104 and C4-1 cells treatment with 
0.1 µM DAC was sufficient to substantially reduce the proliferation rate (Figure 8A). 
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Elevation of DAC concentration to 1.0 µM further enhanced the anti-proliferative effect, 
especially in SiHa and SW756 cells. As shown in Figure 8B, DAC treatment not only 
repressed proliferation but also efficiently inhibited colony formation of the cells. These 
data reveal a potent growth inhibitory effect of DAC on HPV-transformed cell lines. 
Furthermore, outgrowth of cells after removing DAC from the culture medium was not 
observed suggestive of only a low risk for the selection of DAC-resistant cell clones. 
Figure 6: Decrease of LINE-1 methylation levels after DAC treatment indicates global DNA 
demethylation. 
The diagrams show the mean methylation percentage of three CpG dinucleotides located in the LINE-1 
transposable element after treating (A) CaSki and SiHa, (B) UM-SCC-47 and UM-SCC-104 as well as (C) 
C4-1 and SW756 with different concentrations of DAC ranging from 0.1 µM to 1.0 µM. LINE-1 methylation 
levels were determined by bisulfite conversion of isolated DNA and subsequent pyrosequencing using 
PyroMark LINE-1 reagents (Qiagen). (Experiment performed by Maximilian Stich (Stich et al. 2016)). 
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Figure 7: Effects of DAC treatment on HPV oncogene expression as well as on the downstream 
factors p53 and p21. 
(A) HPV 16 and 18 E6*I and E7 mRNA levels were quantified using RT-qPCR in CaSki, SiHa, UM-SCC-
47, UM-SCC-104, C4-1 and SW756 after DAC treatment for 72 hours. Relative mRNA expression levels 
were calculated by using DMSO treated cells as a reference control as well as actin levels as loading 
control. The presented mean values were obtained from three biological replicates and the error bars 
represent the according standard deviation. Student`s t-test was performed to calculate p values. *: 
p<0.05, **: p<0.01, ***: p<0.001 and ns: not significant. (B) HPV E7, p53 and p21 protein levels in DAC-
treated HPV-transformed cell lines were quantified using Western blot analysis. β-actin was used as an 
internal loading control. (Experiments were performed in cooperation with Maximilian Stich (Stich et al. 
2016)) 
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Figure 8: Proliferation and colony formation of HPV-transformed cell lines under DAC treatment. 
(A) Cell proliferation was measured by quantifying the DNA content after DAC treatment for 72 hours. The 
diagrams show the mean proliferation level relative to DMSO-treated cells based on three biological 
replicates as well as the according standard deviation. The p values were calculated by performing 
Student`s t-test. *: p<0.05, **: p<0.01, ***: p<0.001 and ns: not significant. (B) The colony formation 
capacities of HPV-transformed cell lines were monitored by treating the cells with 0.5 µM DAC for 72 hours 
or with the solvent DMSO as indicated. The cells were then cultured without treatment for seven days and 
the formation of colonies was evaluated by staining with crystal violet. Representative images are shown. 
The scale bars reflect 100 µm. (The presented data was produced jointly with Maximilian Stich (Stich et al. 
2016)) 
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3.1.3. DAC treatment reduces E2BS methylation in CaSki and UM-SCC-47 
Previous studies showed that HPV early gene expression is regulated by the interaction 
of the HPV E2 protein with four conserved E2BSs in the HPV URR (Kim et al. 2003, 
Thierry 2009). Methylation of CpGs in the E2BSs was found to prevent binding of E2 
abrogating its regulatory effect and leading to transcriptional activation of the HPV early 
promoter (Bhattacharjee & Sengupta 2006, Leung et al. 2015, Vinokurova & von Knebel 
Doeberitz 2011). Repression of HPV oncogene transcription could therefore be the 
result of the DAC-mediated demethylation of the CpGs located in the E2BSs in the HPV 
URR (Figure 9A). To test this hypothesis methylation of E2BS 3 and 4 was quantified 
after DAC treatment using bisulfite conversion and subsequent pyrosequencing. 
Interaction of E2 with these two E2BSs has previously been demonstrated to reduce 
HPV oncogene transcription by displacing the transcription factors Sp1 and TBP from 
their respective binding sites located in direct proximity to E2BS 3 and 4 (Steger & 
Corbach 1997, Stubenrauch et al. 1998). As expected, treatment with DAC reduced the 
mean methylation levels of CpGs in E2BS 3 and 4 of CaSki as well as UM-SCC-47 cells 
(Figure 9 B and C). In contrast, methylation of E2BS 3 and 4 was not affected in SiHa 
and UM-SCC-104 cells as these E2BSs were not methylated in those cell lines. 
Based on these data, it can be concluded that demethylation of the E2BSs during the 
application of DAC might reactivate the E2-mediated transcriptional regulation of E6 and 
E7 expression in CaSki cells, which were also shown to express E2 proteins (Fernandez 
et al. 2009). Reduced HPV oncogene expression was, however, also observed in the 
other cell lines that either lack expression of intact E2 due to its disruption during viral 
integration into the host genome or show low E2BS methylation levels (Table 3 and 
Figure 9). Therefore, the re-establishment of the E2-mediated transcriptional control 
cannot be the only mechanism silencing E6 and E7 expression observed after DAC 
treatment. 
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3.1.4. DAC-mediated activation of miR-375 reduces HPV oncogene expression 
As DNA demethylation in response to DAC treatment does not only occur in the viral 
genome but also in the host cell genome, regulatory factors might become activated 
repressing HPV oncogene expression. Recently, miR-375 was found to be involved in 
the regulation of HPV 16 and 18 oncogene expression by directly binding and 
subsequently degrading E6 and E7 transcripts (Jung et al. 2014). Furthermore, miR-375 
reduces the expression of the transcription factor Sp1, which interacts with the HPV 
Figure 9: Quantification of E2BS 3 and 4 methylation levels in the HPV 16 URR of CaSki, SiHa, UM-
SCC-47 and UM-SCC-104 cells after DAC treatment. 
(A) Schematic representation of the E2BSs in the HPV 16 URR including CpG dinucleotide positions. The 
E2BS 3 and 4 are highlighted by the red box. Pyrosequencing was used to quantify E2BS 3 (B) and 4 (C) 
methylation levels in CaSki, SiHa, UM-SCC-47 and UM-SCC-104 after DAC treatment. The methylation 
levels are shown as mean values of the two CpGs in the respective E2BS and the error bars indicate the 
according standard deviation. The CpGs are located in the HPV 16 E2BS 3 at nucleotide position 37 and 
43 as well as in E2BS 4 at position 52 and 58. (E2BS methylation data was produced in cooperation with 
Maximilian Stich (Stich et al. 2016)) 
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URR and activates early gene transcription (Jung et al. 2014, Wang et al. 2011). As 
expression of miR-375 is dependent on the methylation level in its promoter region and 
as this region becomes frequently methylated during HPV-mediated cervical 
carcinogenesis, it could be assumed that miR-375 expression is reactivated after DAC 
treatment (Wilting et al. 2013). 
To confirm the assumption the effect of DAC treatment on miR-375 promoter 
methylation was analyzed. Therefore, PCR primers were designed to cover six CpG 
dinucleotides located in the miR-375 promoter region (Figure 10A) as reported in a study 
published previously (Wilting et al. 2013). After bisulfite treatment of the isolated DNA, 
methylation-specific qPCR (MSP) was performed to specifically quantify methylated 
DNA strands. As depicted in Figure 10B, miR-375 promoter methylation was reduced 
after treating HPV-transformed cell lines using 0.5 µM DAC. The strongest 
demethylating effects were detected in SiHa and SW756 cells. The levels of miR-375 
promoter demethylation slightly varied between the tested cell lines and are potentially 
the consequence of different growth rates. Overall, the results resemble the 
demethylation effects detected in LINE1. 
Next, miR-375 expression was monitored by utilizing TaqMan qPCR assays. DAC 
treatment resulted in a substantial increase in miR-375 expression in all six analyzed cell 
lines as shown in Figure 11. Treatment with increasing DAC concentrations also tended 
to elevate miR-375 expression levels. Especially SiHa cells and the HNSCC cell lines 
UM-SCC-47 and UM-SCC-104 showed strong increases in miR-375 expression under 
DAC treatment. 
To evaluate whether elevated miR-375 expression would lead to reduced E6 and E7 
expression, CaSki and SiHa cells were transfected with miR-375 mimics and HPV 16 
oncogene levels were quantified by RT-qPCR as well as Western blot analysis. As 
indicated in Figure 12 transfection of miR-375 mimics led to reduced HPV 16 E6*I and 
E7 mRNA levels in both cell lines compared to the levels in cells transfected with non-
specific control miRNAs. Moreover, E7 protein levels decreased after transfection of 
miR-375 mimics. These data suggest that expression of HPV E6 and E7 is reduced by 
miR-375. Therefore, reactivation of miR-375 expression and subsequent degradation of 
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E6 and E7 mRNA transcripts provides another explanation for the reduction of E6 and 
E7 oncogene expression in HPV-transformed cell lines when treated with DAC. 
In conclusion, DAC treatment of HPV-transformed cells appears to be a potent approach 
to significantly decrease HPV oncogene expression, which is assumed to contribute to 
the inhibition of cell growth as well as colony formation. Several mechanisms seem to 
play a role in the DAC-mediated reduction of E6 and E7 levels including demethylation 
Figure 10: MiR-375 promoter methylation in DAC-treated HPV-transformed cell lines. 
(A) The graphic schematically illustrates the miR-375 promoter region including six CpG dinucleotides that 
were covered by the primers used for the methylation-specific qPCR (MSP) assay to amplify bisulfite 
converted and methylated template DNA. The respective CpGs are located in close proximity to the start of 
the miR-375 gene (Wilting et al. 2013). (B) Relative miR-375 promoter methylation of HPV-transformed cell 
lines after treatment with 0.5 µM DAC. The methylation level was quantified using MSP and is shown 
relative to the level detected after treatment with DMSO. To verify successful bisulfite conversion and 
sufficient DNA quality, bisulfite converted and unmethylated β-actin sequences were amplified. The 
presented diagram shows the mean methylation levels from at least three independent experiments and 
error bars indicate the according standard deviation. P values were calculated by performing Student`s t-
test. *: p<0.05 and **: p<0.01 (Stich et al. 2016). 
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of E2BSs in E2-expressing cells and reactivation of miR-375 expression. Additionally, 
there might be also other mechanisms involved in repressing E6 and E7 expression as 
well as in reducing cell proliferation, as DAC treatment globally affects the DNA 
methylation pattern. 
 
  
Figure 11: Expression of miR-375 in HPV-transformed cell lines after treatment with DAC. 
TaqMan qPCR assays were performed to quantify the expression of miR-375 in DAC-treated HPV-
transformed cell lines. The bars of the diagrams indicate miR-375 expression levels based on at least three 
independent replicates relative to the expression in DMSO-treated cells. The error bars represent the 
according standard deviation and snRNA U6 expression was quantified as internal loading control. 
Student`s t-test was performed to calculate p values in reference to DMSO. *: p<0.05, **: p<0.01, ***: 
p<0.001 and ns: not significant. (The presented data was generated in cooperation with Maximilian Stich 
(Stich et al. 2016)) 
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Figure 12: Expression of HPV 16 oncogenes in CaSki and SiHa cells after transfection of miR-375 
mimics. 
(A) RT-qPCR quantification of HPV 16 E6*I and E7 mRNA in CaSki and SiHa cells transfected either with 
100 nM miR-375 mimics or 25 nM non-specific control miRNAs. The diagram shows the mean levels of 
HPV 16 E6*I and E7 mRNA detected 48 hours after transfection as well as the according standard 
deviation. The experiment was performed at least in biological duplicates. P values were calculated using 
Student`s t-test and non-specific control was utilized as a reference. β-actin was quantified as loading 
control. *: p<0.05, **: p<0.01 and ns: not significant. (B) Western blot was performed to detect HPV 16 E7 
protein levels in CaSki and SiHa cells 48 hours after miR-375 transfection. The miRNA concentrations 
used for transfection were identic to (A). Actin levels were measured as internal control (Stich et al. 2016). 
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3.2. Development of novel model system to study the effects of HPV 
16 oncogenes 
As the identification of pathways that are manipulated by the HPV oncoproteins depends 
on model systems that precisely mimic the effects of E6 and E7, another aim of this 
study was the generation of an inducible E6 and E7 expression system in an 
immortalized, but chromosomally stable cell line to comprehensively study the effects of 
HPV 16 oncogene expression in a time-controlled manner. For this, the microsatellite-
unstable colon cancer cell line HCT116 was selected (Brattain et al. 1981). In contrast to 
HPV-transformed tumor cells, immortalization of HCT116 cells is caused by MMR 
deficiency due to a mutation in the hMLH1 gene. Consequently, HCT116 cells acquire 
and accumulate mutations, especially in microsatellites, which may lead to the 
inactivation of affected genes, e.g. the tumor suppressive gene encoding TGFβ receptor 
2, and to the expression of truncated proteins. However, outgrowth of these cells does 
not require chromosomal destabilization or high rates of aneuploidy as observed in HPV-
transformed tumor cells (Ertych et al. 2014, Lengauer et al. 1997, Steinbeck 1997). 
Therefore, inducible HPV 16 oncogene expression in HCT116 cells might represent an 
ideal model system to evaluate short- and long-term effects of E6 and E7 on 
chromosomal stability. 
3.2.1. Generation of dox-inducible HCT116-HPV 16 E6 and E7 clones 
In order to generate HCT116 clones for the dox-inducible expression of HPV 16 E6 and 
E7 either individually or in combination, HCT116-HygTK cells were used as parental 
master cells (Lee et al. 2013). These cells, which were kindly provided by Dr Johannes 
Gebert and Dr Jennifer Lee, constitutively express a reverse tetracycline-controlled 
transactivator (rtTA) (Welman et al. 2006). Additionally, these cells contain a hygromycin 
B phosphotransferase-thymidine kinase (HygTK) expression cassette integrated as a 
single copy resulting in resistance to hygromycin B as well as sensitivity to ganciclovir. 
As the HygTK expression cassette is flanked by a wild-type (F) and a mutant (F3) 
Flippase (Flp)-recombinase target site, expression of Flp-recombinase allows 
replacement of the cassette by any construct of interest. Thereby, these cell clones 
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allow the integration of constructs encoding the HPV 16 oncogenes as single copies into 
a defined chromosomal locus (Lee et al. 2013). 
The retroviral vector S2F-cLM2CG-FRT3 (Supplementary Figure 1) was used to 
generate plasmids that enable dox-inducible expression of HPV 16 E6 and/or E7 (Loew 
et al. 2006, Weidenfeld et al. 2009). S2F-cLM2CG-FRT3 contains a tetracycline (tet)-
controlled bidirectional promoter (Ptetbi) for concurrent regulation of the two reporter 
genes firefly luciferase and red fluorescent protein mCherry. This expression cassette is 
flanked by two heterospecific Flp-recognition sites F and F3 required for subsequent 
RMCE (Schlake & Bode 1994). For the generation of S2F-cLM2CG-FRT3-HPV16-E6 
and S2F-cLM2CG-FRT3-HPV16-E7 the mCherry fragment in the S2F-cLM2CG-FRT3 
vector was replaced by HPV 16 E6 (GenBank: K02718.1, nt 83-560) or HPV 16 E7 
(GenBank: K02718.1, nt 562-858), respectively. To create the vector S2F-cLM2CG-
FRT3-HPV16 E6-E7 for the expression of both HPV 16 oncogenes, the mCherry 
fragment of S2F-cLM2CG-FRT3 was exchanged for the HPV 16 E6 sequence, while the 
firefly luciferase reporter gene was substituted by the HPV 16 E7 coding sequence. 
Maps of the resulting vectors can be found in Supplementary Figure 1. 
As a next step, the HygTK expression cassette in the HCT116-HygTK master cells was 
replaced by the HPV 16 oncogene-encoding sequences of the three generated vectors 
(Figure 13). RMCE was conducted by co-transfecting HCT116-HygTK master cells with 
the HPV 16 oncogene-encoding constructs and the Flp recombinase expression plasmid 
pCAGGS-Flpo-IRES-Puro obtained from Michael Hahn (DKFZ, Heidelberg). 
Replacement of the HygTK cassette resulted in the loss of both hygromycin B resistance 
and ganciclovir sensitivity. Thus, single clones were selected by treating the cells with 
ganciclovir as shown in Figure 14. Thereby, three different cell clones were established: 
HCT116-HPV 16 E6 and HCT116-HPV 16 E7 for the dox-inducible expression of HPV 
16 E6 or E7 respectively, as well as HCT116-HPV 16 E6 and E7 for the dox-inducible 
expression of HPV 16 E6 and E7 in combination. In subsequent steps, the clones were 
characterized for their dox-inducible HPV 16 oncogene expression by RT-qPCR as well 
as Western blot analysis. 
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3.2.2. Quantification of dox-inducible HPV 16 oncogene expression 
Dox-inducible expression of the HPV 16 oncogenes in the generated HCT116 clones 
was analyzed on mRNA and protein level. The clones were treated with two different 
concentrations of dox (100 or 500 ng/mL) for 48 hours or nine days. As shown in Figure 
15A, dox treatment of the HCT116-HPV 16 E6 clone resulted in 25- to 40-fold induction 
of HPV 16 E6 mRNA levels. Treatment of the HCT116-HPV 16 E7 clone led to an 
Figure 13: Generation of HCT116 clones for the dox-inducible expression of HPV 16 E6 and E7. 
The master cell line HCT116-HygTK, which was obtained from (Lee et al. 2013) was used to generate 
HCT116 clones for the dox-inducible expression of HPV 16 E6 and E7. Therefore, Flp-recombinase-
mediated cassette exchange was used to replace the HygTK expression cassette in the master cell line by 
constructs encoding HPV 16 E6 and/or E7 controlled by the bidirectional dox-inducible promoter Ptetbi. 
Thereby, three different HCT116 clones were generated for the dox-inducible expression of the HPV 16 
oncogenes either individually or in combination. The clones, in which the expression cassettes were 
successfully replaced, were selected by treatment with ganciclovir. 
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increase in HPV 16 E7 mRNA levels of about 40 (48 hours) to almost 200-fold (nine 
days) compared to untreated cells. Induction of the expression of both HPV 16 
oncogenes was observed after dox treatment of HCT116-HPV 16 E6 and E7 cells 
reaching from 91-fold (HPV 16 E6, 100 ng/mL dox for nine days) to 291-fold (HPV 16 
E7, 500 ng/mL for 48 hours). As expected, HPV 16 oncogene expression tended to 
increase with elevated dox concentrations. The expressed HPV 16 E6 and E7 mRNA 
was subsequently sequenced reassuring the absence of mutations (Supplementary 
Figure 2). 
After confirming the dox-inducible expression of HPV 16 E6 and E7 mRNA, Western blot 
analysis was performed to validate the translation into HPV 16 E6 and E7 proteins. Due 
to the lack of sensitive and selective HPV 16 E6 antibodies, p53 and p21 levels were 
monitored as indirect markers for the presence of HPV 16 E6 proteins. As shown in 
Figure 15B, p53 and p21 levels decreased in the HCT116-HPV 16 E6 clone and in the 
HCT116-HPV 16 E6 and E7 clone after dox treatment indicating the production of 
functional HPV 16 E6 proteins. Dox-dependent synthesis of HPV 16 E7 proteins was 
detected in the clones selected for HPV 16 E7 expression either individually or in 
combination with E6. In agreement with the mRNA expression data, increasing dox 
concentrations and prolonged treatment periods also resulted in elevated HPV 16 
oncoprotein levels. Importantly, HPV 16 oncoproteins could neither be detected in the 
absence of dox nor in the dox-treated master cell line HCT116-HygTK indicating 
antibody specificity and excluding any significant leakiness of the expression system. 
In the following step, activation and repression of the promoter was characterized in 
more detail by first adding dox and then removing it again from the growth medium. 
Information about how fast HPV 16 oncogene expression can be turned off after dox 
removal represent the basis to study whether E6- and E7-mediated effects might be 
reversible. For this, the generated clones were treated with dox for 48 hours. Afterwards, 
dox was removed from the growth medium and HPV 16 oncogene expression was 
quantified after six, 24, and 48 hours (Figure 16A). Consistent with previous results, dox 
treatment induced HPV 16 E6 and E7 mRNA and protein expression in all three clones 
(Figure 16B and C). After removing dox from the medium, the system was rapidly turned 
off as reflected by significant reduction of E6 and E7 mRNA levels already six hours 
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after dox removal. These results were also confirmed on protein level. As proteins 
possess longer half-lives than mRNA molecules and as the mRNA transcribed before 
dox removal is still translated into protein, the decline in HPV oncoprotein levels was 
slower than for HPV 16 E6 and E7 mRNA levels. However, 24 hours after dox removal 
no HPV 16 E6 or E7 proteins were detected by Western blot anymore. 
Figure 14: Treatment of HCT116 clones with hygromycin B and ganciclovir.  
HCT116 clones generated for the inducible expression of HPV 16 oncogenes as well as the master cell 
line HCT116-HygTK were treated with DMSO (solvent control), 200 ng/mL hygromycin B or 40 µM 
ganciclovir to monitor the replacement of the HygTK expression cassette during the cloning process. 
Representative images are shown. The scale bars reflect 100 µm. 
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Taken together, the generated HCT116 clones allow rapid and sustained expression of 
HPV 16 E6 and E7 either individually or in combination from a defined chromosomal 
locus after dox induction. Dox removal in return results in re-silencing of the promoter 
suggesting stringent HPV 16 oncogene expression only in the presence of dox. 
Therefore, the generated clones were used in subsequent analyses to study the effects 
of HPV 16 oncogene expression on proliferation, chromosomal stability, gene 
expression levels and DNA methylation patterns. 
Figure 15: Quantification of inducible HPV 16 oncogene expression in HCT116-HPV 16 E6 and E7 
clones. 
(A) Inducible expression of HPV 16 E6 and E7 mRNA was monitored by RT-qPCR after treating the 
generated HCT116 clones with dox (100 or 500 ng/mL) for 48 hours or nine days. The diagrams show the 
mean HPV 16 E6 and E7 mRNA levels relative to those obtained in the untreated clone, respectively. The 
data are based on three independent treatments and the error bars represent the according standard 
deviation. Expression of β-actin mRNA was used as internal loading control. Student`s t-test was 
performed to calculate p values. *: p<0.05, **: p<0.01 and ***: p<0.001. (B) Production of HPV 16 
oncoproteins was monitored by performing Western blot analysis. Due to the lack of potent HPV 16 E6 
antibodies p53 and p21 protein levels were analyzed to indirectly confirm the presence of HPV 16 E6. β-
actin was used as internal loading control. 
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3.2.3. Growth behavior of HCT116 clones after expressing HPV 16 oncogenes 
In order to investigate whether induction of HPV 16 oncogene expression affects the 
growth behavior of the generated HCT116 clones, cell proliferation was indirectly 
quantified by measuring the DNA content. As shown in Figure 17, expression of HPV 16 
E6 and E7 neither individually nor in combination substantially altered the proliferation of 
HCT116 cell clones during the measured time period ranging from six to 96 hours. After 
inducing the joint expression of HPV 16 E6 and E7 for 48 and 72 hours, proliferation 
slightly reduced compared to untreated cells. Despite being statistically significant the 
decrease in cell growth was only marginal and was not observed after 96 hours of HPV 
16 oncogene induction anymore. To exclude that the dox concentrations used in this 
experiment had any effect on the proliferation of the clones, the growth behavior of the 
master cell clone HCT116-HygTK was also monitored. Comparing dox-treated with 
untreated master cells, two time points were significantly altered. However, the 
difference in proliferation was minor and was not detected after dox treatment for 72 and 
96 hours. 
Additionally, the growth behavior of the HCT116 clones after induction of HPV 16 
oncogene expression was monitored microscopically using crystal violet cell staining. In 
agreement with the proliferation assay data, relevant differences in cell growth could not 
be observed after inducing the expression of HPV 16 E6 or E7 (Figure 17). These data 
suggest that neither dox treatment nor the induction of HPV 16 oncogene expression 
significantly affect the growth behavior of HCT116 clones during the analyzed time 
period. However, influences of the HPV 16 oncogenes on the proliferation rate after 
longer induction periods cannot be excluded. 
 
3.2.4. Effects of HPV 16 E6 and E7 on chromosomal stability in HCT116 clones 
As discussed in previous sections, the roles of both HPV 16 oncogenes in inducing 
chromosomal instability are well described for NHK cells as well as for cervical 
carcinoma cell lines (reviewed in (Korzeniewski et al. 2011)). Therefore, studying the 
effects of inducible HPV 16 E6 and E7 expression on chromosomal stability in the 
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generated HCT116 clones was used on the one hand to validate the biological 
relevance of the established model system and on the other hand to gain a more 
detailed picture about how and when these effects are induced. 
Figure 16: Characterization of inducibility of HPV 16 oncogene expression in the HCT116 clones. 
(A) The graphic illustrates the procedure of the experiment. First, HCT116 clones were seeded and HPV 
oncogene expression was then induced by treating the cells with 500 ng/mL dox for 48 hours. In the next 
step, dox was removed from the medium to prevent HPV oncogene expression. Afterwards, the cells were 
harvested six hours (Sample 1), 24 hours (Sample 2) and 48 hours (Sample 3) later. (B) Expression of 
HPV 16 E6 and E7 was quantified using qRT-PCR. The bars represent mean E6 and E7 mRNA levels of 
two independent experiments relative to the expression in untreated cells cultured for 48 hours. The 
according standard deviation is given by the error bars and Student`s t-test was used to determine p 
values. *: p<0.05; **: p<0.01; ***: p<0.001; ns: not significant. (C) Western blot was conducted to monitor 
the production of HPV 16 oncoproteins. Similar to Figure 15, p53 and p21 levels were used as indirect 
markers for the presence of HPV 16 E6. β-actin levels were detected as loading controls. The small 
numbers below the lanes indicate the fold changes of the densiometric quantification relative to the 
detected levels in not-induced cells. 
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3.2.4.1. Centrosome duplication and mitotic progression 
Centrosomes are the main microtubule forming organelles in the cells and therefore play 
an important role in regulating bipolar mitosis and chromosomal segregation. During S 
phase of the cell cycle the centrosome duplicates exactly once facilitating the formation 
of two spindle poles during mitosis. Centrosome duplication is tightly regulated and 
coupled to DNA replication. However, DNA and centrosome replication are frequently 
deregulated in cancer cells resulting in structural and numerical centrosomal 
aberrations. During subsequent mitosis these cells tend to form abnormal spindle poles 
Figure 17: Proliferation of dox-inducible HCT116-HPV 16 E6 and E7 clones. 
The proliferation of HPV 16 E6- and E7-expressing HCT116 clones was monitored by quantifying the DNA 
content. The diagrams show the mean proliferation levels of at least three independent experiments after 
treatment with 500 ng/mL dox for six, 24, 48, 72 and 96 hours. The according standard deviation is 
represented by the error bars and Student`s t-test was performed to calculate p values using untreated 
cells as a reference control. *: p<0.05, **: p<0.01 and ns: not significant. For the cell staining using crystal 
violet, the cells were treated for 96 hours with 500 ng/mL dox and then stained as described in the 
respective chapter in the methods section. Representative images are shown. The scale bar has a size of 
500 µm. 
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that may lead to the generation of aneuploid daughter cells. Due to chromosomal 
damage most of the progeny cells are assumed to be unable to undergo subsequent cell 
divisions. Permanent mitotic errors may, however, promote high levels of genetic 
variations potentially increasing the risk for the generation of cells that are capable to 
divide and to produce viable offspring. Thereby, genomic and chromosomal instability 
continuously contribute to the generation and potential outgrowth of highly proliferative 
subclones, a common characteristic of several tumor types (reviewed in (Holland & 
Cleveland 2009, McGranahan et al. 2012)). 
Previous studies showed that stable as well as transient expression of HPV 16 E6 and 
E7 in NHKs elevated the number of centrosomes in interphase cells leading to abnormal 
spindle pole formation during mitosis (Duensing et al. 2000). The aim of the present 
study was to investigate these effects in more detail by analyzing centrosome numbers 
and spindle pole formation after HPV 16 oncogene induction in the generated HCT116 
clones. Using a dox-inducible expression system enables evaluation of centrosome 
numbers and spindle pole formation during a defined time period of HPV 16 E6 and E7 
expression. Therefore, HPV 16 oncogene expression was induced for 48 hours and nine 
days reflecting about two and ten cell cycles, respectively. Afterwards, the cells were 
fixed and centrosomes as well as spindle poles were stained using antibodies targeting 
the pericentriolar marker γ-tubulin. 
Induction of HPV 16 E6 expression led to a moderate increase in the proportion of 
interphase cells containing more than two centrosomes (Figure 18). Similar results were 
observed after inducing the expression of HPV 16 E7. Dox treatment of the HCT116-
HPV 16 E7 clone raised the number of cells containing abnormal centrosomes from less 
than 2% in the untreated cell population to 5-6%. The percentage of interphase cells 
containing aberrant centrosomes again increased about 3-4% after expressing both 
HPV 16 oncogenes. As expected, increasing the concentrations of dox not only resulted 
in higher HPV 16 E6 and E7 expression levels, as shown in previous chapters, but also 
tended to elevate the percentage of cells carrying abnormal centrosome numbers. This 
effect was already observed after 48 hours of dox treatment. Extending the treatment 
period to nine days was, however, not found to further increase the level of cells 
containing aberrant centrosome numbers. Treatment of the parental clone HCT116-
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HygTK did not cause elevated numbers of cells carrying aberrant centrosomes, thereby 
excluding any dox-related effects. 
In the next experiment it was investigated whether the observed modest increase in cells 
containing aberrant centrosome numbers would also result in an increase in cells 
forming abnormal spindle poles during mitosis. Therefore, spindle pole formation was 
analyzed after inducing HPV 16 oncogene expression. As shown in Figure 19, the 
number of cells forming aberrant spindle poles tended to increase moderately after 
inducing the expression of HPV 16 oncogenes. In accordance with the evaluation of 
Figure 18: Quantification of abnormal centrosome numbers in HCT116 clones upon expression of 
HPV 16 oncogenes. 
(A) Centrosomes were visualized by staining the pericentriolar marker γ-tubulin in the generated HCT116 
clones induced for HPV 16 oncogene expression using either 100 or 500 ng/mL dox for 48 hours or nine 
days. The diagram shows the mean percentage of cells with more than two centrosomes of at least two 
independent experiments. The standard deviation is indicated by the error bars and Student`s t-test was 
performed to calculate p values using the respective untreated HCT116 clone as reference control. *: 
p<0.05, **: p<0.01 and ns: not significant. (B) The presented microscope images show examples of cells of 
the respective HCT116 clone containing different numbers of centrosomes after induced HPV 16 
oncogene expression (as indicated by the white arrows). To visualize centrosomes the pericentriolar 
marker γ-tubulin was immunofluorescently labeled. The included scale bars reflect 10 µm. 
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centrosome numbers, this effect was already observed after 48 hours of oncogene 
induction and was again not further enhanced after extending the oncogene induction 
period to nine days. Dox treatment of the parental control cells had no significant effect 
on spindle pole formation. 
To conclude, the level of abnormal centrosome duplication and aberrant spindle pole 
formation in untreated HCT116 cells is low making these cells a suitable model system 
to study the effects of HPV 16 oncogene expression. Induction of both oncogenes in the 
generated HCT116 clones moderately increases the number of cells containing 
abnormal centrosomes. These cells might then form aberrant spindle poles when 
entering mitosis as reflected by the slightly elevated number of multipolar spindles after 
induction of HPV 16 oncogene expression. 
 
3.2.4.2. DNA damage in HPV 16 E6- and E7-expressing HCT116 clones 
High levels of replicative stress as typically observed in proliferating tumor cells 
promotes the formation of DNA single- and double-strand breaks during S phase of the 
cell cycle (reviewed in (Hills & Diffley 2014)). Especially DSBs can significantly 
compromise chromosomal segregation and successful completion of mitosis. Therefore, 
cell cycle checkpoints have evolved to arrest cell cycle progression before entering 
mitosis, which allows the activation of DNA damage repair factors. Deregulated 
expression of the HPV 16 oncoproteins was, however, shown to impair cell cycle 
checkpoints as well as DNA damage response pathways in NHK cells resulting in 
increased levels of DNA breakages (Duensing & Munger 2002, White et al. 1994). To 
further study the effects of HPV 16 oncogene expression on DNA damage rates and to 
understand how fast DNA damage might occur, formation of DSBs was analyzed in HPV 
16 E6- and E7-expressing HCT116 clones. 
Formation of DSBs was monitored by immunofluorescent staining of histone H2AX 
phosphorylated at serine 139 (γH2AX). This histone component is rapidly 
phosphorylated after the induction of DSBs and is involved in the recruitment and 
activation of DNA damage response factors (Paull et al. 2000, Rogakou et al. 1998). 
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After inducing the expression of HPV 16 E6 the number of DNA-damaged cells, which 
was defined as containing more than three γH2AX foci, slightly increased from about 
40% in untreated cells to 45-50% in the dox-treated cells (Figure 20). Expression of HPV 
16 E7 also resulted in a moderate increase in DNA-damaged cells from 38% in 
untreated cells up to 50% after dox treatment. Similar effects were detected after 
inducing the combined expression of both HPV 16 oncogenes. In all tested HCT116 
clones the increase in DSBs was already observed after 48 hours of dox treatment. 
Extending the treatment duration to nine days seemed to only result in slightly higher 
Figure 19: Analysis of spindle pole formation during mitosis in HPV 16 oncogene-expressing 
HCT116 clones. 
(A) The formation of spindle poles during mitosis was monitored by immunofluorescent staining of γ-tubulin 
in HCT116-HPV 16 E6 and/or E7 clones after treatment with 100 or 500 ng/mL dox for 48 hours or nine 
days. The bars shown in the diagram represent the mean percentage of cell forming abnormal spindle 
poles based on at least biological duplicates. Cells forming either one or more than two spindles during 
mitosis were classified as abnormal. The error bars indicate the according standard deviation and p values 
were calculated by Student`s t-test using the respective untreated clone as a reference. *: p<0.05, **: 
p<0.01 and ns: not significant. (B) The images give examples for cells of the respective HCT116 clone 
forming multipolar, tripolar, pseudo bipolar and normal bipolar spindles during mitosis (highlighted by the 
white arrow). Spindle poles were visualized by immunofluorescent staining for γ-tubulin. The scale bars 
represent 10 µm. 
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levels of DNA-damaged cells. In contrast, the number of DNA-damaged cells remained 
unchanged when treating parental HCT116-HygTK cells excluding any dox-dependent 
effects on DSB formation. The presented data suggest that HPV 16 E6 but 
predominantly E7 might affect the formation of DSBs in HCT116 clones potentially 
compromising the genomic integrity of the cells. 
 
3.2.4.3. Quantification of aneuploid cells after HPV 16 oncogene expression 
Chromosomal missegregation and high levels of DNA damage during cell division 
promote the generation of aneuploid daughter cells. To detect those cells the DNA 
content of the HCT116 clones was quantified after HPV 16 oncogene induction by 
propidium iodide (PI) staining and subsequent flow cytometry. Thereby, the current cell 
cycle phase could be determined. Cells containing more chromosomal material than the 
cells in G2/M phase were defined as aneuploid. 
Induction of HPV 16 E6 expression for 48 hours did not affect the number of aneuploid 
cells. However, extending the treatment to nine days resulted in slightly elevated levels 
of aneuploidy (Figure 21). Stronger effects were observed after inducing the expression 
of HPV 16 E7 in the HCT116-HPV 16 E7 clone. Already 48 hours of E7 induction were 
sufficient to increase the number of aneuploid cells from 5% in untreated cells up to 10% 
after dox treatment. Similar effects were also detected after extending HPV 16 E7 
expression to nine days. Expression of both HPV 16 oncogenes for 48 hours was, 
however, not found to dramatically affect aneuploidy in the HCT116-HPV 16 E6 and E7 
clone, whereas extension of the E6 and E7 expression to nine days resulted in a modest 
but significant increase in the number of aneuploid cells. Irrespective of the dox 
treatment extended cultivation periods seemed to elevate the number of aneuploid cells. 
To exclude any dox-related effects aneuploidy was also quantified in the parental 
HCT116-HygTK cells identifying no significant changes. 
3. Results 
 
78 
 
Based on these data it can be concluded that the moderate increase in abnormal 
spindle pole formation during mitosis as well as the slight elevation in DNA damage 
rates after expression of HPV 16 oncogenes may promote the generation of aneuploid 
cells. Extended cultivation as well as prolonged oncogene induction were found to 
enhance this effect potentially due to the elevated number of cell cycle phases. 
 
Figure 20: Analysis of DNA double-strand breaks in HPV 16 oncogene-expressing HCT116 clones. 
(A) Phosphorylation of the histone component γH2AX was used as a marker for the induction of DSBs in 
the generated HCT116 clones. DSBs were analyzed by counting immunofluorescently labeled γH2AX foci. 
Cells showing more than three foci were considered as DNA damaged. The analysis was performed after 
inducing HPV 16 oncogene expression for 48 hours or nine days in the indicated clones by treating the 
cells either with 100 or 500 ng/mL dox. The bars in the diagrams show the mean percentage of DNA 
damaged cells from at least two independent experiments. The standard deviation is indicated by the error 
bars and Student`s t-test was performed to calculate p values using untreated cells of the respective clone 
as reference control. *: p<0.05, **: p<0.01 and ns: not significant. (B) The microscope images show cells 
containing different levels of DNA damage (as highlighted by the white arrows). Phosphorylated γH2AX 
was immunofluorescently stained after induction of HPV 16 oncogene expression as described in (A). The 
scale bars reflect 10 µm. 
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3.2.4.4. Genomic copy number variations after HPV 16 oncogene expression 
Chromosomal missegregation during mitosis in combination with high levels of DNA 
damage might not only increase the number of aneuploid cells but also the frequency of 
genomic copy number variations (CNVs). To detect CNVs in HCT116 clones in 
response to HPV 16 oncogene expression, isolated and bisulfite converted DNA was 
hybridized to Infinium® MethylationEPIC BeadChips (Illumina), which were designed to 
assess the methylation status of about 850,000 CpG sites in the genome. For this 
purpose, the array detects methylated as well as unmethylated DNA copies, which 
allows quantification of the methylation level at genomic loci and also provides 
information about the copy number of the respective genomic region (Feber et al. 2014). 
Bisulfite treatment of the isolated DNA and subsequent hybridization to the arrays was 
performed at the DKFZ Genomics and Proteomics Core Facility. Raw data retrieval and 
subsequent processing was conducted in cooperation with colleagues from the 
Neuropathology Department, who had previously developed a CNV analysis pipeline 
that resulted in numerous publications (Sahm et al. 2017) (Herrlinger et al. 2016). 
Pairwise comparison of CNV profiles between dox-treated and untreated HCT116 
clones did not reveal substantial alterations that would reflect gains or losses of whole 
chromosomes or chromosomal arms (Figure 22). In the next step, the CNV profiles were 
analyzed in more detail by specifically focusing on chromosomal regions that have 
previously been described to be frequently gained or lost during HPV-driven cervical 
carcinogenesis, respectively. In HPV 16-transformed cervical carcinomas the following 
DNA copy number alterations have been reported: gain at chromosome 3q (rate 0.84), 
gain at chromosome 1q (rate 0.54), gain at chromosome 5p (rate 0.38), loss at 
chromosome 3p (rate 0.32) and loss at chromosome 11q (rate 0.3) (Steenbergen et al. 
2014, Thomas et al. 2014). Induction of HPV 16 oncogene expression in the generated 
HCT116 clones could, however, not be correlated with gains or losses of any of these 
chromosomal arms. 
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The observed discrepancy might be the result of different factors complicating direct 
comparison between the published data and the results generated in the present study. 
First, specific hotspots of CNVs might only be detectable after analyzing additional 
biological replicates increasing the probability to identify enriched or lost chromosomal 
sites. Additionally, discrepancies might be the result of differences in the methods used 
to detect CNVs, as most of the published studies use either classical comparative 
genome hybridization (CGH) to karyotypically normal metaphase chromosomes or 
array-based CGH platforms. Finally, in the present study CNV profile analysis was 
performed after nine days of HPV 16 oncogene induction reflecting a rather short period 
of E6 and E7 expression as most cervical cancers evolve over several years or even 
decades. 
Taken together, CNV profile analysis in HCT116 clones after induction of HPV 16 
oncogene expression did not reveal any hotspots of DNA CNVs that specifically 
occurred in a sufficient number of cells to be detectable using Infinium® 
MethylationEPIC BeadChips (Illumina). The resolution for the detection of CNVs might 
be increased by selecting single clones after inducing HPV 16 oncogene expression for 
a defined time period. Thereby, cells containing identical CNVs might become enriched 
increasing the likelihood for their detection. 
Figure 21: Number of aneuploid HCT116 cells after induction of HPV 16 E6 and E7 expression. 
The number of aneuploid cells was determined by performing flow cytometry of propidium iodide stained 
HCT116 clones after inducing HPV 16 oncogene expression for 48 hours or nine days. The results are 
presented as mean values based on at least five biological replicates. Error bars indicate the according 
standard deviation and p values were calculated by performing Student`s t-test using the respective 
untreated HCT116 clone as a reference control. *: p<0.05, **: p<0.01, ***: p<0.001 and ns: not significant. 
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Figure 22: Copy number variation profiles of HPV 16 oncogene-expressing HCT116 clones 
The effects of HPV 16 oncogene expression on copy number variations in HCT116 clones was analyzed 
by hybridizing bisulfite converted DNA to Infinium MethylationEPIC BeadChips (Illumina). Therefore, the 
respective HCT116 clone was cultured for nine days either without treatment or in the presence of 500 
ng/mL dox. The conducted microarray analysis allows the quantification of copy numbers in about 850,000 
genomic sites. Gains (green) and losses (red) of copies of the respective genomic sites were calculated 
relative to the hg19 reference genome. 
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3.2.5. Differential gene expression upon HPV 16 oncogene induction 
In order to evaluate whether HPV 16 oncogene induction affects gene expression in 
HCT116 clones whole transcriptome analysis was performed using Illumina HumanHT-
12 microarrays. Therefore, HPV 16 oncogene expression was induced for 48 hours and 
total RNA was isolated. Hybridization to the array as well as subsequent data processing 
was performed in cooperation with the DKFZ Genomics and Proteomics Core Facility. 
Expression of the vast majority of about 31,000 tested genes remained unchanged, 
while a subset of genes was found to be differentially expressed following HPV 16 E6 
and/or E7 induction. In particular, expression of HPV 16 E6 led to the upregulation of 
512 genes, whereas 273 genes were found to be downregulated (p<0.01) (Benjamini & 
Hochberg 1995). 48 hours induction of the HCT116-HPV 16 E7 clone resulted in 
elevated expression levels of 161 genes and reduced expression of 63 genes. After 
activating both HPV 16 oncogenes 1575 genes appeared to be upregulated, whereas 
1900 genes were found downregulated. Dox treatment of the parental clone HCT116-
HygTK led to the upregulation of 455 genes and downregulation of 748 genes 
suggesting that the list of genes regulated by HPV 16 E6 and/or E7 might contain a 
number of false positive genes. 
Therefore, the most differentially expressed candidate genes were validated by RT-
qPCR. As shown in Table 4, upregulation of Kruppel-like factor 11 (KLF11) and 
Chemokine-like factor (CKLF) as well as downregulation of CDKN1A after induction of 
HPV 16 E6 expression could be confirmed. KLF11 functions as transcription factor for 
genes involved in the regulation of cell growth and apoptosis (Lomberk & Urrutia 2005), 
whereas CKLF is assumed to play a role in regulating proliferation (Tan et al. 2015). 
Reduced expression of CDKN1A, which encodes the protein p21, can be explained as a 
consequence of E6-mediated degradation of p53, which acts as transcription factor for 
CDKN1A. 
In conclusion, expression of HPV 16 oncogenes seems to affect mRNA transcription of a 
panel of genes. Some of these candidate genes were validated by performing RT-qPCR. 
However, not all of the candidate genes obtained by Illumina HumanHT-12 microarray 
analysis could be confirmed suggesting that there might be a number of false positive 
3. Results 
 
83 
 
candidates. Therefore, the microarray data need to be interpreted carefully and should 
be further validated by using additional methods. 
 
3.2.6. Effects of HPV 16 oncogenes on DNA methylation levels 
As discussed in previous chapters, alterations in the methylation pattern seem to play an 
important role during HPV-mediated host cell transformation. These alterations not only 
occur in the viral, but also in the host cell genome. Several tumor suppressor genes 
have been shown to become transcriptionally silenced by hypermethylation during 
cervical carcinogenesis including E-cadherin (CDH1), Cell Adhesion Molecule 1 
(CADM1) and Death-Associated Protein Kinase 1 (DAPK1) (Bierkens et al. 2013, 
Henken et al. 2007, Kalantari et al. 2014, Laurson et al. 2010, Narayan et al. 2003). 
Moreover, both HPV 16 oncoproteins seem to affect CpG methylation levels, as HPV 16 
E6 was reported to indirectly upregulate DNMT1 transcription by targeting the 
Table 4: RT-qPCR validation of differentially expressed genes identified by using Illumina 
HumanHT-12 microarrays upon HPV 16 oncogene expression. 
To confirm the data retrieved from Illumina HumanHT-12 gene expression analysis, the mRNA levels of a 
panel of differentially expressed genes were measured using RT-qPCR. The table lists the fold changes of 
mRNA expression levels of the respective HCT116 clone comparing dox-treated [500 ng/mL] and 
untreated conditions after culturing for 48 hours. For direct comparison between the two assays the fold 
changes obtained by microarray analysis are also given. The listed fold changes represent mean values 
from at least three independent experiments. Student`s t-test was used to calculate p values. *: p<0.05, **: 
p<0.01, ***: p<0.001. 
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transcriptional suppressor p53 (Au Yeung et al. 2010). Additionally, HPV 16 E7 has 
been found to directly bind and activate DNMT1 (Burgers et al. 2007). Recently, it was 
also shown that shRNA knock down of HPV 16 E6 and E7 in SiHa and CaSki cells 
downregulates the expression of DNA methyltransferases resulting in elevated 
expression levels of a panel of tumor suppressor genes (Li et al. 2015). These findings 
suggest that the overexpression of the HPV 16 oncogenes might contribute to the 
observed increase in methylation levels during HPV-induced carcinogenesis. 
The present study used Infinium® MethylationEPIC BeadChips (Illumina) to analyze the 
effects of HPV 16 oncogene expression on the methylation level in HCT116 clones. 
Thereby, CpG methylation at about 850,000 sites located in CpG islands, promoter and 
enhancer regions as well as in gene bodies was quantified. To investigate whether HPV 
16 E6 and E7 expression would have an effect on global methylation levels, mean beta 
values of all CpGs located in promoter regions as well as gene bodies were calculated. 
In all tested HCT116 clones the mean methylation levels ranged between 46% and 48% 
(Figure 23). Neither 48 hours nor nine days of HPV 16 oncogene induction were found 
to dramatically affect the mean methylation levels suggesting that E6 as well as E7 had 
only minor effects on the global methylation pattern. 
Despite being globally unchanged, the methylation pattern in specific genes might be 
substantially altered. Therefore, all genes containing at least three CpG sites in their 
promoter or in the gene body that showed more than 5% difference in their methylation 
level after HPV 16 oncogene expression were identified. After induction of HPV 16 E6 
expression for 48 hours the methylation of eight genes increased whereas ten genes 
showed decreased methylation levels. Extending the HPV 16 E6 expression to nine 
days resulted in elevated CpG methylation in eleven genes and reduced methylation in 
17 genes. 48 hours of HPV 16 E7 expression led to increased methylation in 39 genes 
and decreased levels in 77 genes, whereas induction of HPV 16 E7 for nine days only 
resulted in ten genes that showed elevated methylation levels and in twelve genes with 
lower methylation levels. After expressing both HPV 16 oncogenes raised methylation 
levels were identified in eleven genes after 48 hours and in 17 genes after nine days, 
whereas methylation was reduced in nine genes after 48 hours and in 15 genes after 
nine days. 
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Alterations in gene methylation levels mediated either by HPV 16 E6 or E7 should be 
detectable in the respective clone expressing E6 or E7 individually as well as in the 
clone expressing both oncogenes in combination. One of the candidate genes fulfilling 
this criterion was keratin 38. CpG methylation in the keratin 38 gene was found to 
increase after induction of HPV 16 E6 expression for nine days either individually or in 
combination with E7. Other candidates might be Olfactory Receptor Family 5 Subfamily 
D Member 16 (OR5D16) and Protein Kinase C Alpha Antisense RNA 1 (PRKCA-AS1). 
Expression of both HPV 16 oncogenes either individually or in combination resulted in 
elevated methylation levels in the OR5D16 gene and in reduced levels in the PRKCA-
AS1 gene. Hypermethylation of the tumor suppressor genes, which have been reported 
during cervical carcinogenesis in previous studies, could not be detected in the present 
analysis. However, the analyzed data are only based on a single biological sample per 
treatment condition and therefore need to be further validated. Additionally, the HPV 16 
E6 and E7 induction period of 48 hours or nine days might not be long enough to select 
Figure 23: Mean CpG methylation of HPV 16 oncogene-expressing HCT116 clones. 
The mean CpG methylation level of HPV 16 E6 and/or E7 expressing HCT116 clones was calculated using 
Infinium® MethylationEPIC BeadChips (Illumina) data after dox treatment [500 ng/mL] for 48 hours or nine 
days. 
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a sufficient large number of cells containing HPV 16 oncogene-specific methylation 
changes to be detected by the analysis. 
Altogether, expression of HPV 16 oncogenes in HCT116 clones was not found to 
substantially affect the global methylation level. In contrast, CpG methylation of several 
gene promoters as well as gene bodies seemed to be altered after HPV 16 E6 and/or E7 
expression. Especially keratin 38 as well as OR5D16 and PRKCA-AS1 might be 
candidate genes that are differentially methylated upon HPV 16 oncogene expression. 
Due to the lack of biological replicates the presented data need to be interpreted 
carefully. 
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4. Discussion 
4.1. Role of altered DNA methylation during HPV-mediated 
transformation 
Persistent hr-HPV infections may cause cervical and other types of tumors (zur Hausen 
2002). The formation of HPV-associated tumors generally spans years or even decades 
and represents the final stage of multiple precancerous precursor lesions. The 
progression from persistent HPV infections to invasive cancer is accompanied by 
substantial alterations in the methylation pattern of the viral and host cellular genome 
(reviewed in (Johannsen & Lambert 2013, Steenbergen et al. 2014)). These include the 
gradual increase in HPV genome methylation, especially in the genes coding for the 
structural proteins L1 and L2 as well as for E2 and E5 (Brandsma et al. 2009, Fernandez 
et al. 2009, Kalantari et al. 2004, Mirabello et al. 2013). In addition, changes in the HPV 
URR methylation level have been observed and are assumed to play a major role during 
the progression of HPV-associated lesions (Bhattacharjee & Sengupta 2006, Ding et al. 
2009, Hong et al. 2008). Modifications in the URR methylation pattern strongly depend 
on host cell differentiation as well as on the integration status of the viral genome. Due 
to their importance for the regulation of HPV oncogene expression, alterations in E2BS 
methylation during cervical carcinogenesis have been analyzed in several studies 
(Chaiwongkot et al. 2013, Kalantari et al. 2008, Kim et al. 2003, Vinokurova & von 
Knebel Doeberitz 2011). High levels of E2BS methylation were either detected if the viral 
genome was in episomal state or if it was integrated into the host genome as 
concatemers. In contrast, the E2BSs were found hypomethylated in lesions containing 
single copy HPV integrates with disrupted E2 open reading frames. These data suggest 
that in lesions with intact E2 gene, the E2-dependent transcriptional control of E6 and E7 
is inhibited by hypermethylation either preventing E2 expression or its interaction with 
methylated E2BSs. 
In addition to the viral genome, alterations in DNA methylation during the progression of 
HPV-associated lesions have been observed in host cellular genes. Hypermethylation 
and, as a consequence, repression of transcription have been detected in numerous 
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tumor suppressor genes including E-cadherin (CDH1), Cell Adhesion Molecule 1 
(CADM1) and Death- Associated Protein Kinase 1 (DAPK1) (Bierkens et al. 2013, 
Kalantari et al. 2014, Laurson et al. 2010, Narayan et al. 2003). Moreover, the 
expression of several host cellular miRNAs was found to be affected by 
hypermethylation in their promoter regions (Jimenez-Wences et al. 2014). Especially, 
the hypermethylation-mediated silencing of the miR-375 promoter detected during the 
progression of HPV-infected lesions seems to play a predominant role in the 
deregulation of E6 and E7 expression, as this miRNA was demonstrated to directly bind 
and promote the degradation of HPV oncogene transcripts (Bierkens et al. 2013, Wang 
et al. 2011, Wilting et al. 2013, Yan et al. 2014). The tumor suppressive role of miR-375 
is further pronounced by its ability to prevent the expression of several other genes 
including those encoding the transcription factor Sp1, which contributes to tumor 
development and progression, the protein CIP2A, which inhibits the degradation of the 
transcription factor MYC, as well as the ubiquitin-protein ligase E6AP that is involved in 
the E6-mediated degradation of p53 (Gartel et al. 2001, Jung et al. 2014, Junttila et al. 
2007, Wang et al. 2011, Yao et al. 2004, Yuan et al. 2007). 
The complexity of changing DNA methylation levels during the progression of HPV-
associated lesions is further highlighted by recent studies, which show that the 
expression of E6 and E7 is not only affected by altered DNA methylation levels, but both 
HPV oncoproteins itself also manipulate the DNA methylation machinery. HPV 16 E6 
was demonstrated to induce the expression of DNMT1 by degrading its transcriptional 
repressor p53, and HPV 16 E7 was reported to directly bind and activate DNMT1 (Au 
Yeung et al. 2010, Burgers et al. 2007). In addition, short-hairpin RNA-mediated knock-
down of E6 and E7 expression was found to reduce the levels of DNA 
methyltransferases in SiHa and CaSki cells. Thereby, DNA methylation levels decreased 
leading to elevated expression of a panel of tumor suppressor genes and to inhibited 
proliferation (Li et al. 2015). In summary, the published data indicate that the alterations 
in the DNA methylation pattern during the progression of HPV-associated lesions are 
complex and crucial for the deregulation of HPV oncogene expression. Especially 
hypermethylation of CpGs in the E2BSs, as well as in tumor suppressor genes seems to 
play a predominant role during the formation of HPV-driven tumors. Therefore, the 
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application of demethylating substances might represent an attractive strategy to 
interfere with increasing DNA methylation levels, thereby re-establishing the regulatory 
functions of the E2BSs and of affected tumor suppressor genes. 
 
4.2. Treatment of HPV-transformed cell lines with the demethylating 
agent DAC 
Demethylating agents have been extensively used for the treatment of hematopoietic 
malignancies (Sorm & Vesely 1968). The most potent group of demethylating 
substances is the group of cytidine analogs, which are incorporated into the DNA during 
replication irreversibly binding to DNMT1. In addition, these substances induce the 
proteasomal degradation of DNMT1 thereby mediating global DNA demethylation in 
replicating cells (Creusot et al. 1982, Jones 1985, Jones & Taylor 1980). One of the 
most prominent members is DAC, whose demethylating effects have been thoroughly 
studied resulting in the FDA approval for the treatment of myelodysplastic syndrome 
(Kantarjian et al. 2006, Tefferi & Vardiman 2009). In addition to hematological diseases, 
the effects of DAC treatment on solid tumors have been investigated in several clinical 
trials (reviewed in (Cowan et al. 2010, Nie et al. 2014)). In these studies the response to 
DAC treatment strongly relied on the tumor type, however, the level of DNA 
demethylation in the tumor cells was not directly measured. Numerous reports have 
demonstrated that the level of DAC-mediated DNA demethylation highly depends on its 
administered dose (Issa et al. 2004, Tsai et al. 2012). High concentrations of DAC have 
been observed to cause cytotoxicity without inducing DNA demethylation (Juttermann et 
al. 1994). As a consequence, the administration of lower doses seems to be more 
promising for clinical application especially when DNA demethylation is expected to 
provide tumor specific effects. 
In the present study, the effects of DAC treatment were systematically analyzed in a 
panel of HPV-transformed cell lines. To consider its dose dependent mechanism of 
action, different DAC concentrations were tested ranging from 0.1 µM to 1.0 µM. DNA 
demethylation was examined by monitoring LINE-1 methylation levels, which decreased 
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in all of the analyzed cell lines. Especially in CaSki cells, increasing the concentration of 
DAC to 1.0 µM did not further enhance the demethylating effect resulting in the 
previously discussed characteristic U-shaped LINE-1 methylation profile. 
After confirming DNA demethylation, the effects of DAC treatment on the expression of 
E6 and E7 in the HPV-transformed cell lines were investigated. Transcription of E6 and 
E7 decreased in all of the analyzed cell lines. The most significant effects were detected 
in CaSki, UM-SCC-47 and UM-SCC-104 cells, whereas moderate decreases of E6 and 
E7 expression were observed in SiHa cells. Western blot analysis, however, revealed 
substantial reductions in E7 protein levels in all cell lines including SiHa cells. 
Repression of HPV 16 E6 and E7 expression in CaSki and UM-SCC-47 cells after DAC 
treatment have also been described in other publications (Fernandez et al. 2009, Zhang 
et al. 2015). In one of these reports as well as in a study published by Kalantari et al., 
DAC treatment was, however, not found to significantly affect the expression levels of 
HPV 16 oncogenes in SiHa cells (Kalantari et al. 2008). 
In addition to the inhibition of HPV oncogene expression, DAC treatment caused 
significant increases in p53 and p21 levels in the cell lines. Enhanced presence of p53 
and p21 can be explained by decreases in HPV E6 levels after DAC treatment. As both, 
p53 and p21, are potent cell cycle inhibitors, reduced cell proliferation was expected and 
also detected by quantifying the DNA content as well as the colony formation capacity of 
the cells. The inhibition of proliferation might, however, be caused by multiple 
interconnected mechanisms. In addition to the elevation of p53 and p21 levels, reduction 
of HPV oncogene expression affects several other factors, which regulate cell cycle 
progression. In particular, reactivation of pocket proteins (pRb, p107 and p130), 
potentially as a consequence of repressed HPV E7 production, decelerates the cell 
cycle by binding E2F transcription factors. Moreover, DAC treatment inhibits proliferation 
independent of the presence of HPV by forming covalent bonds with DNMT1. These 
bonds are cytotoxic because gene transcription and DNA replication are prevented 
(Juttermann et al. 1994). Furthermore, global DNA demethylation might inhibit cell 
division by activating the expression of numerous tumor suppressor genes and by 
inducing cell differentiation (Baylin 2005, Jones & Taylor 1980). Taken together, several 
mechanisms are involved in the DAC-mediated inhibition of cell proliferation. These can 
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be distinguished in mechanisms that are either dependent or independent of DNA 
demethylation. The effects caused by reduced DNA methylation levels can, in turn, be 
grouped into those specific for HPV-transformed cells or those independent of HPV 
infections. Due to the HPV specificity of some of these mechanisms, it can be 
hypothesized that especially patients suffering from HPV-associated lesions might 
benefit from DAC therapy. 
 
4.3. DAC-dependent mechanisms that inhibit HPV oncogene 
expression 
The present study aimed to investigate DAC-dependent mechanisms that lead to the 
inhibition of HPV oncogene expression. As introduced previously, one of the potential 
mechanisms regulating E6 and E7 transcription is the alteration of E2BS methylation 
levels, which affects the binding of E2 and thereby the transcriptional activity of the HPV 
URR. Therefore, the methylation levels of the E2BS 3 and 4 were quantified after DAC 
treatment. These two E2BSs were selected for the analysis because the interaction of 
E2 with these has been reported to silence the transcriptional activity of the HPV early 
promoter by preventing the interaction of the transcription factors Sp1 and TBP with their 
respective binding sites located in close proximity to E2BS 3 and 4 (Steger & Corbach 
1997, Stubenrauch et al. 1998). Hypermethylation of E2BS 3 and 4 sites has, in turn, 
been demonstrated to prevent the E2-mediated repression of URR transcription 
(Chaiwongkot et al. 2013, Kim et al. 2003, Thain et al. 1996). 
As expected, DAC treatment decreased the methylation levels of CpGs located in the 
E2BS 3 and 4 in CaSki and UM-SCC-47 cells. These cell lines have previously been 
shown to express E2, further substantiating the hypothesis that the E2-mediated 
transcriptional regulation of E6 and E7 expression is reactivated after DAC treatment 
(Akagi et al. 2014, Olthof et al. 2015, Zhang et al. 2015). Demethylation of E2BS 3 and 4 
was, however, not detected in SiHa and UM-SCC-104 cells, as the E2BSs in these cell 
lines are not methylated. Moreover, SiHa and UM-SCC-104 cells lack intact E2 gene 
copies and consequently do not express functional E2 proteins (Akagi et al. 2014, Olthof 
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et al. 2015). Therefore, additional mechanisms exist explaining the decrease in HPV 
oncogene expression in E2-disrupted cells after DAC treatment. 
One of these additional mechanisms seems to be the reactivated expression of miR-
375. Transcription of miR-375 has been demonstrated to depend on the methylation 
level of CpGs located in its promoter region (Wilting et al. 2013). Elevated methylation, 
as observed during HPV-driven transformation of the host cells, has been found to 
silence the transcription of miR-375 precursors (Bierkens et al. 2013, Wang et al. 2011). 
Reduced miR-375 expression directly affects HPV oncogene levels because this miRNA 
has been demonstrated to bind to E6 and E7 transcripts promoting their degradation 
(Jung et al. 2014). To further investigate the role of miR-375 in the regulation of HPV 
oncogene expression, the methylation level of six CpGs in the miR-375 promoter was 
analyzed. DAC treatment caused significant demethylation of this region in the analyzed 
cell lines. Subsequent quantification of miR-375 expression revealed a substantial 
increase after DAC treatment. To finally demonstrate the functional relevance of 
reactivated miR-375 transcription in repressing HPV oncogene expression, miR-375 was 
transfected into CaSki and SiHa cells. As a consequence, E6 and E7 expression was 
found to decrease in both cell lines, thereby underlining the role of this miRNA in the 
regulation of HPV oncogene expression levels. 
In conclusion, DAC treatment effectively represses proliferation and colony formation of 
HPV-transformed cell lines. This effect is mediated by several mechanisms, which 
predominantly depend on global DNA demethylation (at least in the tested dose ranges). 
In addition, it can be hypothesized that HPV-infected cells are specifically sensitive to 
the treatment with DAC, as reduced E2BS methylation in the presence of E2 proteins as 
well as demethylation-mediated reactivation of miR-375 strongly inhibit the expression of 
HPV oncogenes. Therefore, the application of DAC as demethylating therapy might be a 
promising approach for the treatment of HPV-associated lesions. The systematic 
analysis of this substance in clinical trials is, thus, highly needed. The data presented in 
the current study might represent the basis legitimating those future clinical trials as well 
as subsequent analyses investigating, for example, immunological pathways including 
antigen expression and presentation, which have previously been reported to be 
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affected by the application of DAC (Mora-Garcia Mde et al. 2006, Nie et al. 2001, Weber 
et al. 1994). 
 
4.4. Generation of a model system for the inducible HPV 16 oncogene 
expression 
Deregulated expression of the HPV oncogenes E6 and E7 is the key event for the 
progression from permissive to transforming HPV infections. As discussed previously, 
overexpression of both oncogenes abrogates cell cycle checkpoints, interferes with 
apoptosis pathways and induces chromosomal instability in proliferating cells (reviewed 
in (Klingelhutz & Roman 2012, Moody & Laimins 2010, Roman & Munger 2013)). For 
this reason, several approaches have been tested to target E6 and E7 in HPV-infected 
cells. Especially trials using antisense RNAs directed against E6 and E7 transcripts 
showed promising results in vitro, but could not be transferred into the clinics (Alvarez-
Salas & DiPaolo 2007, Gu et al. 2007). As direct targeting of E6 and E7 seems to have 
limited success, the inhibition of HPV oncogene expression or the interference with the 
effects mediated by E6 and E7 expression might be more promising. Approaches aiming 
to repress HPV oncogene expression have been introduced and discussed in the 
previous chapters. The development of effective treatment options for patients suffering 
from HPV-driven tumors, however, also relies on the precise understanding of the 
biological effects resulting from E6 and E7 overexpression. 
The role of the oncogenes during the formation of HPV-associated tumors has been 
extensively studied in normal human keratinocytes as well as in HPV-transformed cell 
lines. These model systems, however, show a number of limitations that complicate the 
investigation of HPV oncogene-dependent effects especially during the transformation of 
the host cells. Primary human keratinocytes are very critical for continuous culturing and 
can therefore not be used to study medium- and long-term effects of HPV oncogene 
expression. In contrast, established cervical cancer cell lines are already HPV-
transformed and can easily be cultured over long time periods. These cell lines, 
however, do not allow investigating the mechanisms that initiated the formation of tumor 
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cells. Therefore, the present study aimed to overcome some of these limitations by 
generating an inducible HPV 16 E6 and E7 expression system. 
The human colon cancer cell line HCT116 was selected as a model system because the 
development of these tumor cells can be distinguished from HPV-mediated 
immortalization. HCT116 cells are MMR deficient due to a mutation in the hMLH1 gene 
(Boland & Goel 2010, Parsons et al. 1993). Consequently, these cells accumulate 
frameshift mutations, especially in microsatellites, during DNA replication. As 
microsatellites can be found in several tumor suppressor genes including TGFBR2 and 
hMSH3, these genes are frequently mutated in microsatellite-unstable tumors. Despite 
showing a high mutation rate, HCT116 cells are characterized by low numbers of 
chromosomal variations, which is also reflected by their stable and almost diploid 
karyotype (Brattain et al. 1981, Ertych et al. 2014). In contrast, chromosomal instability 
and aneuploidy seem to play a fundamental role during the development of HPV-driven 
tumors, as both can already be detected in early HPV-associated lesions (Hashida & 
Yasumoto 1991, Solinas-Toldo et al. 1997, Steinbeck 1997). The formation of HPV-
transformed cells depends on the expression of the oncogenes E6 and E7, which target 
a variety of host cellular factors, in particular p53 and the retinoblastoma protein family 
members. Inhibition of the respective signaling pathways not only relaxes cell cycle 
checkpoints, but also promotes the completion of abnormal mitosis (Duensing et al. 
2000, Duensing & Munger 2002, Moody & Laimins 2010). Consequently, HPV-
transformed cells show high rates of numerical and structural chromosomal alterations 
(Heselmeyer et al. 1996, Steenbergen et al. 2014, Thomas et al. 2014). The tumor 
suppressor genes p53 and the retinoblastoma family members are not mutated in 
HCT116 cells (Liu & Bodmer 2006). In conclusion, immortalization of HCT116 cells is 
characterized by a mutator phenotype, whereas HPV-driven transformation requires 
chromosomal instability. 
For the generation of HCT116 cells allowing the dox-inducible expression of HPV 16 E6 
and E7, the master cell line HCT116-HygTK was used. These cells have been 
established previously and were kindly provided by Dr Jennifer Lee and Dr Johannes 
Gebert (Lee et al. 2013). HCT116-HygTK cells continuously express the reverse 
tetracycline-controlled transactivator (rtTA). The HygTK expression cassette of these 
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cells is flanked by Flp-recombination sites. By expressing Flp recombinase this locus 
was re-targeted to insert constructs allowing the dox-inducible expression of HPV 16 E6 
and E7 either individually or in combination. For that reason, the performed strategy 
allowed to integrate single copies of the HPV 16 oncogenes into a defined chromosomal 
locus, thereby excluding mutational effects resulting of the random integration of multiple 
E6 and E7 sequences. Moreover, this integration strategy is assumed to only have a 
minimal risk for epigenetic silencing of the inserted construct because the expression of 
the HygTK cassette was found to remain active in the parental cell clone over long 
cultivation periods (discussed in the dissertation submitted by Dr. Jennifer Lee). 
The dox-inducible expression of the HPV 16 oncogenes was subsequently confirmed by 
systematically treating the generated clones using different concentrations of dox over 
varying time periods. As expected, elevated doses of dox as well as prolonged treatment 
led to increasing HPV 16 E6 and E7 expression levels. This effect was observed on 
mRNA and on protein level. Presence of HPV 16 oncoproteins was not detected in the 
absence of dox excluding any significant leakiness of the system. Due to the lack of 
specific antibodies, the presence of HPV 16 E6 was monitored indirectly by measuring 
p53 and p21 levels, which were found to decrease after induction of HPV 16 E6 
expression. As the HPV 16 E6-mediated degradation of p53 occurs on the protein level 
and as transcription of p53 is not known to be affected by HPV 16 E6, slight expression 
of p53 was still detectable and also expected after HPV 16 E6 induction. 
Deactivation of the dox-dependent promoter was then studied by removing dox from the 
growth medium. In all of the HCT116 clones HPV 16 E6 and E7 transcript levels 
decreased significantly already six hours after dox-removal. Due to their prolonged half-
lives, HPV 16 oncoprotein levels declined more slowly than mRNA levels and could not 
be detected 24 hours after removing dox. These data indicate the immediate 
deactivation of the dox-inducible promoter in the absence of dox. 
In conclusion, the generated model system enables the rapid and sustained induction of 
HPV 16 E6 and E7 expression either individually or in combination from a defined 
chromosomal locus in HCT116 cells. In contrast to other model systems, which have 
been used to study HPV infections, the presented inducible system has several 
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advantages. First, short- and long-term effects of HPV 16 oncogene expression can 
easily be investigated by adding dox to the growth medium. As HPV 16 oncogene 
expression can be deactivated by removing dox, the system might, additionally, be used 
to distinguish between effects that depend on continuous presence of E6 and E7 and 
those that are irreversibly initiated by the oncoproteins. Finally, inducible expression of 
the HPV 16 oncogenes in HCT116 cells might be specifically advantageous to 
systematically analyze the consequences of both oncoproteins on the chromosomal 
stability of the cells. Therefore, several experiments were performed to investigate 
whether HPV 16 oncogene induction compromises chromosomal integrity in HCT116 
cells, which would, in turn, also confirm the biological functionality of E6 and E7 in this 
system. 
 
4.5. Effects of HPV 16 oncogenes on chromosomal stability in HCT116 
cells 
After generating an inducible HPV 16 E6 and E7 expression system, the next objective 
of the project was to validate its biological relevance as well as to use the system for the 
discovery of yet undescribed effects of the HPV 16 oncogenes. First, proliferation of the 
generated HCT116 clones was analyzed showing no substantial differences between 
dox-induced and untreated cells during 96 hours induction period. Thus, short-term 
expression of the HPV 16 oncogenes seems not sufficient to significantly affect the 
proliferation of already immortalized HCT116 cells. The induction phase of 96 hours, 
however, reflects a rather short time period and can be interpreted as a starting point for 
more detailed analyses of the growth behavior. As alterations in the proliferation rate 
were also not detected in the parental HCT116-HygTK cells, these data indicate the 
absence of significant dox-related growth modulatory effects. 
Due to the chromosomal stability of HCT116 cells and due to the E6- and E7-dependent 
induction of genomic instability in NHK cells, the biological functionality and relevance of 
the generated system could be evaluated by investigating the consequences of HPV 16 
oncogene expression on chromosomal stability and genomic integrity in HCT116 cells. 
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Transient and stable expression of HPV 16 E6 and E7 in NHK cells were shown to 
increase the number of interphase cells containing abnormal centrosomes (Duensing et 
al. 2000). Aberrant centrosome numbers are assumed to result from the uncoupling of 
DNA replication form centrosome duplication during S phase of the cell cycle. Especially 
the E7-mediated degradation of the pocket proteins pRb, p107 and p130 seems to 
contribute to this effect because the expression of several factors, which coordinate 
centrosome duplication, is regulated by the transcription factor E2F (Martin et al. 1998, 
Zerfass et al. 1995). As centrosomes separate in prophase forming the spindle poles 
during mitosis, it is not surprising that aberrant numbers of centrosomes strongly 
increase the risk for the occurrence of multipolar spindles. In fact, elevated rates of 
abnormal spindle pole formation have been observed after expressing HPV 16 E6 and 
E7 in NHK cells (Duensing et al. 2000). In addition, presence of HPV 16 E6 
compromises DNA integrity due to the degradation of p53, which plays an important role 
in the activation of the DNA damage repair machinery (Duensing & Munger 2002). The 
combination of aberrant mitosis and destabilized DNA is assumed to increase the risk 
for the generation of aneuploid daughter cells. Although most of these daughter cells are 
presumably not viable, the genomic variability in the cell population might be 
substantially elevated, thereby increasing the probability for the outgrowth of potent 
subclones, which, in turn, can be considered as a source for genomic instability. 
The effects of HPV 16 oncogene expression on chromosomal stability in HCT116 cells 
were analyzed by quantifying centrosome numbers in interphase cells, by monitoring 
spindle pole formation during mitosis and by measuring the presence of DNA double-
strand breaks. In addition, the number of aneuploid cells was determined and the 
occurrence of gene copy number variations was evaluated potentially reflecting hotspots 
of chromosomal instability. 
After inducing HPV 16 oncogene expression in the generated HCT116 clones, the 
number of interphase cells containing abnormal centrosomes as well as the number of 
aberrant spindle poles during mitosis moderately increased. In accordance with 
published data, this effect seems to be specifically pronounced in the E7-expressing 
clones (Duensing et al. 2000). Elevated centrosome and spindle pole numbers were 
already detected after 48 hours of dox treatment and remained relatively constant, as no 
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further increases were noticed after nine days of dox treatment. Induction of HPV 16 E6 
expression also slightly elevated centrosome numbers and spindle pole formation in the 
respective HCT116 clones. The effects were, however, not as apparent as after 
induction of HPV 16 E7 expression. 
In addition to centrosome and spindle pole numbers, we also detected a modest 
elevation of DNA double-strand breaks after inducing HPV 16 E6 and E7 expression in 
HCT116 cells as indicated by γH2AX foci. As discussed previously, expression of HPV 
16 E6 interferes with DNA damage repair pathways by reducing the levels of p53, 
whereas HPV 16 E7 is assumed to promote DNA breakages by degrading pRb, which 
effectively prevents cell cycle arrest upon DNA damage induction (Harrington 1998). 
Expression of both oncogenes in combination led to slightly higher numbers of DNA 
double-strand breaks compared to the individual induction of either E6 or E7, potentially 
indicating the presence of cooperative effects. 
Chromosomal missegregation, caused by multipolar mitosis, in combination with 
impaired genomic integrity, reflected by high numbers of DNA double-strand breaks, 
promotes the generation of aneuploid daughter cells. As expected, aneuploidy increased 
after induction of HPV 16 E6 and E7 expression revealed by FACS-based cell cycle 
analyses. Again, stronger effects were detected in the HPV 16 E7-expressing cells 
compared to those expressing HPV 16 E6. Extended cultivation periods of the cells as 
well as prolonged HPV 16 oncogene expression resulted in elevated numbers of 
aneuploid cells. Although most of the cells undergoing abnormal mitosis might not be 
viable, this observation suggests that a subset of these cells potentially survives and 
subsequently divides, thereby increasing the percentage of aneuploid cells in the 
population over time. 
To study alterations in the genome of HPV 16 oncogene-expressing HCT116 cells in 
more detail, gene copy number variations were quantified using Infinium® 
MethylationEPIC BeadChips (Illumina). These microarrays were designed to assess the 
methylation status of more than 850,000 CpGs in the human genome by detecting 
methylated as well as unmethylated DNA copies of the respective CpG containing locus. 
Thereby, the method not only facilitates the quantification of methylation levels, but also 
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provides data about the number of copies of specific loci. To identify hotspots of copy 
number variations, HPV 16 E6 and E7 expression was induced for nine days reflecting 
approximately ten cell division cycles. Induction of HPV 16 oncogene expression was 
not found to cause significant gains or losses of whole chromosomes or chromosomal 
arms in a sufficient number of cells to be detected by the analysis. Thus, DNA copy 
number alterations, which have been published in HPV 16-transformed cervical 
carcinoma cells, could not be detected and therefore not directly be correlated to the 
presence of the HPV 16 oncoproteins. 
There are a number of factors, which may explain this discrepancy and that need to be 
kept in mind when interpreting the presented data. First, the copy number variation data 
were generated from a single biological replicate per treatment condition. Therefore, 
these preliminary data may provide first insights, but do not allow statistical 
interpretations. The complexity of the analysis is further increased, due to the absence 
of information about the time-span of HPV 16 oncogene induction that would be optimal 
to identify CNV hotspots. Ten cell division cycles might, thus, not be enough to generate 
a sufficient number of cells containing the same alteration to be detected by the array. 
To further enrich the number of cells with identical CNVs, it might be necessary to select 
and expand single clones after the induction of HPV 16 oncogene expression. Following 
this strategy would, however, require the analysis of a sufficient number of clones to 
identify common CNVs and to estimate their rate of occurrence. Therefore, this 
approach would be comparably budget- and time-consuming. The comparison of CNV 
data between different studies is further complicated due to the different methods that 
have been used for the analysis. The majority of the publications performed either 
classical comparative genome hybridization (CGH) to karyotypically normal metaphase 
chromosomes or array CGH. 
In conclusion, the presented gene copy number variation analysis constitutes a primary 
and preliminary experiment. Additional biological replicates and potentially the inclusion 
of generated subclones allowing a profound statistical analysis are highly needed. 
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4.6. Gene expression and DNA methylation upon HPV 16 oncogene 
induction 
The final aim of the present study was the identification of yet undiscovered effects of 
the HPV 16 oncogenes. Due to the simplicity of HPV 16 E6 and E7 activation and 
deactivation in the generated HCT116 clones, these cells represent an ideal model 
system to analyze direct consequences of E6 and E7 expression in a time dependent 
manner. In order to obtain a complete picture of E6- and E7-mediated effects in the 
cells, global gene expression and methylation analyses were performed. Although E6 
and E7 are not known to directly affect gene expression, both inhibit factors, like p53 or 
pRb, which in turn regulate the transcription of down-stream genes. Therefore, E6 and 
E7 are assumed to have a more indirect effect on the gene expression pattern of the 
cells. 
Here, we used Illumina HumanHT-12 microarrays to identify differentially expressed 
genes after 48 hours of HPV 16 oncogene expression. Afterwards, the most promising 
candidate genes were further validated by performing RT-qPCR. As expected, one of 
the transcriptionally silenced genes in the HPV 16 E6, but not HPV 16 E7, expressing 
clones was CDKN1A, which codes for the cyclin-dependent kinase inhibitor p21. 
Expression of p21 is directly dependent on p53 and, thus, HPV 16 E6-mediated 
degradation of p53 was anticipated to inhibit the expression of CDKN1A, thereby again, 
highlighting the biological functionality of the HPV oncoproteins and the significance of 
the performed analysis. In addition to the downregulation of CDKN1A, gene expression 
analysis as well as RT-qPCR validation revealed the upregulation of KLF11 and CKLF 
after the induction of HPV 16 E6 expression. Up to now, these two proteins have neither 
been extensively studied, nor linked to the presence or progression of HPV infections. 
KLF11 has been reported to regulate the expression of genes that play a role in the 
control of cell growth and apoptosis (Lomberk & Urrutia 2005). CKLF has also been 
suggested to contribute to the control of cell proliferation (Tan et al. 2015). However, the 
function and biological relevance of the HPV 16 E6-mediated upregulation of these two 
factors during HPV infection or during the progression of HPV-associated lesions needs 
to be further evaluated by more comprehensive investigations. To translate the results 
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from mRNA to protein level, Western blot quantification of KLF11 and CKLF protein 
levels after induction of HPV 16 E6 expression could be performed. Furthermore, it 
needs to be analyzed whether HPV 16 E6 directly affects the expression of these genes, 
or whether the effects are mediated indirectly, potentially as a consequence of the 
reduction of p53 levels. 
In addition to global gene expression analysis, alterations in the methylation pattern of 
gene promoter, CpG islands and enhancer regions were determined in response to HPV 
16 oncogene expression. As summarized in the Introduction, the transformation of HPV-
infected cells frequently involves changes in the CpG methylation levels in specific host 
cellular and viral genes. During HPV-driven cervical carcinogenesis, increasing 
methylation levels have especially been observed in tumor suppressor genes including 
E-cadherin (CDH1), Cell Adhesion Molecule 1 (CADM1) and Death-Associated Protein 
Kinase 1 (DAPK1) (Bierkens et al. 2013, Henken et al. 2007, Kalantari et al. 2014, 
Laurson et al. 2010, Narayan et al. 2003). Thereby, the regulation of transcriptional 
activity of these genes is disturbed promoting the transformation of the host cell and the 
progression of HPV-associated lesions. Alterations of methylation patterns during 
cervical carcinogenesis might be caused by different mechanisms. First, changes in the 
cellular differentiation status are usually accompanied by substantial alterations in the 
DNA methylation level (Khavari et al. 2010). Transformation of HPV-infected cells and 
overexpression of the oncogenes E6 and E7 prevents differentiation of the cells, 
thereby, efficiently avoiding cell cycle exit. As differentiation seems to be linked to 
reduced methylation levels in specific gene panels, HPV-transformed cells have been 
found to become hypermethylated in numerous sites (Fernandez et al. 2009). Recent 
publications suggest that the deregulated HPV oncogene expression, which constitutes 
a key event during HPV-mediated transformation of the host cells, plays an important 
role in this process by manipulating the DNA methylation machinery. HPV 16 E6 has 
been demonstrated to activate DNMT1 expression by degrading its transcriptional 
suppressor p53, whereas HPV 16 E7 has been reported to directly interact with DNMT1 
enhancing its activity (Au Yeung et al. 2010, Burgers et al. 2007). The assumption that 
both oncoproteins deregulate the expression and the activity of DNA methyltransferases 
has further been substantiated by the study of Li et al. The authors demonstrated that 
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the knock down of HPV 16 E6 and E7 expression in SiHa and CaSki cells causes a 
reduction in DNA methyltransferase levels, thereby decreasing CpG methylation levels 
and promoting the expression of several tumor suppressor genes (Li et al. 2015). 
Based on these findings, we hypothesized that induction of HPV 16 oncogene 
expression might affect the CpG methylation levels in HCT116 cells. To determine the 
methylation status of as many CpG dinucleotides as possible, hybridization of bisulfite-
converted DNA to Infinium® MethylationEPIC BeadChips (Illumina) was performed. This 
state-of-the-art technique allows the quantification of CpG methylation levels in about 
850,000 sites in the human genome in parallel. Due to the previously performed analysis 
of gene copy number variations, the information about CpG methylation levels was 
already available and therefore, only needed to be bioinformatically processed and 
interpreted. Changes in the genome-wide CpG methylation level were neither detected 
after 48 hours nor after nine days of HPV oncogene induction. In contrast, alterations in 
the methylation pattern of several genes were identified including keratin 38, OR5D16 
and PRKCA-AS1. However, the biological relevance of the differential methylation in 
these genes in response to HPV 16 E6 and E7 expression needs to be evaluated, as 
none of these candidates has yet been linked to the progression of HPV infections. 
Alterations in the methylation level of tumor suppressor genes that have been reported 
to become hypermethylated during HPV-associated cervical carcinogenesis in previous 
publications, was not observed in the current study. This discrepancy might have several 
interconnected reasons. First, the described hypermethylation of tumor suppressor 
genes might not only be mediated by the overexpression of the HPV oncogenes, but 
also by other mechanisms, especially differentiation-related processes. Furthermore, 
HPV-driven transformation of the host cells is assumed to span a long time period. 
Therefore, nine days of HPV oncogene expression represent a reasonable starting point 
for the analysis of short-term effects, but might not be sufficient to identify long-term 
changes in gene methylation patterns. Finally, it is important to point out that these data 
represent a preliminary experiment to acquire first insights into global methylation 
changes. As indicated previously, the presented data are based on single biological 
samples per treatment condition, therefore, complicating the statistical interpretation. 
4. Discussion 
 
103 
 
To conclude, the present analysis did not reveal substantial alterations in the global 
methylation level after nine days of HPV 16 oncogene expression. Thus, the HPV 16 E6 
and E7 induction period might not be long enough to induce differential methylation in a 
sufficient number of cells to be detected by the analysis. Nevertheless, differential CpG 
methylation was observed in a small subset of genes potentially indicating the ability of 
HPV 16 E6 and E7 to affect the methylation level of specific genes. However, these 
findings need to be validated by analyzing additional biological replicates. Altogether, 
the performed methylation analysis represents a sound basis for more comprehensive 
trials, which are important long-term aims of this project. 
 
4.7. Outlook 
The present study combines two essential aspects characteristic for translational 
research. One of these aspects is the systematic testing of previously selected 
candidate substances in preclinical settings. Here, the demethylating agent DAC has 
been identified as a promising candidate for the treatment of HPV-related tumors 
because previous studies had indicated the importance of hypermethylation during the 
progression of HPV-associated lesions. Therefore, investigating the efficacy of DAC 
treatment can be interpreted as logical consequence of previous findings and also 
constitutes a necessary step towards a more comprehensive evaluation of the 
substance in vivo and in clinical trials. The second aspect involves determined research 
that aims to identify novel candidate genes, mechanisms and pathways that might 
represent potential drug targets. This aspect strongly depends on the presence of 
powerful model systems that precisely mimic the in vivo situation and also allow to 
address important scientific questions. In the current study, we have introduced an 
inducible HPV 16 E6 and E7 expression system, which represents a unique 
experimental platform to study the effects of both HPV 16 oncoproteins in a time-
controlled manner. 
Due to the promising results of the DAC treatment and the successful validation of the 
inducible HPV 16 oncogene expression system, both parts of this study constitute a 
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starting point for future analyses. These may include the investigation of additional 
pathways, which are assumed to be influenced by the treatment with demethylating 
agents. Especially immune regulatory mechanisms seem to be affected, as DAC 
treatment has been reported to alter endogenous tumor antigen expression and 
presentation (Mora-Garcia Mde et al. 2006, Nie et al. 2001, Weber et al. 1994). By 
enhancing the expression of tumor antigens, DAC treatment might improve the 
recognition and subsequent elimination of tumor cells by immune effector cells. As these 
effects are difficult to study in cell culture experiments in vitro, the next step of the 
project would comprise the systematic testing in vivo, for example, by conducting animal 
studies. However, as the application of DAC has already been approved by the FDA for 
the treatment of myelodysplastic syndrome, it seems to be more efficient to directly 
evaluate its effects on HPV-associated tumors in clinical trials. 
The generation and validation of the inducible HPV 16 E6 and E7 expression system as 
well as the investigation of the consequences of HPV 16 oncogene expression on 
chromosomal stability, gene expression and CpG methylation levels also led to a 
number of open questions. First, the detailed mechanism of the E7-mediated uncoupling 
of centrosome duplication from DNA replication is still not completely understood. As the 
deregulation of this mechanism is assumed to substantially contribute to the induction of 
chromosomal instability, future experiments might use the established model system to 
elucidate this mechanism in further detail. These may include the immunocytological 
staining of γ-tubulin in combination with the Centrosomal protein 170 (CEP170) after 
induction of HPV 16 oncogene expression. As CEP170 is specifically localized at mature 
mother centrioles, its immunostaining in combination with γ-tubulin allows to discriminate 
mother from daughter centrioles. As a consequence, centrosome accumulation, which is 
characterized by multiple mother and daughter centrioles, could be clearly distinguished 
from centrosome overduplication, which requires the increased number of daughter 
centrioles in the presence of a single mother centriole (Guarguaglini et al. 2005). 
In addition, the ability of the HPV 16 oncogenes to induce gene copy number variations 
awaits further investigation. Prolonged HPV induction and subsequent outgrowth of 
single clones might significantly advance the validity of the analysis, thereby elevating 
the probability to identify hotspots of chromosomal alterations. The data generated from 
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these experimental trials could also be used for genome-wide DNA methylation analyses 
potentially improving the understanding of HPV oncogene-mediated epigenetic 
modifications. 
Overall, the generation and the validation of a novel, inducible HPV 16 E6 and E7 
expression system have paved the way for subsequent studies, which may further 
investigate the consequences of HPV 16 oncogene expression. Thereby, the present 
thesis not only contributes to a better understanding of the role of E6 and E7 during 
HPV-mediated transformation of infected cells, but might also represent the basis for 
future approaches to target the effects of HPV oncogene expression in the clinics. 
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6. Appendix 
6.1. Supplementary Figures 
 
Supplementary Figure 1: Schematic illustration of the vectors used for RMCE. 
The vector S2F-cLM2CG-FRT3 was used to generate vectors that allow dox-inducible expression of the 
HPV 16 oncogenes. S2F-cLM2CG-FRT3 contains a tet-controlled bidirectional promoter (Ptetbi) 
regulating the expression of firefly luciferase and the red fluorescent protein mCherry. This expression unit 
is flanked by the two heterospecific Flp-recognition sites F and F3 allowing RMCE upon expression of Flp 
recombinase. For the generation of the vector S2F-cLM2CG-FRT3 HPV 16 E6 the mCherry fragment was 
replaced by the sequence encoding HPV 16 E6 (GenBank: K02718.1, nt 83-560). Therefore, the NotI and 
EcoRI integration sites were used. The same strategy was performed to integrate HPV 16 E7 (GenBank: 
K02718.1, nt 562-858) into the vector resulting in the generation of S2F-cLM2CG-FRT3 HPV 16 E7. 
Expression of both HPV 16 oncogenes in combination was facilitated by replacing the mCherry fragment 
by HPV 16 E6 and the firefly luciferase encoding region by HPV 16 E7. Thereby, the bidirectional HPV 16 
E6 and E7 vector S2F-cLM2CG-FRT3 HPV 16 E6-E7 was generated. 
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Supplementary Figure 2: Alignment of HPV 16 E6 and E7 mRNA expressed after induction of 
HCT116 clones with the published sequences. 
Sequence identity between the HPV 16 E6 and E7 mRNA expressed from the respective HCT116 clone 
was confirmed by cDNA sequencing and subsequent alignment with either the published sequence of (A) 
HPV 16 E6 (GenBank: K02718.1, nt 83-560) or (B) HPV 16 E7 (GenBank: K02718.1, nt 562-858). 
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6.2. Supplementary Tables 
Supplementary Table 1: Densiometric quantification of Western blot bands presented in Figure 7B. 
 
 
Supplementary Table 2: Densiometric quantification of Western blot bands presented in Figure 
12B. 
 
